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SUMMARY
Traditionally, accelerated bone resorption has been considered to 
play the principal pathogenic role in malignancy-associated 
hypercalcaemia (MH), by one of two basic mechanisms. Hypercalcaemia 
in patients with metastatic bone disease, is thought to be due to the 
local release of skeletal calcium at a rate in excess of that which 
can be excreted by the kidney. In patients without bone metastases, 
hypercalcaemia is also thought to arise as the result of bone 
resorption, in this case stimulated by humoral mediators, which are 
released by the primary tumour. Although both humoral and metastatic 
mechanisms of hypercalcaemia could in theory coexist, the 
demonstration of bone metastases has conventionally been considered to 
provide reason enough for the occurrence of hypercalcaemia without 
invoking an additional humoral component.
The humoral mediators responsible for MH are at present poorly 
defined, but have been generally been considered to differ from 
parathyroid hormone (PTH) both structurally and functionally. Previous 
investigators have failed to find evidence of increased renal tubular 
calcium reabsorption or stimulation of 1,25 dihydroxyvitamin 
(1,25(OH)2 d3 ) synthesis in MH. The skeletal effects of these humoral 
mediators have also been considered to be distinct from PTH, in 
causing "uncoupling" of bone cell activity, with greatly increased 
osteoclastic bone resorption and depressed bone formation.
While metastatic bone disease has traditionally been considered to 
be the commonest cause of MH, a retrospective study of 195 cancer 
patients undergoing bone scan examinations showed no correlation 
between the extent of skeletal involvement and serum calcium values.
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These observations, indicated that, in most cases, the development of 
hypercalcaemia could not simply have been explained on the basis of 
local bone destruction, but rather may have been due to humoral 
mechanisms (chapter 3.1). A further prospective study of bone scan 
appearances in 87 consecutive cancer patients confirmed these results 
but in addition, showed that other biochemical indices of bone 
resorption were significantly higher in hypercalcaemic when compared 
with normocalcaemic patients, and were disproportionately raised with 
respect to the extent of metastatic disease seen on the bone scan. 
These observations indicated that in MH, bone resorption was largely 
occurring on a systemic, humorally mediated basis, rather than on a 
local "metastatic" basis (chapter 3.2).
Further studies compared renal tubular reabsorption of calcium in 
MH, primary hyperparathyroidism (HPT) and normal subjects undergoing 
acute calcium infusions. While immunoreactive PTH levels were 
invariably low or undetectable in the cancer patients, renal tubular 
reabsorption of calcium was raised to a level comparable with that in 
HPT. These observations raised the possibility that there frequently 
may be released a humoral mediator in MH which, although 
immunologically distinct from PTH, did possess a "PTH-like" effect on 
renal tubular reabsorption of calcium (chapter 4.1). Studies of renal 
tubular calcium reabsorption in patients with benign, non-parathyroid 
hypercalcaemia revealed generally normal results, excluding the 
possibility that the raised levels of renal tubular calcium 
reabsorption in malignancy may simply have been the result of chronic 
hypercalcaemia per se (chapter 4.2). Further studies also excluded the 
possibility that the raised levels of renal tubular reabsorption of
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calcium in malignancy may have been due to sodium depletion, since the 
renal handling of sodium in relation to renal tubular calcium 
reabsorption was similar in MH and HPT (chapter 4.3).
Studies performed during the surgical exploration of tumours 
associated with humoral hypercalcaemia (HHM) demonstrated that a fall 
in renal tubular calcium reabsorption was the major factor responsible 
for the normalisation of serum calcium values after surgical 
resection (chapter 6.1). A comparison of the mechanisms of 
hypercalcaemia in patients with early and advanced HHM showed that in 
the early stages, increased renal tubular reabsorption of calcium was 
the most important pathogenic mechanism, often occurring in the 
absence of increased bone resorption. With progression of the tumour 
and increasing immobilisation however, accelerated osteoclastic bone 
resorption with depressed bone formation became more apparent. This 
indicated that, the HHM-associated humoral factor, like PTH itself, 
had more potent effects on the kidney than on osteoclastic bone 
resorption. A possible explanation for the increased bone resorption 
and depressed bone formation associated with advanced tumours may 
however have been due to the synergistic effects of immobilisation 
and HHM-associated humoral factors on bone cells (chapter 6.2).
In further studies, serum levels of 1,25 (OH) 2 D were found to be 
inappropriately detectable or raised in about 50% of patients with 
cancer-associated hypercalcaemia, (chapter 5.1) However, intestinal 
calcium absorption, was depressed when compared with primary 
hyperparathyroidism, despite the fact that 1,25 (OH) 2 D levels were 
raised within the hyperparathyroid range in some cases. This data 
indicated that there may have been end-organ resistance to the effects
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of the vitamin D metabolite in malignancy (chapter 5.2). Other aspects 
of PTH-like activity such as raised urinary cAMP excretion indicated 
that the detectable 1,25 (OH) 2 D levels were likely to have been due to 
a PTH-like effect on renal 1-(X -hydroxylase activity. These PTH-like 
effects were noted less commonly in breast carcinoma, myeloma and 
other tumours with very extensive metastases however, indicating that 
in these cases a true local osteolytic mechanism of hypercalcaemia may 
have been operative (chapters 5.2, 5.3, 6.3)
A randomised study of antihypercalcaemic therapy in malignancy 
showed that most treated patients improved symtomatically, although 
survival remained short. The diphosphonate APD was found to be the 
most effective agent in the longer-term due to potent supression of 
bone resorption although some APD-treated patients remained 
hypercalcaemic after treatment, due to humorally-mediated elevations 
in renal tubular calcium reabsorption. The combination of 
corticosteroid and calcitonin was useful because of its rapid effect, 
but rarely controlled hypercalcaemia in the long term. Mithramycin had 
intermediate effects due to inhibition of bone resorption and renal 
tubular calcium reabsorption (chapter 6.1). A further study using a 
combination of APD and calcitonin gave rapid control of 
hypercalcaemia, with a sustained duration of action (Chapter 6.2). In 
analysing the calcium-lowering response to the above agents, it 
appeared that the most important factor in predicting response was a 
raised level of renal tubular calcium reabsorption.
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CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW
1.1 PATHOGENIC MECHANISMS OF HYPERCALCAEMIA
1.1.1 INTRODUCTION
Two mechanisms are commonly invoked in the pathogenesis of 
malignancy associated hypercalcaemia; in patients with metastatic 
bone disease, hypercalcaemia is usually attributed to local release of 
skeletal calcium by invading tumour, at a rate exceeding the renal 
capacity for its excretion (1,2,3,4,5). When hypercalcaemia occurs 
in patients who do not have bone metastases, the elevation in serum 
calcium values is also thought to be due to increased bone resorption. 
In this case however, osteoclastic bone resorption is increased on a 
systemic basis, stimulated by a circulating osteolytic humoral 
mediator, which is released by tumour tissue (5,6,7,8,9).
1.1.2 HYPERCALCAEMIA AND METASTATIC BONE DISEASE
Although this is currently considered to be the commonest 
mechanism of hypercalcaemia in malignancy (5,10,11,12), evidence in 
favour of a causal relationship between hypercalcaemia and metastatic 
deposits in bone is mainly circumstantial. Early case reports between 
the 1920ls-1930's documented that hypercalcaemia was a relatively 
common occurrence in patients with tumours such as breast carcinoma 
and myeloma which were characteristically associated with extensive 
osteolytic disease (13,14,15,16,17,18,19,20,21). The first substantial 
review of calcium biochemistry in cancer patients was reported by 
Gutman (22), who in 1936, noted a 12% incidence of hypercalcaemia in 
patients with metastatic bone disease overall, compared with a 25% 
incidence in those with radiologically osteolytic lesions only. 
Hypercalcaemia subsequently became recognised as a common cause of
FIGURE 1.1
Photomicrograph (x343 magnification; Masson stain) of bone biopsy 
through an osteolytic lesion in a patient with breast carcinoma. Note 
presence of multinucleated osteoclasts in resorption lacunae 
(arrowed) , interpositioned between tumour cells (T) and bone surface.
morbidity and mortality in patients with breast carcinoma 
(1,2,3,5,10,22,23,24,25) and myeloma (5,10,11,13,15,16,18,20,22). 
Indeed, these tumours, when combined accounted for the majority of 
patients with cancer-associated hypercalcaemia in Myers' large series 
of 1960 (10). Surprisingly, a rather poor correlation was noted to 
exist between the radiological extent of skeletal metastases , and the 
development of hypercalcaemia in both of these tumours (26,27,28) 
although this was thought to relate to the relative insensitivity of 
standard radiological methods in detecting occult bone metastases (5). 
The mechanisms of hypercalcaemia in patients with bone metastases due 
to tumours other than breast carcinoma and myeloma are rather less 
well documented. It has been assumed however, that in these tumours 
also, hypercalcaemia occurs as the result of excessive skeletal 
calcium release by invading tumour metastases.
At a cellular level, bone resorption in metastatic lesions is 
thought to be mediated by the osteoclast, rather than by the tumour 
cells themselves (5,29,30,31). Thus, while breast carcinoma cells 
have been shown to be capable of directly resorbing bone in vitro(32), 
two lines of evidence suggest that this mechanism of bone resorption 
is less important in vivo. These are; the proven efficacy of specific 
osteoclast inhibitory drugs in the treatment of bone resorption 
(33,34) and hypercalcaemia (35) associated with metastatic lesions, 
and histological data which usually show osteoclasts interpositioned 
between tumour cells and resorption lacunae, in actively osteolytic 
lesions (29,30,31) (Figure 1,1).
At a subcellular level, the mediators of osteoclast activation 
in metastatic lesions remains unclear, although a number of substances
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have been implicated in this respect. Since many of these have also 
been implicated as circulating mediators of bone resorption and 
hypercalcaemia in patients without metastatic bone disease, all will 
be considered together in a later section.
1.1.3 HYPERCALCAEMIA UNASSOCIATED WITH METASTATIC BONE DISEASE
Hypercalcaemia was first noted to occur in a patient without bone 
involvement by Zondek in 1924 (36), and subsequently in one patient 
with bronchial carcinoma from Gutman's series of 1936 (22). The
mechanism of hypercalcaemia was unclear to these workers however, as 
the concept s of parathyroid hormone action and ectopic hormone 
production had not then evolved. In 1941 however, Albright recognised 
that hypercalcaemia in situations like these may be due to the 
"ectopic" release of a humoral substance by tumour tissue (6). This
postulate was made on the basis of a case report in which
hypercalcaemia and hypophosphataemia in a patient with metastatic 
hypernephroma was corrected by irradiation of a solitary ileal 
metastasis. Since there was no e v i d e n c e  of p r i m a r y  
hyperparathyroidism on post-mortem examination, Albright reasoned that 
the metabolic abnormalities may have been caused by a parathyroid 
hormone-like substance released by tumour tissue. Subsequently, 
further case reports appeared in the literature, documenting 
hypercalcaemia and hypophosphataemia in cancer patients without 
metastatic bone disease (37,38,39). Data from 50 “such patients were
reviewed by L a f f e r t y  in 1966 (7) using the term
"pseudohyperparathyroidism" previously coined by Fry (39). Lafferty 
delineated three important features of the syndrome. Firstly, and by 
definition, Lafferty considered that the syndrome of humorally-
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mediated hypercalcaemia could only be made in the absence of 
metastatic bone disease. Secondly, patients suffering from this 
syndrome were noted to exhibit certain "hyperparathyroid-like" 
features, in that the hypercalcaemia was usually associated with 
hypophosphataemia and renal phosphate wasting. Thirdly, the tumour 
types associated with this syndrome comprised mainly of squamous or 
genitourinary cancers. The absence of breast carcinoma as a cause 
could, of course, have been be explained by Lafferty's first 
stipulation that the presence of bone metastases excluded the 
diagnosis.
Conclusive evidence that such hypercalcaemia was indeed due to 
the release of a humoral factor by tumour tissue, was gained by 
studies which demonstrated that, in patients with localised tumours, 
surgical resection reversed both the hypercalcaemia and 
hypophosphataemia (8,9).
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1.2 PROPOSED MEDIATORS OF HYPERCALCAEMIA IN MALIGNANCY
1.2.1 OSTEOCLAST ACTIVATING FACTORS
In 1972, Horton and his colleagues discovered that supernatant 
fluid from cultures of normal human lymphocytes possessed bone- 
resorbing activity in vitro (40). This activity was attributed to the 
release of an osteoclast-activating substance (OAF) by these cells. A 
variety of cell lines was subsequently demonstrated to exhibit 
similar activity including; normal and activated human leukocytes 
(40,41,42,43), B- and T- lymphocytes (44), myeloma cell-lines (31,45), 
lymphosarcoma cell-lines (46), normal monocytes (47), and possibly 
some solid-tumour cell lines (48).
Although it was originally thought that OAF was a single 
substance (40) , subsequent data indicated that the _in vitro bone 
resorbing activity referred to as OAF was probably due to the release 
of a heterogeneous group of mediators (5,49). Thus, recent studies 
have shown that tumour necrosis factor-alpha (TNFtX) anc^  tumour 
necrosis factor —beta (TNF ) all possess OAF—like bone — rssorptivc 
properties in vitro (47,51). Since TNF (X and TNFp are both present 
in activated leukocyte cultures in vitro, and T N F i s  produced by 
myeloma cell-lines (52), Bertolini (51) has recently suggested that 
TNF production may account, in whole or in part, for the bone- 
resorbing activity previously referred to as OAF. Other cytokines 
which may also contribute to this activity include interleukin-1 (47) 
and the prostaglandins (53).
Because of their association with cells of the lymphoid series, 
OAF's have been implicated predominantly in the pathogenesis of
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hypercalcaemia caused by haematological cancers such as myeloma and 
lymphosarcoma (5,31,46,50,54) While OAF-like material has been 
detected by radio-immunoassay in the circulating blood of patients 
with myeloma (55) , it is probable that the OAF's bring about their 
effects by a local, rather than systemic action. Osteoclastic bone 
resorption has been found to be markedly elevated in areas of the 
skeleton which are infiltrated by myeloma cells (31), but is normal in 
uninvolved bone (56). When bone-resorbing doses of OAF's are injected 
into experimental animals hypercalcaemia does not occur (41), and in 
man, serum calcium values in patients with myeloma correlate more 
closely with renal glomerular function than OAF production (28).
With one possible exception (48), OAF's, as defined above, have 
not been shown to be produced by solid malignant tumours. However, it 
is possible that, in metastatic bone lesions, the presence of solid 
tumour cells could lead to release of OAF's by lymphocytes and 
monocytes, as the result of a cell-mediated immune response, leading 
to a local increase in bone resorption (57).
1.2.2 PROSTAGLANDINS
Prostaglandins were first invoked in the pathogenesis of 
malignancy-associated hypercalcaemia, shortly after Klein and Raisz, 
showed that they possessed potent bone-resorbing activity in vitro 
(53). Tashjian described bone-resorbing activity in extracts of 
tumour from two animal models of human hypercalcaemia; the HDSM-1 
mouse fibrosarcoma and the rabbit VX-2 carcinoma (58,59). Conditioned 
media from the HDSM-1 tumour cells in culture were shown to contain 
large amounts of prostaglandin E2 (PGE2 ). The bone resorbing 
activity normally present in in this medium was abolished by pre­
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incubation of the HDSM-1 cells with aspirin or indomethacin - potent 
inhibitors of prostaglandin synthesis (60). In the rabbit VX-2 
carcinoma, tumour-bearing animals were found to have raised 
circulating PGE2 levels when compared with normal controls; moreover, 
PGE2 levels were particularly high in the venous drainage of the 
tumours (59). Pre- treatment with indomethacin prevented the 
development of hypercalcaemia in animals, into whom the VX-2 carcinoma 
had been transplanted. From these observations, it was postulated 
that the hypercalcaemia may have been due to the systemic release of 
PGE2 by tumour tissue. In a complementary study by Galasko, intense 
osteoclastic bone-resorption was found in the ipsilateral femur of 
rabbits, whose adjacent muscle had been injected with VX-2 carcinoma 
cells (30). In these experiments, the bone-resorbing effects of the 
tumour were blocked by indomethacin, and the tumour tissue was found 
to contain PGE2 ~like bioactivity. Nonetheless, Galasko failed to find 
evidence of significantly increased bone resorption in areas of the 
skeleton distant from the tumour implants, indicating that the 
osteolytic mediator had a local, rather than systemic action (30).
Prostaglandins were first invoked in the pathogenesis of human 
hypercalcaemia of malignancy by Brereton (61) who found raised levels 
of PGE2 and prostaglandin F (PGF) in tumour tissue from a patient with 
hypercalcaemia and renal adenocarcinoma. Although plasma 
prostaglandins were undetectable in the above patient, the 
hypercalcaemia seemed to respond to indomethacin therapy, leading the 
authors to suggest that release of prostaglandins by tumour tissue may 
have been responsible for the hypercalacemia. In a similar report by 
Robertson (62) , raised levels of immunoreactive PGE were found in
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serum and tumour tissue from a patient with hypercalcaemia and a renal 
adenocarcinoma. While a striking increase in PGE levels seemed to 
coincide with worsening of hypercalcaemia in this patient, aspirin 
therapy failed to correct the hypercalcaemia, despite reducing serum 
PGE levels to normal. The most extensive studies of prostaglandins in 
human hypercalcaemia of malignancy were those of Seyberth, who 
measured the common metabolite of PGE^ and PGE2 in the urine of 
patients with cancer associated hypercalcaemia {63). Levels of the 
PGE metabolites were found to be substantially raised in 
hypercalcaemic solid-tumour patients when compared with those in 
"control" groups of patients with haematological cancers, primary 
hyperparathyroidism and normocalcaemic solid-tumour patients. In four 
out of six hypercalcaemic patients who were treated with aspirin or 
indomethacin, serum calcium values fell, leading the authors to 
suggest that a PGE - mediated increase in bone resorption may have 
been responsible for the hypercalcaemia.
Other workers however, have failed to confirm that prostaglandin 
synthetase inhibitors such as indomethacin and aspirin have a 
significant c a 1 c i u m - 1 o w e r i ng effect in cancer-associated 
hypercalcaemia (64). They have similarly been found to be ineffective 
in preventing the progression of metastatic bone disease in clinical 
practice (5). Additional evidence which weighs against a causal role 
for PGE as a circulating mediator of hypercalcaemia in malignancy is 
as follows: studies of plasma immunoreactive PGE levels in cancer 
patients have shown a substantial overlap between hypercalcaemic and 
normocalcaemic subjects, and a poor correlation between serum calcium 
values and circulating PGE levels (65,66). The circulating 
concentrations of PGE hitherto observed in humans with cancer-
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associated hypercalcaemia would in addition, be insufficient to 
account for a systemic increase in bone resorption (67). Indeed, in 
vivo, circulating PGE2 is rapidly broken down in the pulmonary 
circulation to metabolites which have relatively weak bone-resorbing 
activity in vitro (67). Finally, infusions of PGE2 intra-arterially 
in dogs failed to produce significant hypercalcaemia, except when the 
doses used were so high as to cause haemoconcentration due to 
diarrhoea (69). In rats, intravenous PG E2 infusions at high doses 
were noted to cause hypercalcaemia in one study (70), although the 
relevance of this to the in vivo situation in man is doubtful.
From the above data, it is unlikely that the prostaglandins are 
commonly involved as circulating humoral mediators of bone resorption 
or hypercalcaemia in human cancers. They may however, be involved as 
local mediators of increased bone resorption in metastatic lesions 
(71,72,73,74). Furthermore, it has recently been shown that in vitro 
the bone-resorbing effects of many factors such as complement- 
sufficient serum (75), epidermal growth factor (76) and extracts of 
tumour associated with hypercalcaemia (77,78) are mediated by 
increased prostaglandin production in bone at a local level
1.2.3 VITAMIN D METABOLITES
The metabolites of vitamin D (25-hydroxycholecalciferol, and 
1,25-dihydroxycholecalciferol) are potent stimulators of bone 
resorption in vitro (79) and i_n vivo (80), and cause enhanced 
absorption of calcium and phosphate from the intestine (80,81,82). 
The former effect in particular, prompted Gordan to suggest, in 1966, 
that hypercalcaemia and bone resorption associated with breast 
carcinoma was due to a "vitamin-D like" sterol which he and his
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colleagues had isolated from breast cancer tissue (83,84). Subsequent 
investigations by Haddad however, demonstrated that similar sterols 
were also present in the circulating blood of normal women, lactating 
women, and normocalcaemic patients with breast carcinoma (85). In 
addition, the concentrations of these sterols were considered by 
Haddad to be insufficient to account for significant increases in bone 
resorption, at least as judged by in vitro evidence (85). At the 
intestinal level, Coombes (8 6 ) found low rates of calcium absorption 
in both normocalcaemic and hypercalcaemic cancer patients, also 
implying that vitamin-D like effects were not usually evident in 
these situations.
In patients with lymphoreticular cancers, the active vitamin D 
metabolites may play a part in the pathogenesis of hypercalcaemia 
however. Breslau (87), Rosenthal (8 8 ), and Davies (89) all have noted 
elevated circulating levels of 1,25-dihydroxycholecalciferol 
(1,25 (OH) 2 d3 ) an<3 raised intestinal absorption of calcium (87) in 
hypercalcaemic patients with certain types of lymphoma. In this 
situation, metabolism of vitamin D is abnormal, in that synthesis of
1,25 (OH) 2 D3 is directly related to levels of the precursor, 25- 
hydroxycholecalciferol (25(OH)D^) (89), reflecting failure of normal
feedback control mechanisms (80,81,82). It is currently considered 
that these abnormalities arise as the result' of 1,25(OH)2 D3 synthesis 
by tumour tissue itself (90,91). Accordingly, the local and systemic 
effects of l,25(OH)2D3 may be invoked as a contributory factor in the 
pathogenesis of hypercalcaemia associated with these tumours (92). In 
solid tumours, similar mechanisms of hypercalcaemia are not thought to 
be operative however, as circulating l,25(OH)2D3 levels have been 
found to be depressed (93).
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1.2.4 TUMOUR AND PLATELET-DERIVED GROWTH FACTORS
Three growth factors have so far been implicated in the 
pathogenesis of malignancy-associated hypercalcaemia; Transforming 
Growth Factor-alpha (TGFoO, Transforming Growth Factor-beta (TGF (3 ), 
and Platelet-Derived Growth Factor (PGDF) (90). These substances are 
peptides, which are produced by both normal (94,95,96) and malignant 
tissues (97,98). In addition to a variety of other biological 
effects, these growth factors possess, in common, powerful bone- 
resorbing properties in vitro (90,99,100). While the TGF's share many 
biological properties in common with Epidermal Growth Factor (EGF) 
(101,102,103), these substances are clearly different, as antibodies 
to EGF do not cross-react with TGF's (90). Nonetheless, the bone- 
resorbing effects of TGF o( at least, appears to be mediated by 
interaction with EGF receptors since these effects are blocked by 
antisera directed against the EGF receptor (104).
To-date, TGF (X has been implicated in the pathogenesis of 
hypercalcaemia in two situations; the rat leydig-cell tumour model of 
humorally mediated hypercalcaemia in malignancy (104), and the 
hypercalcaemia associated with one human tumour (105). In both cases, 
extracts of tumour tissue contained potent bone-resorbing activity 
which co-eluted with TGFC< bio-activity in gel-filtration collumns. 
Moreover, the bone-resorbing activity was inhibited by antisera to the 
EGF receptor, lending support to the hypothesis that TGF was the 
factor responsible (104,105).
TGFjl has similar biological effects to TGFCX but is an entirely 
different molecule, encoded by a separate gene (106). While TGFp is
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produced by many malignant tissues (106) it is also found in other 
replicating tissues including normal platelets, fibroblasts, and bone 
cells (90). Hitherto, TGF/i has been implicated in the pathogenesis 
of bone resorption and hypercalcaemia associated with one animal 
model of cancer associated hypercalcaemia - the rat Walker 
Carcinosarcoma (107). In this situation, bone resorbing activity was 
found to co-elute from gel-f iltration collumns with TGF jB bio­
activity, thus implicating TGF as the cause of hypercalcaemia.
Platelet Derived Growth Factor, in common with the above factors 
has been implicated as a potential mediator of hypercalcaemia in 
malignancy (90). It is known to stimulate bone resorption in vitro 
(1 0 0 ) and it is of intrest that many cancers associated with 
hypercalcaemia in vivo express the v-sis oncogene, which encodes a 
peptide with considerable homology to PDGF (108,109). However, PDGF 
has not yet been implicated in the hypercalcaemia associated with any 
particular human or animal tumour.
In view of their powerful bone-resorbing effects in vitro 
(90,99,100), and a s s o c i a t i o n  with c a n c e r o u s  tissues
(97.98.104.105.106.107), the above named growth factors may well be 
involved as local mediators of bone resorption in metastatic lesions. 
It is currently unclear however, whether these factors can also be 
implicated as systemically active, humoral mediators of 
hypercalcaemia. Indeed, while TGF's have been shown to occur in 
tumour tissue from patients with humorally-mediated hypercalcaemia
(104.107) they are also present in tumours unassociated with 
hypercalcaemia (97,98). Moreover, in order to implicate TGF's as 
humoral mediators of hypercalcaemia, two major criteria must be
fulfilled: firstly, they must be released into the circulation by
tumour tissue in an active form sufficient to cause bone resorption at 
sites distant from tumour deposits. Secondly, if injected or infused 
into experimental animals at bone-resorbing doses, these growth 
factors would be expected to cause hypercalcaemia. Since the effects 
of the TGF's and PDGF have not yet been studied i_n vivo, these 
questions remain unanswered.
1.2.5 PARATHYROID HORMONE
Parathyroid hormone (PTH) excess has long been recognised as a 
cause of hypercalcaemia and hypophosphataemia (1 1 0 ,1 1 1 ), by virtue of 
its effects on osteoclastic bone resorption (112,113), renal tubular 
reabsorption of calcium (114) and phosphate (111), and intestinal 
absorption of calcium (115) via increased production of l,25(OH)2D2 
(116). Since many of the biological effects of PTH are mediated by 
interaction with an adenyl-cyclase linked receptor (117) , patients 
with PTH excess also exhibit elevated urinary excretion of cyclic- 
adenosine 3' 5' monophosphate (cAMP) (118).
For many years, similarities have been noted between primary 
hyperparathyroidism and "non-metastatic" hypercalcaemia of malignancy 
(6,7). In both conditions, the elevated serum calcium levels are 
associated with hypophosphataemia, renal phosphate wasting (9,10), and 
elevated levels of nephrogenous cyclic AMP (NcAMP) (93). On removal 
of the malignant tumour (9,10) or parathyroid adenoma (119), these 
abnormalities are reversed. Because of these similarities,"ectopic" 
PTH production was one of the first mechanisms postulated to explain 
the development of hypercalcaemia in patients without metastatic bone 
lesions (6,7,120,121).
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With the advent of immunoassay techniques in the 1960's, many 
investigators found detectable PTH-activity in serum and/or tumour 
extracts from patients with "non-metastatic" hypercalcaemia. For 
example, Tashjian's group, using quantatative complement fixation 
techniques, found evidence of PTH-like activity in tumour tissue from 
patients with humorally-inediated hypercalcaemia (122,123). In later 
studies, using more sensitive radio-immunoassays, Sherwood also 
detected PTH in tumour tissue from about 50% of patients with "non- 
metastatic" hypercalcaemia - but at much lower concentrations than in 
parathyroid adenomata (124). Similar findings were also reported by 
Knill-Jones (125), Melick (126), Maviligit (127) and Blair (128) in 
subsequent individual case-reports.
Benson, using a radio-immunoassay with carboxyl-terminal 
specificity found serum immunoreactive PTH (iPTH) levels to be 
"innapropriately detectable" in over 90% of unselected patients with 
cancer-associated hypercalcaemia (129). These findings were 
interpreted by the authors as indicating that "ectopic" release of 
PTH was responsible for the hypercalcaemia (129). Other workers, 
using similar radio-immunoassays, also found detectable levels of 
circulating iPTH in cancer-ass.ociated hypercalcaemia (130,131). A 
consistent feature in all of the above studies however, was the fact 
that the iPTH levels observed in hypercalcaemia of malignancy were 
lower than those in true primary hyperparathyroidism for any given 
level of serum calcium (129,130,131). Moreover, in other studies, 
elevated iPTH levels were frequently noted in normocalcaemic cancer 
patients - particularly those with oat-cell or adenocarcinoma of lung
(121,131). In contrast with the above data, Powell, using a different 
radio-immunoassay system with amino-terminal specificity, failed to
detect iPTH in either serum or tumour tissue from a series of patients 
with "non-metastatic" hypercalcaemia (132). Recent findings indicate 
that the differences between Powell's data and those of other workers
(129,130,131), were largely due to the different characteristics of 
the assay systems used. Thus, in recent studies, Stewart (93) has 
shown that iPTH levels were frequently detectable in the serum of 
hypercalcaemic cancer patients using carboxyl-terminal specific 
assays. However, using amino-terminal assays, serum from the same 
patients usually yielded undetectable iPTH concentrations. Moreover, 
when compared with true primary hyperparathyroidism, iPTH levels in 
malignancy-associated hypercalcaemia were invariably low,irrespective 
of the assay system used.
The probable explanation for these rather paradoxical findings is 
as follows; normal parathyroid glands, in vivo and in vitro appear to 
possess an element of "non-suppressible" PTH secretion, in that they 
continue to release small amounts of intact PTH and its fragments 
even under hypercalcaemic conditions (133,134). Moreover, under these 
conditions there is secreted a higher relative proportion of carboxyl- 
terminal fragments to intact hormone (134). Since these carboxyl- 
terminal fragments are cleared slowly from the circulation - 
particularly in the presence of renal impairment (135), it is apparent 
that the detectable levels of iPTH observed using carboxyl-terminal- 
specific assays may have derived from normally supressed parathyroid 
glands rather than the tumour itself (135). Such a mechanism would 
certainly be consistent with recent studies which failed to detect 
messenger RNA, coding for PTH, in tumour tissue derived from human 
breast cancers and other animal and human tumours associated with 
hypercalcaemia (13 7).
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From the above data, it is currently considered that true 
"ectopic" PTH production is a rare cause of hypercalcaemia in 
malignancy (138). There are, however a few cases documented in whom 
such a mechanism seems to have been operative (124,125,126,127,128).
1-2-6 PARATHYROID HORMONE-LIKE FACTORS
Reference has been made to the many biochemical similarities 
which exist between humoral hypercalcaemia of malignancy (HHM) and 
primary hyperparathyroidism. There are also major differences between 
these conditions however. These were first noted by Lafferty who 
commented on the absence of periosteal bone erosions and tendency to 
hypochloraemic alkalosis in HHM, when compared with primary 
hyperparathyroidism which is classically associated with subperiosteal 
bone erosions and a tendency to hyperchloraemic acidosis (7).
In recent years, Stewart and his colleagues have made detailed 
studies of the biochemical differences between primary 
hyperparathyroidism and hypercalcaemia of malignancy (93). Stewart 
divided patients with cancer-associated hypercalcaemia into two groups 
by the pattern of nephrogenous cyclic AMP (NcAMP) excretion. In 
patients with high NcAMP values, squamous and genitourinary cancers 
were the commonest tumours, and bone metastases were infrequent - 
consistent with previous series' of patients with humorally mediated 
hypercalcaemia (7,8,10). In contrast, low NcAMP values were usually 
found in patients with hypercalcaemia due to breast carcinoma and 
myeloma where skeletal metastases were extensive, suggesting that 
non-humoral mechanisms of hypercalcaemia were operative (5). In the 
group of patients with a presumed humoral mechanism of hypercalcaemia, 
NcAMP excretion and renal tubular phosphate reabsorption were
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indistinguishable from patients with primary hyperparathyroidism. 
Immunoreactive PTH values were, of course low or undetectable in the 
patients with malignancy, using four separate region-specific 
immunoassays. In comparison with primary hyperparathyroidism, the 
levels of urinary calcium excretion in malignant hypercalcaemia were 
significantly raised, and the levels of 1,25 (OH) 2 0 -^/ significantly 
depressed, indicating to the authors that PTH-like effects on distal 
renal tubular reabsorption and renal 1 (X hydroxylase activity were 
largely absent.
Subsequent studies by Stewart also demonstrated differences in 
bone histology between the humoral hypercalcaemia of malignancy (HHM) 
and primary hyperparathyroidism (139). Examination of undecalcified 
bone biopsy specimens by quantatative histomorphometry confirmed that 
in HHM, there was a marked increase in osteoclastic bone resorption in 
bone at sites distant from areas of tumour involvement. Similar 
findings had been noted by previous workers in non-histomorphometric 
studies of patients with HHM (140,141,142). In addition, Stewart 
noted that there was a striking reduction in osteoblastic activity in 
HHM when compared with primary hyperparathyroidism, and suggested that 
the putative humoral mediator responsible for HHM specifically caused 
"uncoupling" of bone resorption and bone formation (139). These 
observations were taken as further evidence of a fundamental 
difference between the functional effects of the HHM-associated 
mediator and parathyroid hormone.
Subsequent studies aimed at identifying the putative humoral 
mediator responsible for HHM were based on the in vivo biochemical 
evidence which suggested that some of its biological effects were
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mediated by interaction with a adenyl-cyclase linked receptor in the 
kidney (93). In 1980, Goltzman had shown that serum samples from HHM 
patients possessed glucose-6 -phosphate dehydrogenase stimulating 
activity in a PTH-sensi tive bioassay system i_n vitro (143).
Further studies by Stewart (144), Strewler (145) and Rodan (146) 
demonstrated that extracts of tumours which caused the clinical 
syndrome of HHM in man contained adenyl-cyclase stimulating activity 
in vitro, which was competitively inhibited by synthetic antagonists 
of PTH. Characterisation of the substances responsible for this 
activity indicated that they were peptides with molecular-weights 
ranging between 9000 and 50,000 daltons and were distinct from PTH 
itself (144,145,146). From these observations it has been considered 
that in HHM a humoral substance is released which can interact with 
the PTH receptor in kidney and bone, yet is structurally quite 
distinct from PTH (144,145,146). Whether this substance is indeed the 
cause of hypercalcaemia in these patients is as yet unclear; Stewart 
and other workers have failed to find evidence of increased renal 
tubular reabsorption of calcium in HHM (93,147,148). Similarly, 
1,25(OH) 2 D3 levels and intestinal calcium absorption have been 
reported to be depressed in HHM (86,93). These data contrast markedly 
with the analogous situation in primary hyperparathyroidism where 
increased renal tubular reabsorption of calcium and increased 
intestinal absorption of calcium make a greater contribution to 
hypercalcaemia than increased bone resorption (4,114,115,116). 
Indeed., in most conditions associated with accelerated bone 
resorption alone, hypercalcaemia is rare since efficient renal 
homeostatic mechanisms tend to preserve normocalcaemia at the expense 
of hypercalciur ia (4). Moreover, while HHM is, in many cases
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associated with release of the adenyl-cyclase stimulating factors 
discussed above (144,145,146) these have not convincingly been shown 
to possess bone-resorbing properties in vitro. Although Stewart and 
his colleagues have identified both bone-resorbing and adenylate 
cyclase-stimulating activity in the rat Leydig cell tumour model of 
HHM (149) , it has been suggested that the bone-resorbing activity 
associated with this tumour is due to the effects of TGF <X , rather 
than the adenylate cyclase stimulating factor (90). Thus, recent data 
has shown that bone resorption stimulated by extracts of the rat 
Leydig tumour in vitro is inhibited by antiserum to the EGF receptor 
but not by synthetic antagonists of PTH (150).
Moreover, while Stewart and his colleagues (93) found a bimodal 
distribution of NcAMP values in patients with cancer-associated 
hypercalcaemia, and on this basis were able to separate their patients 
into "humorally-mediated" and "non-humorally-mediated" subgroups, 
other workers have failed to find such clear-cut differences in the 
patterns of NcAMP excretion in patients with malignancy. Rude (151) 
found a substantial overlap of NcAMP values between patients with 
"non-metastatic" hypercalcaemia and those with extensive metastatic 
disease due to myeloma and breast carcinoma, where a local-osteolytic 
mechanism of hypercalcaemia would have been predicted. In addition, 
both Rude (151) and Kukreja (152) found that NcAMP values were 
elevated in many normocalcaemic cancer patients - particularly those 
with squamous lung carcinoma. From these data it is apparent that 
elevated levels of NcAMP may be a relatively non-specific feature of 
some cancers rather than a biochemical marker for PTH-like humoral 
mediators of hypercalcaemia.
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1.2.7 SUMMARY
Relevant points with regard to the putative humoral mediators of 
hypercalcaemia discussed above may be summarised as follows:
(1) Virtually all of the putative humoral mediators of 
hypercalcaemia in malignancy are thought to raise serum 
calcium by stimulating osteoclastic bone resorption
(5,6,30,31,51,64,77,73,90,93,139,140,141,142).
(2) In most cases it is probable that tumour tissues contain 
more than one substance with in. vitro bone resorbing 
activity. Since many normal tissues also possess such 
activity [eg platelets (95,100) ,placenta (94), normal 
serum (75)], the demonstration of bone-resorbing activity 
in tumour tissue does not necessarily mean that this is 
the cause of hypercalcaemia.
(3) Ectopic production of bioactive PTH by non parathyroid 
tumours, although documented (124,125,126,127,128), is a 
rare cause of malignancy-associated hypercalcaemia (137,138).
(4) In haematological cancers, the mechanisms of 
hypercalcaemia are best-established; local osteolysis on
a multifocal basis, stimulated by mediators which are 
best characterised - the OAF's (31,40,44,45,46) , TNF's (51] 
Interleukin-1 (47) and 1,2 5 (0 8 )2 ^ 3  (87,88,89).
(5) In solid tumours associated with a heavy skeletal tumour 
load - breast carcinoma for example, local osteolysis is 
though to be the principal mechanism of hypercalcaemia
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(2,3,5). The mediators of hypercalcaemia are less clear 
in this situation, although possible candidates include 
the prostaglandins (71,72), TGF's (97), EGF (103) and 
others as yet undefined.
(5) In solid tumours other than breast carcinoma (eg squamous 
carcinoma of lung) humorally mediated effects on bone and 
possibly other target organs of calcium homeostasis are 
the likely cause of hypercalcaemia. The PTH-like factors 
are released in a high proportion of these tumours (93) 
but the mechanisms by which they could cause 
hypercalcaemia are unclear; unlike PTH they are thought 
not to increase renal tubular calcium reabsorption or 
l,25(OH)2D3 synthesis (93), nor have they been shown to 
possess bone resorbing properties in vitro (150). The 
release of other bone -resorbing factors by these tumours 
such as the transforming growth factors, for example, may 
prove to be important in the pathogenesis of 
hypercalcaemia in these situations (5,90,104).
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1.3 PATHOPHYSIOLOGY OF HYPERCALCAEMIA
In health, the concentration of ionised calcium in the 
extracellular fluid (ECF) is maintained within a narrow range by 
homeostatic mechanisms which control the processes of calcium exchange 
in three main target tissues; bone, kidney and intestine (153) The 
The most important calcium regulating mechanisms are hormonal in 
nature and involve, in particular, parathyroid hormone (PTH) and
1,25 (OH) 2 d3 * Together, these hormones form a classical endocrine 
system which serves principally to regulate the ECF calcium 
concentration (154,155). This system can be regarded as having two 
main components: a rapidly-acting component of limited capacity which 
accounts for the minute-to-minute regulation of ECF calcium and a 
slowly-acting component of almost infinite capacity which in involved 
in control of calcium balance in the longer term.
The rapidly acting system is largely controlled by PTH, via its 
effects on renal tubular reabsorption of calcium (114) and non­
osteoclast mediated exchange of calcium at the ECF-bone interface 
(4,156). In the longer term, calcium balance is achieved by the 
combined effects of both hormones; intestinal absorption of calcium 
is modulated by circulating 1,25 (OH^D^ levels (116), which in turn, 
are determined mainly by the circulating levels of PTH (157). The 
body's main reserves of calcium are in bone however, and long-term 
changes in calcium balance in the adult are usually due to alterations 
in skeletal remodelling which result from the combined effects of PTH 
and 1,25 (OH) 2 D^ on bone forming (158,159,160) and bone resorbing cells 
(80,112)
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In man, about 50% of the calcium in serum is in the ionised form, 
a further 1 0 % is ultrafilterable but ligand-bound and the remaining 
40% protein bound (153). Since the ionised fraction of serum calcium 
is that which is biologically active (15 3,151,162) and under 
homeostatic control (153,164), hypercalcaemia may be defined to exist 
when there is an elevation in ionised calcium levels. Over 90% of the 
protein-bound calcium is bound to albumin (165) by mechanisms which 
are affected by pH (166). Accordingly plasma or serum ionised calcium 
measurements may not correspond with measurements of total calcium 
values in dysalbuminaemic states or where there is a significant 
disturbance in acid-base status (153). Nonetheless, several nomograms 
have been devised to "correct" for differences in albumin binding so 
that it is possible to obtain a "derived" calcium figure from total 
serum calcium and albumin measurements which approximates to the 
measured ionised calcium value, provided that there are no major 
disturbances in acid-base status (153,161,167).
In figure 1.2, the principal elements of calcium homeostasis are 
shown schematically in a normal individual with a steady state of zero 
external calcium balance. Although the actual quantities of calcium 
exchanged at each site are approximate, the figure serves to 
illustrate that hypercalcaemia may potentially arise when alterations 
in calcium flux occur at any one of the three regulatory sites in bone 
kidney or intestine.
Traditionally, most attention has been paid to factors which 
increase the amount of calcium released from bone in the pathogenesis 
of malignancy-associated hypercalcaemia (5). However, Parfitt has 
estimated that, given the normal characteristics of tubular calcium
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FIGURE 1.2
Schematic representation of calcium homeostasis in a normal adult. 
Note that a state of zero net balance is maintained by homeostatic 
mechanisms despite large daily fluxes of calcium at regulatory sites 
in bone, kidney and intestine. Numbers refer to daily exchanges in 
mmol.
reabsorption (114) and normal renal glomerular function, 5mmol of 
calcium would need to be released from bone to account for each 
O.lmmol/1 rise in serum calcium. Since actual measurements of calcium 
balance in normal individuals give values of between l-2 mmol/day 
(168,169), it would be anticipated that a 15-30 fold increase in net 
bone resorption would be required to raise serum total calcium from 
2.50mmol/l to a modestly elevated level of 3.10mmol/l. Relatively few 
detailed studies of calcium balance have been carried out in patients 
with malignant disease. However, Laszlo has estimated that, in 
patients with metastatic bone disease associated with breast carcinoma 
and myeloma the negative calcium balance varies between 2 -1 0 mmol/day 
in normocalcaemic patients to between 5 and 15mmol/day in 
hypercalcaemic subjects (23,170). From the data in normal individuals 
cited above (168,169), negative calcium balances of this magnitude can 
be calculated to represent a net increase in bone resorption of 
between 2-15 fold at most. In the presence of normal renal function, 
such increases in bone resorption would not be expected to cause 
substantial hypercalcaemia. This is exemplified by the fact that in 
most benign disorders associated with incr.eased bone resorption, 
hypercalcaemia is rare because of the efficient renal homeostatic 
mechanism (4,153).
In malignant disease however, further mechanisms are invoked to 
explain the development of hypercalcaemia on the basis of a "bone- 
resorptive" mechanism. Histological evidence has suggested that in 
HHM, there is "uncoupling" of bone resorption and bone formation 
leading to a net loss of skeletal calcium far greater than that 
observed in benign conditions where bone resorption is increased 
(139). Patients with cancer are also prone to impairment of renal
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function because of dehydration, which may develop as the result of 
nausea, vomiting and anorexia associated with the tumour itself, with 
a central effect of hypercalcaemia or with chemotherapy and 
radiotherapy (5). Since the kidney plays a central role in 
elimination of excess calcium from the ECF, impairment of renal 
glomerular function (GFR) critically impairs the ability to respond to 
a calcium load (4,153)
In hypercalcaemia of malignancy the following scheme has been 
proposed (171); a point is reached where, due to a combination of mild 
dehydration and increased bone resorption, release of calcium from 
bone exceeds renal calcium excretion thus causing serum calcium to 
rise. The resultant hypercalcaemia brings homeostatic mechanisms into 
play which tend to restore calcium levels toward normal; PTH secretion 
is suppressed and as a result, renal tubular calcium reabsorption 
falls (114) and efflux of skeletal calcium at quiescent bone surfaces 
is reduced (156). In addition, synthesis of l,25(OH)2D3 is suppressed 
resulting in reduced intestinal absorption of calcium (155). If these 
homeostatic mechanisms are inadequate however, hypercalcaemia becomes 
established with deleterious effects on renal function. Severe 
hypercalcaemia is associated with a direct reduction in renal blood 
flow and GFR (171,172). Tubular abnormalities also occur, leading to 
inappropriate losses of sodium chloride (172,173), water (173), 
potassium (171) and a metabolic alkalosis (174). When these renal 
tubular defects are combined with decreased fluid intake as the result 
of nausea, vomiting and anorexia, sodium depletion and dehydration 
become increasingly severe (175). There then ensues a deteriorating 
spiral of worsening hypercalcaemia due to increased sodium-linked 
reabsorption of calcium in the proximal renal tubule (176) and
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impairment of GFR (172). Ultimately this sequence of events 
culminates in hypercalcaemic crisis and death.
Parfitt (4) has drawn attention to the important differences 
which exist between the stable type of hypercalcaemia generally 
associated with primary hyperparathyroidism, and the unstable 
hypercalcaemia described above, which is traditionally associated with 
malignant disease. In primary hyperparathyroidism hypercalcaemia is 
largely mediated by increased renal tubular calcium reabsorption which 
may or may not be accompanied by an increase in net bone resorption. 
Accordingly, most patients with primary hyperparathyroidism have a 
steady-state type of hypercalcaemia which changes little with time due 
to a raised "set-point" for control of serum calcium as the result of 
an elevated renal tubular threshold for calcium reabsorption (4,114). 
In contrast, renal tubular calcium reabsorption is generally 
considered to be depressed in cancer-associated hypercalcaemia 
provided that dehydration and sodium depletion are not present 
(4,5,93,147,148). In this situation, hypercalcaemia cannot be due to 
a stable elevation in the renal tubular calcium threshold by 
definition. Accordingly, it is currently considered that when 
established, the hypercalcaemia associated, with malignancy always 
progresses due to the positive feedback system described above
(4,5).
Another difference between the hypercalcaemia of malignancy and 
primary hyperparathyroidism deserves further emphasis. In primary 
hyperparathyroidism, intestinal calcium absorption is enhanced as the 
result of increased l,25(OH)2D3 synthesis (115,116,157). Indeed, 
patients with mild primary hyperparathyroidism may only exhibit
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hypercalcaemia after provocative testing with an oral calcium load
(177). In malignant disease however, intestinal calcium absorption 
has been found to be depressed (8 6 ) , which corresponds with the 
finding of low l,25(OH)2D3 levels in hypercalcaemic cancer patients 
(93) .
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1.4 CLINICAL FEATURES OF CANCER-ASSOCIATED HYPERCALCAEMIA
Cancer-associated hypercalcaemia is important to the clinician 
for two reasons: it is a common condition, second only to primary 
hyperparathyroidism as a cause of hypercalcaemia in the general 
community (178). In hospitalised patients, cancer is the commonest 
cause of hypercalcaemia (179). Although it has been estimated that 
about 10% of all cancer patients develop hypercalcaemia (175) the 
proportion of patients developing hypercalcaemia varies markedly in 
different tumour types (5). For example, squamous carcinoma of the 
lung, renal carcinoma, breast carcinoma and myeloma are common causes 
of hypercalcaemia In contrast, small-cell lung carcinoma, and 
adenocarcinoma of colon, although common tumours, are rare causes of 
hypercalcaemia (5,179,180,181). These difference in the incidence of 
hypercalcaemia are not wholly related to the pattern of metastatic 
bone involvement; although bone metastases are a prominent feature of 
hypercalcaemic patients with myeloma and breast carcinoma, such 
metastases are also common in normocalcaemic patients with small-cell 
lung carcinoma. Accordingly, it is probable that the differences in 
prevalence of hypercalcaemia between different tumour types relates to 
other factors such as the release of calcium-elevating humoral 
substances by tumour tissue.
It is important for the clinician to recognise hypercalcaemia in 
patients with malignancy, principally because of its symptomatic 
effects. These were first noted by Collip in 1925 (110) , when he 
reported that dogs which were overdosed with parathyroid extract 
suffered from anorexia, obtundation, coma, asthaenia, hypotension, 
renal failure and ultimately, death. In man, mild elevations in serum
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calcium (<3.00mmol/l) may not be accompanied by obvious symptomatology
(178). However, the hypercalcaemia associated with malignancy is often 
symptomatic. Warwick (175), in a review of the clinical features 
associated with cancer-associated hypercalcaemia noted gastro­
intestinal symptoms such as nausea, anorexia, vomiting and 
constipation in 75% of cases. Disturbances of the central nervous 
system such as muscular weakness, confusion and obtundation were noted 
in 85%, thirst and polyuria in 1 1 %, and generalised malaise and 
fatigue in 5%. Similar findings have also been reported by Myers (10) 
and Fisken (179) although in the latter study, "non-specific" symptoms 
such as fatigue and malaise were predominant. A rather unusual 
feature which has been noted by a number of workers in cancer- 
associated hypercalcaemia is an apparent lowering of the pain 
threshold (5,10,175,179). With extreme elevations in serum calcium, 
cardiovascular effects such as hypotension and arrythmias may be 
observed, either as the result of the hypercalcaemia per se (182) , or 
in association with the electrolyte disturbances of acute renal 
failure (172). It is probable that these cardiac abnormalities are the 
immediate cause of death in untreated patients dying from 
hypercalcaemic crisis.
Many of the symptoms and signs of hypercalcaemia are non-specific 
and may easily be confused with the terminal features of malignant 
disease itself. However, these features are important to identify, as 
the may be reversed by appropriate antihypercalcaemic therapy (5). In 
malignant disease, antihypercalcaemic therapy is probably not given as 
often as it should be; in one study, less than 50% of patients with 
severe hypercalcaemia received specific therapy aimed at reducing 
serum calcium levels (183).
5 3
1.5 MANAGEMENT OF CANCER-ASSOCIATED HYPERCALCAEMIA
A variety of drugs and other theraputic manoeuvers have been used 
in the treatment of malignancy-associated hypercalcaemia. These are 
discussed below:
1.5.1 INORGANIC PHOSPHATE
This was probably the first effective treatment to be widely used 
in cancer-associated hypercalcaemia following Bulger's demonstration 
in 1920 that phosphate had a powerful calcium-lowering effect in 
primary hyperparathyroidism (184). The first large series of 
phosphate-treated cancer patients with hypercalcaemia was reported by 
Goldsmith in 1966 (185). In this study, intravenous and oral
phosphate were found both to be effective in lowering serum calcium 
concentrations and improving symptoms in patients with malignancy- 
associated hypercalcaemia due to a variety of malignant tumours. 
While similar beneficial effects were noted by other workers using 
phosphate therapy (186,187,188,189), problems also arose; a number of 
reports appeared in the literature documenting massive extraskeletal 
calcification, acute renal failure and hypotension in patients who had 
been given intravenous phosphate (190,191,192). Oral phosphate, 
although less likely to cause extraskeletal calcification (193), had 
other adverse effects including nausea, abdominal discomfort and 
diarrhoea which limited it's use in up to 40% of hypercalcaemic cancer 
patients (187,188,189). The mechanism by which intravenous phosphate 
lowers blood calcium has been studied in most detail by Herbert (194). 
There is an acute calcium-lowering effect which is operative within 
minutes of starting phosphate infusion, due to the precipitation of 
insoluble calcium - phosphate salts in bone and soft tissues. After
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phosphate infusion is stopped however, there is a delayed return of 
serum calcium to the pre-treatment level possibly as the result of a 
more sustained inhibition of osteoclastic bone resorption (195). The 
mechanisms by which oral phosphate lowers serum calcium in malignancy 
are less clear but are probably similar to those described above. A 
further potential mode of action of oral phosphate is inhibition of 
calcium absorption by the intestine (196). Although this may be 
relevant in hyperparathyroidism, it is probably of minor importance in 
cancer-associated hypercalcaemia as in the latter, intestinal calcium 
absorption is depressed (8 6 ).
1.5.2 SODIUM SULPHATE
Sodium sulphate infusions were employed in the clinical treatment 
of hypercalcaemia following Walser's experiments, which showed that 
sodium sulphate infusion caused marked hypercalciuria and 
hypocalcaemia in dogs (197). Although subsequent evidence indicates 
that this effect may, in part, have been due to a natriuresis (176) , 
the calciuric effect of sodium sulphate was 5-fold greater than that 
observed with a similar quantity of sodium chloride. Walser 
postulated that the greater effect of sodium sulphate was due to the 
formation of ultrafilterable, non-reabsorbable calcium sulphate 
complexes. Sulphate infusions were first employed in clinical 
practice by Kenny (198), in the treatment of a hypoparathyroid patient 
who had been accidentally overdosed with parathyroid extract. Lemann 
subsequently used sodium sulphate in the treatment of primary 
hyperparathyroidism (199). These and other studies in cancer- 
associated hypercalcaemia (186,188,200) , confirmed that sodium 
sulphate had potent calcium-lowering effects in man. Although most
workers found that sodium sulphate had a reliable calcium-lowering 
effect, problems were encountered in some cases because of 
hypernatraemia and sodium overload (200,201). Finally, the short 
duration of sodium sulphate's action and intravenous mode of 
administration render it impractical as an option for the long-term 
management of hypercalcaemia (186,188). Accordingly, in recent years, 
sodium sulphate treatment of hypercalcaemia has fallen out of general 
usage (189).
1.5.3 ETHYLENEDIAMINE TETRA ACETIC ACID (EDTA)
EDTA has the specific effect of chelating calcium in the blood - 
a process which directly decreases ionised calcium without affecting 
total calcium concentration. The EDTA-calcium complexes so formed are 
soluble and ultrafiltrable but are not reabsorbed by the renal tubules 
(202,203). These combined effects give EDTA potent hypocalcaemic and 
hypercalciuric effects. EDTA has two major drawbacks however; it's 
effects are transient (204), and with repeated doses, there is a 
substantial risk of severe renal damage (205,206). For these reasons 
EDTA. is seldom used now in the treatment of hypercalcaemia.
1.5.4 CORTICOSTEROIDS
Corticosteroids have been used for many years in the treatment of 
cancer-associated hypercalcaemia with variable results. In some 
studies they have been found to be highly effective (207,208), whereas 
in others they have been relatively ineffective (186,189,209,210). It 
is probable that some of the early reports of successful "responses" 
to corticosteroids were accounted for by simultaneous administration 
of intravenous fluids to steroid- treated patients (207,208).
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Accordingly in two recent studies, corticosteroids were strikingly 
inneffective in the treatment of cancer-associated hypercalcaemia when 
patients were adequately rehydrated to begin with (209,210). A 
beneficial response to steroids may be observed however, when the 
tumour itself is steroid sensitive such as is the case in 
lymphoreticular neoplasms and some patients with breast or prostatic 
carcinoma (211).
Glucocorticoids have been shown to inhibit bone resorption 
stimulated by OAF's released by myeloma and lymphosarcoma cell lines 
in vitro (46,212). Glucocorticoids have also been shown to inhibit 
bone resorption stimulated by a number of other substances in vitro 
such as prostaglandins, vitamin A, and dibutyryl cyclic AMP (213). 
However, the bone resorbing effects of PTH and the vitamin D 
metabolites are inhibited little, if at all, by corticosteroids 
(213). Certainly, in clinical practice, corticosteroids are not 
effective inhibitors of bone resorption in most patients with solid 
tumour hypercalcaemia (209,210).
An additional potential mode of action for glucocorticoids would 
be inhibition of intestinal calcium absorption (214). Indeed, this 
effect is though to explain the calcium- lowering response to 
corticosteroid treatment in hypercalcaemic patients with sarcoidosis 
and vitamin D intoxication (215,216,217). As stated previously 
however, intestinal calcium absorption is usually low in cancer- 
associated hypercalcaemia so rendering this action of minor 
importance.
1.5.5 MITHRAMYCIN
Mithramycin is a cytotoxic agent which has been used in 
the treatment of a variety of malignant tumours (218). A number of 
workers have drawn attention to its calcium-lowering effects 
(218,219,220) which appear to be due to inhibition of bone resorption 
(220,221,222), as the result of a cytotoxic effect on bone cells (5). 
Mithramycin, used in doses much lower than those employed for an 
antitumour effect is an effective treatment for cancer-associated 
hypercalcaemia (223,224,225). Mithramycin's major disadvantage is 
toxicity however; specific side-effects include a coagulopathy which 
may be due to thrombocytopenia, altered platelet function, a vascular 
defect, or reduced levels of clotting factors (226). Hepatic 
dysfunction, usually manifest by an elevation in serum transaminases 
is common although more serious and even fatal hepatic necrosis has 
been described (218,226). Renal dysfunction may also occur due to 
direct renal tubular and glomerular damage (227). Despite these 
adverse effects, it should be emphasised that, in the relatively small 
doses used to treat hypercalcaemia, mithramycin is usually free of 
troublesome toxicity. As safer alternatives are available however, 
some workers advise that mithramycin should only be given as a last 
resort in patients who have failed to respond to other measures (5). 
The converse is also true however; because of it's reliable and potent 
calcium-lowering effects, mithramycin is considered by many 
oncologists to be the drug of first choice in cancer-associated 
hypercalcaemia.
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1.5.6 CALCITONIN
Following the postulated existence of a parathyroid gland 
associated calcium-lowering factor by Copp in 1962 (228), Calcitonin
was shown by Me Intyre’s group to be of thyroidal origin (229,230), 
confirming the data of Hirsch (231). The mechanism by which 
calcitonin lowers blood calcium concentration was initially thought to 
depend on inhibition of osteoclastic bone resorption (232,233). 
Indeed, it is under conditions of most rapid bone turnover that 
calcitonin has its most potent calcium-lowering effects (234). In 
addition, however, calcitonin has powerful natriuretic and calciuric 
effects which probably contribute to it's efficacy in the treatment of 
hypercalcaemia (235,236).
Hitherto, calcitonin has been shown to be an effective treatment 
for h y p e r c a l c a e m i a  of v a r i o u s  a e t i o l o g i e s
(232.234.236.237.238.239.240.241.242). Advantages of calcitonin 
therapy include it's rapid onset of action and lack of serious 
toxicity. However, a significant proportion of patients with cancer- 
associated hypercalcaemia fail to respond favourably to calcitonin, 
for reasons unknown (236,241,242). In addition, the hypocalcaemic 
effect may "wear off" despite continued calcitonin administration
(237.238.242) due to "down-regulation" of calcitonin receptors in bone 
(243).
Studies on the effects of calcitonin on bone resorption in tissue 
culture suggest that glucocorticoids may prevent the "escape" from 
calcitonin's inhibitory effect (243). Binstock (244) made practical 
use of these observations by combining calcitonin and corticosteroids 
in the treatment of cancer-associated hypercalcaemia. Although this
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combination of drugs did seem to give better control of hypercalcaemia 
than either agent used alone, the effects of treatment were only 
studied for four days. Accordingly, the role of the calcitonin and 
corticosteroid combination in the long-term management of cancer- 
associated hypercalcaemia is, as yet, unexplored.
1.5.7 PROSTAGLANDIN SYNTHETASE INHIBITORS
The rationale for using these drugs in the management of 
hypercalcaemia in malignant disease lies in the fact that 
prostaglandins were considered by some workers to be of pathogenic 
importance in this syndrome (58,59,62,53,66). Although patients have 
been described in whom therapy with indomethacin or aspirin seemed to 
bring about a reduction in serum calcium values, most workers have 
been disappointed with the results of prostaglandin synthetase 
inhibitors in this situation (64,189,245). It is possible that these 
discrepancies could relate to failure to take account of the 
hypocalcaemic effect of concomitant rehydration in patients given 
these drugs, or the fluid-retaining and plasma-volume expanding 
properties of the drugs themselves (245).
1.5.8 DIPHOSPHONATES
The diphosphonates are a relatively new group of compounds which 
are synthetic analogues of pyrophosphate. Unlike pyrophosphate 
however, the diphosphonates are resistant to enzymatic hydrolysis in 
body fluids (247,248). The diphosphonates possess important effects 
on bone metabolism; they inhibit bone resorption (248,249) and bone 
mineralisation (247) , both in vitro and in vivo. However, their
relative potency with respect to these processes depends on the
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particular diphosphonate being studied. For example, Ethane-1,1- 
hydroxv-diphosphonate (EHDP), used at doses sufficient to inhibit bone 
resorption also has substantial inhibitory effects on bone 
mineralisation (250). On the other hand, 3-amino-l-hydroxypropylidene 
1,1-diphosphonate (APD) and dichloromethylene diphosphonate (C^MDP) 
have negligible effects on mineralisation at doses which effectively 
inhibit bone resorption in vivo (251,252).
In view of their potent inhibitory effects on bone resorption, 
the diphosphonates have been widely used in the treatment of cancer- 
associated hypercalcaemia. In a number of studies, all three 
diphosphonates currently available for clinical usage (EHDP, APD, 
Cl2 MDP) have been shown to be effective agents in the treatment of 
cancer-associated hypercalcaemia, when administered intravenously 
(253,254,255,256,257,258,259). Although Cl2MDP (253,260,261) and APD 
(258) are also effective when given orally, EHDP is not (189). The 
reasons for this are unclear but may be due to EHDP's poor 
gastrointestinal absorption, or its inhibitory effect on bone 
mineralisation (248,250), which by decreasing entry of calcium into 
bone, may theoretically lessen the calcium-lowering effect of 
inhibiting osteoclastic bone resorption (260).
The optimum dosage schedules and duration of action of the 
diphosphonates have yet to be determined in the treatment of cancer- 
associated hypercalcaemia. Athough the diphosphonates1 hold great 
promise because of their lack of obvious side effects and powerful 
effect on osteoclastic bone resorption, they appear to have a 
relatively slow onset of action (254,256) and in some cases, fail to 
return levels of serum calcium to normal (254,255,256,258,259,260).
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1.5.9 WR-2721
This is a recently-discovered compound which has been employed in 
oncological patients to protect normal tissues aganst the toxic 
effects of radiation and chemotherapy (262). During phase-1 clinical 
trials it was noted to cause transient hypocalcaemia in a proportion 
of patients. Subsequent studies by Glover demonstrated that these 
effects were partly due to inhibition of parathyroid hormone 
secretion (263). In clinical practice, WR-2721 has been used in the 
treatment of a hypercalcaemic patient with parathyroid carcinoma, 
where it lowered both serum calcium and parathyroid hormone levels 
(264).
The calcium-lowering effect of WR-2721 is not solely due to 
reduction of circulating PTH levels however; Glover estimated that a 
marked reduction in renal tubular reabsorption of calcium accounted 
for between 50%-60% of the fall in serum calcium after administration 
of WR-2721 (263). In accordance with these findings,Hirshel-Scholz has 
recently demonstrated that in rats, WR-2721 has an inhibitory effect 
on the renal tubular reabsorption of calcium, both in thyro- 
parathyroidectomised and intact animals (265). Although this drug may 
prove to be of value in the treatment of cancer-associated 
hypercalcaemia in humans, no systematic studies on the effects of this 
agent have yet been carried out.
1.5.10 INTRAVENOUS FLUIDS
Patients with severe hypercalcaemia of any aetiology are often 
profoundly dehydrated for the reasons discussed previously 
(171,172,173). Accordingly, rehydration has long been established as
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an important part of routine management in patients with 
hypercalcaemia (5).
The most appropriate intravenous fluid for rehydration in these 
circumstances is isotonic (0.9%) sodium chloride solution (saline) 
although in some cases , hypotonic saline (0.45%) may have to be 
employed in patients who are hypernatraemic because of impaired 
urinary concentrating ability (173). The main reason for using 
sodium-containing intravenous fluids lies in the fact that the renal 
tubular handling of calcium and sodium are closely related. 
Accordingly, measures that promote a sodium diuresis also tend to 
promote a calcium diuresis (176,266,267).
Detailed studies of the effects of rehydration in cancer- 
associated hypercalcaemia have been carried out by Hosking (147), who 
estimated that in these circumstances, there was an initial sodium 
deficit of about 500mmol - equivalent to approximately 4 litres of 
isotonic saline solution. On replacing this fluid deficit, with 4-S 
litres of saline over 24-48 hours, Hosking noted a mean decrement of 
0.40mmol/l in serum calcium - comparable to that observed in response 
to the administration of many pharmacological agents.
Two mechanisms were invoked to explain the calcium-lowering 
effect; firstly, there was an improvement in renal glomerular 
function, as manifest by a fall in serum creatinine values; secondly, 
there was a reduction in renal tubular reabsorption of calcium. 
Indeed, it was noted that many patients showed a modest increase in 
renal tubular calcium reabsorption prior to rehydration which fell 
after sodium repletion. This response was considered to be consistent 
with correction of a sodium-linked elevation in proximal renal tubular
6 3
calcium reabsorption (172,176,268).
Subsequent studies by Sleeboom (259) yielded similar results 
although the mean fall in serum calcium after saline repletion was 
rather less impressive than that noted by Hosking (0.15mmol/l vs 
0.60mmol/l). This difference was probably due to the fact that lesser 
quantities of saline (3 litres/24hours) were used in Sleeboom's 
studies. In agreement with the findings of Hosking however, Sleeboom 
emphasised that, while saline repletion often improved the general 
condition of patients, additional drug therapy was usually necessary 
in the treatment of cancer-associated hypercalcaemia (5,147).
1 - 5 * 1 1  LOOP DIURETICS: FORCED SALINE DIURESIS
This method of treatment was pioneered by Suki (269), who studied 
the effects of large doses of intravenous frusemide (lOOmg every 2 
hours) in combination with a large intravenous fluid load (1 0 - 2 0  
litres daily) , in the treatment of severe hypercalcaemia due to 
malignancy and primary hyperparathyroidism. While substantial falls 
in serum calcium resulted, this regime has fallen out of favour with 
clinicians' since it requires the facilities of an intensive care 
unit. Moreover, even with close monitoring, this procedure carries 
the risk of serious electrolyte disturbances (notably hypokalaemia and 
hypomagnesaemia) and haemodynamic problems. There is no indication 
for the use of loop diuretics alone in the treatment of 
hypercalcaemia; in the absence of a continued "throughput" of renal 
sodium excretion stimulated by intravenous fluids, diuretics would 
tend to make hypercalcaemia worse by causing dehydration (270).
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1.5.12 DIALYSIS
Both haemodialysis and peritoneal dialysis are effective methods 
of transiently reducing serum calcium levels in patients with severe 
hypercalcaemia (271,272). In the setting of cancer-associated 
hypercalcaemia however, dialysis should be regarded as a short term 
measure to buy time for patients with hypercalcaemia and renal failure 
where other treatments are inneffective and specific antitumour 
therapy is available.
1 - 5 - 1 3  ANTITUMOUR THERAPY
This is considered to be the only effective means of controlling 
cancer-associated hypercalcaemia in the long-term (5,273), although 
in point of fact, no detailed studies of have been carried out on the 
precise effects of chemotherapy or radiotherapy in malignancy 
associated hypercalcaemia. It has been established that surgical 
removal of tumours associated with hypercalcaemia causes serum calcium 
values to fall to normal (8,9,138,142,274).
1.5.14 SUMMARY
There have been few substantial comparative studies on the 
relative efficacy of agents used in the treatment of cancer-associated 
hypercalcaemia. Certainly, none of those agents listed above combine 
the desirable qualities of a consistent hypocalcaemic response, rapid 
of action and lack of toxicity. On the basis of current evidence 
however, intravenous phosphate or calcitonin may be the treatments of 
choice when a rapid effect is desired. For a consistent and more 
sustained effect, either mithramycin or one of the diphosphonates 
would seem to be indicated. In all cases, rehydration with
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intravenous fluids should form part of the initial management 
although, as stated above, treatment with fluids alone would not be 
expected to give long-term control of hypercalcaemia in this 
situation. In the long term, effective antitumour therapy is 
necessary for a sustained reduction in serum calcium values. Failing 
this, options for control of hypercalcaemia include; repeated 
administration of one of the diphosphonates, intermittent infusions of 
mithramycin, continuous therapy with combined corticosteroids and 
calcitonin or, if tolerated, continuous oral phosphate therapy.
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CHAPTER 2 
TECHNICAL METHODS
2.1 BIOCHEMICAL TECHNICAL METHODS
2.1.1 ROUTINE BIOCHEMICAL ANALYSES
Calcium, phosphate, creatinine, albumin, bilirubin, 
transaminases, and electrolytes were measured using a standard 
,autoanalyser (Technicon). Serum total calcium was in all cases 
"adjusted" for albumin concentration using the algorithm: 
CalciumAdjusted) _ m e a s u r e 3  calcium(total) +/- [ 4 7 - measured albumin 
(g/1) x 0.019]. This method has been shown to correlate well with 
measured ionised calcium values in previous studies (167).
2.1.2 PARATHYROID HORMONE
Immunoreactive Parathyroid hormone (iPTH) was measured in plasma 
by a double antibody radio-immunoassay which employs bovine PTH (bPTH) 
for standards (iMRC 71/324) and radioiodination (MRC 76/568), and a 
guinea pig anti-bPTH antiserum (Wellcome AS 211/32), which recognises 
both amino- and carboxyl- terminals of the PTH molecule. The mean 
between assay coefficient of variation (cv) was 7% and the normal 
range in our laboratory was from the limit of detection (typically 
150ng/l) to 600ng/l.
2.1.3 CALCITONIN
Calcitonin (iCT) was measured in plasma by a double antibody 
radioimmunoassay which employs a human synthetic calcitonin monomer 
for radioiodination and standards (MRC 70/234). A rabbit anti-human 
calcitonin serum (MRC 77/660) recognises the carboxyl-terminal of the 
calcitonin molecule. The mean between assay cv was 7% and the normal 
range was from the limit of detection (typically 10ng/l) to 45ng/l.
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2.1.4 VITAMIN D METABOLITES
25-Hyaroxyvitamin D (25(OH)D) was measured using a modification 
of the method described by Preece et al (275) , in which extracts of 
serum are chromatographed on silicic acid and the vitamin D 
metabolite is quantitated using human serum as the binding protein and 
charcoal separation. This method measures the sum total of serum 25- 
Hydroxy-ergocalciferol (25(OH)D2) and 25-Hydroxy-cholecalciferol 
(25(OH)D3) concentrations. The mean between assay cv was 10% and the 
normal range for our laboratory was 15-100 nmol/1. The sensitivity of 
the assay was typically 5nmol/l.
1,25 dihydroxyvitamin D (1,25 (OH) 2 D) was measured by a method 
essentially similar to that described by Reinhardt et al (276) with 
the exception that, in our laboratory, a high performance liquid 
chromatography (HPLC) step is retained in the purification of serum 
samples, prior to the protein binding assay. Foetal calf thymus was 
used as the binding protein, prepared in a manner similar to that 
described by Reinhardt et al (276)
In some patients with malignant disease where serum 
concentrations of 1,25 (OH) 2 D were detectable or raised, further 
experiments were carried out to characterise the material recognised 
as 1,25 (OH^D in the routine assay: in all cases, the putative
1,25(OH) 2 D co-chromatographed in an identical fashion to authentic 
tritium-labelled l,25(OH)2D3 (Amersham International pic), during HPLC 
on a silica and reverse phase column, and displaced the radioactive 
ligand from the specific receptor protein in a parallel fashion in the 
competitive protein binding assay. Repeat analyses of serum from the 
same patients yielded similar results.
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The mean between assay cv for the 1,25 (OH) 2 D^ assay was 20% 
and the reference range lay between 20-100pmol/l. The sensitivity of 
the assay was typically 15pmol/l.
2.1.5 CYCLIC ADENOSINE 3 1 5 1 MONOPHOSPHATE
In one study (Chapter 6.1), cyclic adenosine 3' 5' monophosphate 
(cAMP) was measured, after appropriate dilution in plasma and urine 
samples using a radioimmunoassay kit obtained from RIA (UK) Ltd. 
The nephrogenous component of urinary cyclic AMP excretion (NcAMP) was 
derived using the following equation: NcAMP = urine cAMP divided by
urine creatinine, multiplied by serum creatinine, minus plasma cAMP. 
(all values in nmol/1). The mean between assay cv was 10% and the 
reference range lay between 10-35 nmol/1 of glomerular filtrate.
In all other studies, urine cAMP was measured, after appropriate 
dilution using a radioimmunoassay technique as described by O'Reilly 
et al (277). In these studies, cyclic AMP excretion was expressed as 
a molar ratio, relative to urinary creatinine (UcAMP). The reference 
range for UcAMP was 0.10-0.65 nmol/mmol creatinine. Between assay cv 
was less than 1 0 % over the working range and the limit of detection 
2 .6 nmol/l.
2.1.6 HYDROXYPROLINE
Hydroxyproline was measured in true fasting urine specimens using 
a colorimetric technique similar to that described by Goverde et al
(278) using a kit (Organon Diagnostics Ltd). The mean between assay cv 
was 8 % and the typical sensitivity was 50pmol/l. Urinary 
hydroxyproline was expressed as a molar ratio, relative to urinary 
creatinine concentration (OHP/Cr). In the fasting state, OHP/Cr ratio
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is thought to be an index of total bone resorptive activity (153). The 
reference range for OHP/Cr in our laboratory lay between 5-30 
pmol/mmol creatinine.
2.1.7 RENAL TUBULAR REABSORPTION OF PHOSPHATE
The notional threshold for renal tubular reabsorption of 
phosphate (TrnPO^ ) was determined from fasting serum and urinary 
measurements using a nomogram (268). The normal range lay between 
0.80-1.40 mmol/1 of glomerular filtrate.
2.1.8 URINARY CALCIUM EXCRETION
Urinary excretion of calcium was expressed as a molar ratio 
relative to urinary creatinine (Ca/Cr; mmol/mmol; reference range less 
than 0.35). In the fasting state, Ca/Cr ratio is thought to be an 
index of net bone resorption (153). Calcium excretion was also 
expressed as a function of glomerular filtration rate (Ca£) , derived 
from the molar ratio multiplied by the serum creatinine concentration 
(CaE pmol/1 Glomerular filtrate; reference range for normocalcaemic 
subjects less than 50) , and as the ratio of calcium clearance to 
creatinine clearance, derived from the CaE divided by the serum 
calcium concentration (Cl(-.a/ClCr)
Renal tubular reabsorption of calcium was assessed by comparing 
individual serum adjusted calcium and urinary Ca£ points with the 
normal~range obtained by calcium infusion studies in healthy subjects 
(114) (Figure 2.1). The extent to which increased renal tubular 
reabsorption of calcium, increased calcium "throughput" and reduced 
glomerular filtration rate contributed to hypercalcaemia were 
calculated by a graphical method in which the serum and urinary
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FIGURE 2.1
Relationship between urinary calcium excretion (expressed as pmol per 
litre of glomerular filtrate (CaE)) and serum calcium. The dotted 
lines indicates 2 standard deviations from the mean values obtained by 
Peacock et al in normal subjects during calcium infusions (114). 
Points in patients with primary hyperparathyroidism fall to the right 
of the expected normal, indicating that renal tubular calcium 
reabsorption is increased. Conversely, points in patients with 
hypoparathyroidism fall to the left of normal indicating decreased 
renal tubular reabsorption of calcium.
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FIGURE 2.2
Diagram to illustrate method of analysing hypercalcaemia (from 
reference 279). The solid line indicates the mean of values obtained 
by calcium infusion studies in normal subjects (114). Lateral 
deviations from the curvilinear relation between serum calcium and 
urinary excretion of calcium (Ca£) are attributable to changes in 
renal tubular reabsorption of calcium. The increment in serum calcium 
due to increased renal tubular reabsorption in patient X is equivalent 
to the distance between points x and y. In patients with impaired 
glomerular function, the contribution of renal glomerular failure is 
obtained by multiplying the observed fasting urinary Ca/Cr value by a 
theoretically "normal" creatinine level of 80pmol/l. The horizontal 
distance between the observed CaE and the calculated CaE with serum 
creatinine 80pmol/l is measured as y-z on the figure. Any residual 
increment (z-u) in serum calcium compared with a control subject (u) 
with serum calcium 2.50mmol/l is then attributed to increased calcium 
"flow" from bone resorption.
calcium points in any given case are compared with the mean values 
obtained by calcium infusion studies in healthy subjects (279) (Figure 
2.2). The notional renal tubular threshold for calcium reabsorption 
(TmCa/GFR) was used as an index of renal tubular calcium reabsorption 
in one study (Chapter 4.3). TmCa/GFR was calculated using a nomogram
(279).
2.1.9 URINARY SODIUM EXCRETION
Urinary sodium excretion was expressed in two ways; as a function 
of glomerular filtration rate by multiplying the ratio of urinary 
sodium to urinary creatinine by serum creatinine (all values in 
mmol/1) , to give Na£ mmol/1 glomerular filtrate; reference range in 
healthy normocalcaemic subjects 0.10-1.30mmol/l GF. Secondly, as the 
ratio of sodium excretion to creatinine excretion, obtained by 
dividing the NaE value by serum sodium concentration (ClNa/ClCr)'
2.2 BONE HISTOMORPHOMETRY
Except where otherwise stated, histomorphometry was performed on 
bone samples obtained under local anaesthesia from the iliac crest 
using a trephine biopsy needle (8 mm diameter). All bone samples were 
processed and embedded undecalcified in methyl methacrylate as 
described by Boyce et al (280). Bone resorption and formation were 
assessed using a Zeiss II integrating eyepiece by line-intersect 
measurements. In all cases histomorphometry was assessed by one 
observer (S.H.Ralston) and the results were checked by a further 
observer (Dr B.F.Boyce) who was unaware of the individual patient- 
details.
A number of relevant bone-histomorphometric variables were
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derived from line intersect measurements. These were; total osteoid
surface (TOS; reference range <24%), active osteoid surface (AOS;
reference range <2%), absolute osteoid volume (AOV; reference range
<2.4%), total resorption surface (TRS; reference range <7.3%), active
resorption surface (ARS; reference range <2.4%) and number of
2
osteoclasts per mm (NO; reference range <0.28)
2.3 RADIONUCLIDE BONE SCANS
Radionuclide bone scans were performed using standard techniques, 
three hours after the intravenous injection of 530 Megabequerels of 
99mTc labelled methylene diphosphonate.
EXPERIMENTAL WORK
CHAPTER 3
ROLE OF METASTATIC BONE DISEASE IN THE 
PATHOGENESIS OF HYPERCALCAEMIA ASSOCIATED WITH MALIGNANCY
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3.1 RELATION BETWEEN SERUM CALCIUM VALUES AND EXTENT
OF METASTATIC BONE DISEASE IN CANCER PATIENTS
3.1.1 INTRODUCTION
Humoral factors released by tumour tissue are thought to play a 
role in the pathogenesis of hypercalcaemia in some patients with 
malignancy (7). However, direct involvement of the skeleton by 
metastases is generally considered to be the commonest cause of such 
hypercalcaemia (1,5,10). Although hypercalcaemia and bone metastases 
commonly coexist (1,2,3,5,10), there is little direct evidence to 
suggest that such bone lesions are the cause of hypercalcaemia. In 
this study the relation between serum calcium values and metastatic 
bone disease was examined in 195 patients with malignant disease, 
using the radionuclide bone scan as a means of assessment.
3.1.2 PATIENTS AND METHODS
Bone scan reports were scrutinised in 725 patients with malignant 
disease who attended the nuclear medicine department of Glasgow Royal 
Infirmary for bone scan examination between January 1980-January 1982. 
The reports fell into three groups: (1) No evidence of skeletal
metastases (n=385 - negative scan). (2) Abnormalities thought to be 
diagnostic of metastatic bone disease (n=181 - positive scan).
(3) Abnormalities of uncertain significance (n=159 - non-diagnostic 
scan). Biochemical records were traced in the above population and 
those with hypercalcaemia were identified (n=87) . Hypercalcaemic 
patients plus normocalcaemic patients with positive bone scans were 
submitted to further study. In the resultant 216 patients, case notes 
were obtained and clinical data were extracted. A number of patients
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FIGURE 3.1
Photograph of a bone scan showing an example of a light skeletal 
tumour load in a hypercalcaemic patient with squamous carcinoma of 
bronchus. Metastatic lesions are evident as "hot spots" (arrowed) in 
the lumbar and cervical spine. Increased uptake in the hands is due to 
degenerative joint disease.
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FIGURE 3.2
Photograph of bone scan showing an example of a heavy skeletal tumour 
load in a normocalcaemic patient with breast carcinoma. Multiple "hot 
spots" are seen throughout the skeleton.
were excluded because of incomplete biochemical or clinical data, 
leaving a final study population of 195.
In the final study group of 195 patients, bone scans were 
reviewed by an experienced observer who was unaware of the 
individual patient details (Dr I Fogelman). In the 160 cases where 
the scan was considered to be diagnostic of metastatic bone disease a 
subdivision into "light tumour load" and "heavy tumour load" 
categories was made. These corresponded to 6 or less (figure 3.1) and 
more than 6 (figure 3.2) identifiable lesions respectively. In all 
cases serum calcium had been measured within 14 days of the bone scan. 
Hypercalcaemia was defined as an adjusted serum calcium of greater 
than 2.70 mmol/1. In the event of hypercalcaemia, the adjusted serum 
calcium used in analysis was that measured before the administration 
of specific antihypercalcaemic therapy. The statistical method used 
was the Mann-Whitney "U" test for unpaired samples.
3.1.3 RESULTS
Serum Calcium Values in Patients with Metastatic Bone Disease
Bronchial and breast carcinoma were the most common- tumours in 
this group (Table 3.1). In figure 3.3, the distribution of serum 
calcium values is shown on division of patients into "light tumour 
load" and "heavy tumour load" categories. Significant hypercalcaemia 
(>2.70 mmol/1 ) occurred in 32.5% of patients with bone-scan evidence 
of skeletal metastases, 16.9% having a light skeletal tumour load and 
15.6% a heavy skeletal tumour load. Serum calcium values were 
significantly higher in patients with a light skeletal tumour load
(p<0.001).
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TABLE 3.1
TOCGR TYPE IN 160 PATIENTS W33H METASTATIC BCNE DISEASE
TUMOUR TYPE NUMBER (%)
BRONCHUS 76 (47.5)
BREAST 50 (31.2)
PROSTATE 11 (6.8)
MYELOMA 5 (3.1)
ANAPLASTIC 5 (3.1)
BLADDER 4 (2.5)
CERVIX 2 (1.0)
BOWEL 2 (1.0)
THYROID 1 (0.5)
LARYNX 1 (0.5)
CARCINOID 1 (0.5)
CHRONIC LYMPHATIC LEUKAEMIA 1 (0.5)
LYMPHOMA ,  1 (0.5)
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malignancy. Horizontal line indicates mean.
Skeletal Tumour Load in Patients with Hypercalcaemia
In this group, breast and bronchial carcinoma were again 
predominant (figure 3.4). A relatively high proportion of 
hypercalcaemic patients with breast carcinoma had a heavy skeletal 
tumour load (47%). In contrast, few patients with bronchial carcinoma 
and hypercalcaemia had extensive skeletal involvement (2 1 %). 
Hypercalcaemic patients with other malignancies were distributed 
evenly among the three bone-scan categories. In the hypercalcaemic 
group as a whole, 40% had a normal bone scan and mean serum calcium 
values varied inversely with the extent of skeletal involvement, being 
highest in the normal bone scan group and lowest in the heavy tumour 
load group (figure 3.4). These differences were not statistically 
significant however.
3.1.4 DISCUSSION
It has been considered that the occurrence of hypercalcaemia in 
malignancy can usually be explained on the basis of local release of 
skeletal calcium by invading tumour metastases (1,2,3,5,7,10). 
However, a causal relationship between these factors has not been 
proven, and indeed, evaluation of the extent of metastatic bone 
disease has hitherto been made difficult by the relative insensitivity 
of radiological methods used for the detection of skeletal metastases 
(26,27). Discrepancies between severity of hypercalcaemia and extent 
of metastastic bonedisease are frequently apparent in clinical 
practice but have generally been explained on the basis of occult 
skeletal metastases undetected by standard radiological techniques 
(7,26).
In recent years, radioisotope scanning with 99m technetium
78
diphosphonate has emerged as an important means of skeletal imaging. 
The bone scan, which reflects skeletal metabolic activity is an 
extremely sensitive means of detecting skeletal metastases and is 
recognised to be superior to conventional radiology in this respect 
(281). While a false negative bone scan in malignancy may occur 
when there is a dissociation of bone formation from bone resorption, 
this situation is at present recognised to occur commonly only in 
myeloma (281). Of the 5 patients with myeloma in the present series, 
all had positive bone scans.
In this study, the bone scan was used to assess the relation 
between metastastic bone disease and the development of hypercalcaemia 
in malignancy. In 87 hypercalcaemic patients, no positive correlation 
was found between the presence or extent of metastatic bone disease 
and serum calcium values, suggesting that in this group, an elevated 
serum calcium cannot simply be explained on the basis of local 
skeletal destruction by metastatic deposits. Among all 725 patients 
who had bone scans, however, hypercalcaemia occurred in a higher 
proportion of those with a positive scan than a negative one. This 
probably reflects the fact that patients with metastatic bone disease 
have, in general, more advanced malignancies than their counterparts 
with an uninvolved skeleton, a large proportion of whom are patients 
with small tumours or carcinomas-in-situ, in whom a bone scan has been 
requested as as screening procedure prior to curative resection of a 
primary tumour. It is therefore possible that the higher prevalence 
of hypercalcaemia in the positive bone scan group reflects a greater 
total-body tumour load, increased tumour aggressiveness, or other 
factors as yet uncharacterised, rather than a direct consequence of 
calcium release from local areas of bone destruction. Accordingly, in
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160 patients with bone scan evidence of metastatic disease involving 
the skeleton, there was no positive correlation between serum calcium 
values and extent of metastatic bone disease.
A humoral aetiology of hypercalcaemia accompanying malignant 
disease has been thought to be uncommon (1,5,10,183), and has usually 
been invoked only when evidence for skeletal metastases was lacking 
(7). Conversely, the demonstration of skeletal metastases has 
conventionally been thought to provide reason enough for 
hypercalcaemia by causing local bone destruction invoking an 
additional humoral component (5,7,10,90).
This study has shown that, in hypercalcaemic patients, there is 
no positive correlation between the occurrence or extent of metastatic 
bone disease and serum calcium values in malignancy. Further, in 
patients with metastatic involvement of the skeleton, serum calcium 
values were inversely related to the extent of skeletal involvement by 
tumour. These data suggest that the development of hypercalcaemia in 
malignancy may frequently be mediated by an alternative mechanism, 
such 2 s ths production of humors.! suhst3.ncss hy tumour tissus^ 
effects on calcium metabolism at sites or organs distant from local 
areas of tumour involvement.
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3.2 RELATION BETWEEN EXTENT OF METASTASTIC BONE DISEASE AND BIOCHEMICAL
INDICES OF BONE RESORPTION IN HYPERCALCAEMIA OF MALIGNANCY
3.2.1 INTRODUCTION
In the previous retrospective study, no positive correlation was 
found to exist between the extent of metastatic bone disease and the 
presence or severity of hypercalcaemia in malignancy. In this study, a 
prospective analysis was made of the relationship between some other 
biochemical indices of bone resorption and the extent of metastatic 
bone disease in cancer patients.
3.2.2 PATIENTS AND METHODS
A group of 81 patients with proven malignant disease attending 
the nuclear medicine department of Glasgow Royal Infirmary for routine 
bone scans were studied. They comprised 27 patients with 
hypercalcaemia (adjusted calcium >2.70mmol/l) , who had presented 
consecutively over an 18~month period and 54 normocalcaemic patients 
presenting consecutively over three months. Seven patients with breast 
carcinoma had been treated with tamoxifen (3 -normocalcaemic, 4- 
hypercalcaemic) and three with prostatic carcinoma had received 
stilboestrol (1 -hypercalcaemic, 2 -normocalcaemic) for several months 
before the study. These drugs were not considered to have exerted a 
major influence on the variables assessed however, as four patients 
had developed hypercalcaemia while receiving them. Furthermore, 
biochemical measurements in the remaining six normocalcaemic sujects 
were not significantly different from those of their counterparts with 
similar bone scan appearances who had not received hormone treatment. 
No patient had received other anticancer chemotherapy,
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antihypercalcaemic agents (except fluid), or diuretics at the time of 
study. Patients with myeloma and other haematological malignancies 
were excluded.
Hypercalcaemic patients were rehydrated with a standard protocol 
of intravenous 0.9% sodium chloride solution, 3 litres daily given 
over a 48 hour period or until a daily urine output of more than 
2500ml was achieved. Biochemical assessment was then performed during 
the continued infusion of 0.9% sodium chloride solution 2 litres 
daily. Bone scans were assessed and divided into "normal", "light 
skeletal tumour load", "heavy skeletal tumour load", and "non 
diagnostic" categories as described in the previous study (Chapter 
3.1) .
Statistical methods used were the Mann-Whitney test for unpaired 
samples, the Wilcoxon test and Spearman's rank correlation coefficient.
3.2.3 RESULTS
Table 3.2 gives the relevant clinical and biochemical details of 
the patients studied. Patients with hypercalcaemia of malignancy had 
uniformly undetectable plasma levels of iPTH whereas in normocalcaemic 
patients, iPTH values varied from undetectable to levels which lay 
within the normal range. Serum creatinine concentrations were similar 
in normocalcaemic and hypercalcaemic subjects. Tumours were mostly 
breast carcinomas in normocalcaemic patients and squamous bronchial 
carcinoma in patients with hypercalcaemia.
In 6 normocalcaemic patients with a "non diagnostic" bone scan, 
biochemical values correlated most closely with those who had a 
negative scan. However, data from these patients and one other with
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FIGURE 3.7
Urinary hydroxyproline excretion in patients with malignancy, 
expressed as a molar ratio of hydroxyproline relative to creatinine 
(OHP/Cr). Dotted lines indicate normal range. Bars are medians 
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FIGURE 3.8
Renal tubular threshold for phosphate reabsorption (TmPO^ j) in mmol/1 
of glomerular filtrate (GF). Dotted lines indicate normal range. Bars 
are medians. Normal = No evidence of skeletal metastases, Light 
tumour load = 4 6  metastases, Heavy tumour load > 6 metastases.
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hypercalcaemia and a non diagnostic scan (who was later found to have 
no evidence of metastases at necropsy) were excluded from further 
study.
In the remaining 74 patients (figure 3.5), serum calcium values 
were related to extent of metastastic bone disease as judged by the 
bone scan appearance. There was no significant difference in serum 
calcium values when patients were divided by the extent of metastatic 
bone disease. In all subsequent analyses, patients were further 
subdivided on the basis of the adjusted serum calcium value into 
normocalcaemic (<2.70mmol/l) and hypercalcaemic (>2.70mmol/l) groups.
In figure 3.6, the relation between fasting urinary ratio of 
calcium to creatinine (Ca/Cr) is shown, in the hypercalcaemic and 
normocalcaemic groups. Urinary Ca/Cr values were significantly higher 
in the hypercalcaemic group for any given category of metastatic bone 
disease (p<0.001). Although Ca/Cr values tended to rise in 
normocalcaemic patients with increasing extent of metastatic disease, 
there was no statistically significant correlation between Ca/Cr 
values and extent of metastatic disease in either normocalcaemic or 
hypercalcaemic subjects.
Figure 3.7 gives a similar comparison between fasting urinary 
ratio of hydroxyproline to creatinine (OHP/Cr) and extent of 
metastatic disease seen in the bone scans. In normocalcaemic patients 
with bone metastases, OHP/Cr values were significantly raised when 
compared with the normal bone scan group (p<0.01). While median 
OHP/Cr values were lowest in those subjects with a normal bone scan 
and rose with the extent of metastatic bone disease, there was 
considerable overlap between the three bone scan categories. In
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hypercalcaemic patients, OHP/Cr values were significantly higher than 
in normocalcaemic patients for any given category of metastatic bone 
disease (p<0 .0 0 1 ) , and no positive correlation was observed between 
the extent of metastatic disease and OHP/Cr values, although the 
numbers were small in the group categorised as heavy tumour load. No 
positive correlation was observed in normocalcaemic patients between 
OHP/Cr values and serum calcium concentration (r=0.20;NS) or between 
OHP/Cr and Ca/Cr values (r=0.08;NS). In hypercalcaemic patients 
however, OHP/Cr and Ca/Cr values correlated significantly 
(r=0.42 ;p<0.05) , although OHP/Cr and serum calcium values did not 
(r=0.29;NS).
In normocalcaemic patients, the renal tubular threshold for 
phosphate reabsorption (TmPO^) lay within the normal range in most 
cases (figure 3.8). While values tended to rise progressively with the 
category of tumour load the differences were not statistically 
significant. In hypercalcaemic patients, TmPO^ values were 
significantly lower (pcO.OOl) but were similar in each of the three 
bane scan categories. In the study group as a whole, there were 
significant inverse correlations between TmPO^ and OHP/Cr values 
(r= -0.40 ;p<0.001) , TmP04 and Ca/Cr values (r= -0.46 ;P<0.001) and 
TmPO^ and serum calcium concentration (r= -0.56 ;p<0.001).
3.2.4 DISCUSSION
As in the previous retrospective study, (Chapter 3.1) no 
correlation was found in this study between the extent of metastatic 
bone disease and serum calcium values. Moreover, in normocalcaemic 
patients, both Ca/Cr and OHP/Cr values were much lower than in 
hypercalcaemic patients who had a similar extent of metastatic bone
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disease on the bone scan. In hypercalcaemic patients, Ca/Cr and OHP/Cr 
values were generally elevated, but to a similar level in the three 
bone scan groups. Since fasting urinary OHP/Cr and Ca/Cr are 
considered to reflect bone resorptive activity and net release of 
skeletal calcium respectively (153), these observations suggest that 
in many hypercalcaemic patients, bone resorption largely occurred on a 
systemic, humorally mediated basis, rather than as the result of focal 
bone destruction by metastastic lesions. Thus, although OHP/Cr and 
Ca/Cr values were raised in normocalcaemic patients with metastatic 
disease, they did not reach the order of magnitude associated with 
hypercalcaemia, even in patients with a heavy skeletal tumour load.
It has been previously suggested that a reduction in the renal 
threshold for phosphate reabsorption (TmPO^ ) is a useful biochemical 
marker for a humoral mechanism of hypercalcaemia in malignancy 
(6,7,93). In this study, TmPO^ values were noticeably depressed in 
most of the hypercalcaemic patients and in the study group as a whole, 
significant inverse correlations were observed between TmPO^ and 
OHP/Cr, Ca/Cr and serum calcium values, respectively. These 
observations support the concept that hypercalcaemia was caused by a 
single humoral mediator with effects both on bone and on the renal 
tubule.
In summary, this study has shown that biochemical indices of bone 
resorption in hypercalcaemic cancer patients were disproportionately 
increased, relative to the extent of metastatic disease seen in the 
bone scans. Furthermore, the renal threshold for phosphate 
reabsorption was significantly reduced in hypercalcaemic patients when 
compared with those who were normocalcaemic. This suggests that in 
many hypercalcaemic patients with metastatic bone disease, a humoral
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factor is released by tumour tissue which not only stimulates bone 
resorption on a systemic basis, but which also possesses a PTH-like 
effect on the renal tubular reabsorption of phosphate. The release of 
such a humoral factor could partially explain the occurrence of 
hypercalcaemia in patients with a limited extent of metastatic bone 
involvement where release of calcium from metastatic lesions alone 
would not be expected to cause hypercalcaemia on a theoretical basis. 
These data do not exclude the possibility that hypercalcaemia may 
arise as the result of extensive metastatic bone destruction alone in 
some circumstances. However, this mechanism appears to be less common 
in the present study population, where squamous carcinoma of the 
bronchus was the commonest tumour associated with hypercalcaemia.
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CHAPTER 4
ROLE OF THE KIDNEY IN THE PATHOGENESIS 
OF HYPERCALCAEMIA ASSOCIATED WITH MALIGNANCY
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4.1 RENAL TUBULAR REABSORPTION OF CALCIUM IN MALIGNANCY ASSOCIATED
HYPERCALCAEMIA: EVIDENCE FOR A NON-PARATHYROID HUMORAL AGENT
WITH AN EFFECT ON RENAL TUBULAR HANDLING OF CALCIUM
4.1.1 INTRODUCTION
Reference was made in chapter 3.2 to the importance of bone 
resorption in the pathogenesis of cancer-associated hypercalcaemia. 
Indeed, it has been considered that a "bone-resorptive" mechanism of 
hypercalcaemia prevails, both in patients with hypercalcaemia due to 
metastatic bone disease (2,3,5,7,10), and in patients who do not have 
metastatic bone lesions, due to the release of a systemically active 
bone-resorbing factor by tumour tissue (5 ,6 ,8 ,9 , 9  3,139,140,141,142). 
Nonetheless, normocalcaemia is maintained in many conditions 
associated with increased bone resorption, due to the large renal 
reserve for excretion of calcium (4).
An exception is primary hyperparathyroidism, but here, increased 
renal tubular reabsorption of calcium plays a major role in the 
pathogenesis of hypercalcaemia (114). In this study, the role of 
increased renal tubular rabsorption of calcium was assessed in the 
pathogenesis of hypercalcaemia associated with malignancy.
4.1.2 PATIENTS AND METHODS
Thirty one patients presenting consecutively to Glasgow Royal 
Infirmary with hypercalcaemia complicating solid malignant tumours 
were studied. A patient was selected for study on the basis that the 
clinician in charge had considered rehydration an appropriate form of 
management. At the time of study, no patient recieved diuretics, 
vitamin D analogues, or other medication known significantly to effect
calpium homeostasis. Patients were rehydrated with intravenous 
infusions of 0.9% saline, 3 litres daily for a minimum of 48 hours 
and/or until a daily urine output of more than 2500ml was achieved. 
After initial fluid repletion, hydration was maintained by the 
continued infusion of 0.9% saline 2 litres daily. At the time of 
study serum creatinine and urea concentrations had stabilised on 
consecutive days to within +/“ 1 0  pmol/ 1  and 2 mmol/ 1  respectively.
The presence and extent of metastatic bone disease was assessed by 
radionuclide bone scan examination, as described in chapter 3 .1 .
Results from patients with malignancy were compared with similar 
data in 19 patients with primary hyperparathyroidism and a control 
group of 1 2  normal subjects rendered acutely hypercalcaemic by calcium 
infusion, using the methods described by Peacock et al (282). Briefly, 
each calcium infusion study began with the collection of a timed 
fasting urine specimen with a mid-point blood sample. Infusion of 
calcium gluconate 1 0 % was then commenced with the aid of an infusion 
pump at the rate of about 10 mmol/hr. Consecutive timed urine samples 
were then collected over the next 4-6 hours and a blood sample was 
taken at the mid-point of each urine sample. In patients with 
malignancy and primary hyperparathyroidism biochemical analyses were 
made on blood and untimed true fasting urine samples.
Statistical methods used were linear regression analysis, and the 
Mann-Whitney test for unpaired samples.
4.1.3 RESULTS
Relevant clinical and biochemical details in the three groups of 
patients studied are shown in table 4.1 Patients with primary
89
va
lu
es
 
ar
e 
me
an
 
(S
EM
) 
an
d 
(r
an
ge
) 
UD 
= 
un
de
te
ct
ab
le
 
si
gn
if
ic
an
t 
di
ff
er
en
ce
s 
be
tw
ee
n 
no
rm
al
 
co
nt
ro
ls
an
d 
ot
he
r 
gr
ou
ps
.P
at
ie
nt
s 
wi
th
 
ma
li
gn
an
cy
 
an
d 
pr
im
ar
y 
* v
al
ue
s 
in 
no
rm
al
 
co
nt
ro
ls
 
re
fe
r 
to 
da
ta
 
be
tw
ee
n 
3-
4 
ho
ur
s 
of 
ca
lc
iu
m 
in
fu
si
on
, 
hy
pe
rp
ar
at
hy
ro
id
is
m 
di
ff
er
ed
 
on
ly
 
wi
th
 
re
sp
ec
t 
to
 
ex
ce
pt
 
th
eo
re
ti
ca
l 
ca
lc
iu
m 
th
re
sh
ol
d,
 
wh
ic
h 
wa
s 
ca
lc
ul
at
ed
 
fr
cm
 
al
l 
da
ta
 
po
in
ts
. 
se
ni
n 
al
bu
mi
n 
an
d 
PT
H 
va
lu
es
 
(p
cO
.O
Ol
).
hyperparathyroidism had significantly higher iPTH levels when compared 
with both other groups. Serum albumin levels were significantly 
depressed in patients with malignancy-associated hypercalcaemia when 
compared with primary hyperparathyroidism, which in turn vtere lower 
than in normals. Renal tubular threshold for phosphate reabsorption 
(TmPO^ ) was significantly higher in normals when compared with both 
other groups. Tumour types in malignant hypercalcaemia were: squamous
bronchial carcinoma-18; other squamous carcinomas-5; genito-urinary 
cancers-4; cholangiocarcinoma-2; breast carcinoma-2.
Values relating the urinary excretion of calcium (expressed as 
CaE) to serum calcium in normal controls rendered hypercalcaemic by 
calcium infusion were in keeping with those previously described by 
Peacock et al (114) (figure 4.1). In primary hyperparathyroidism 
the points fell to the right of the expected normal indicating 
that renal tubular reabsorption of calcium calcium was increased 
(114). In patients with malignancy associated hypercalcaemia, the 
points also fell to the right of the expected normal, reflecting a 
similar increase in renal tubular reabsorption of calcium. There were 
no significant differences in the gradients of the lines of linear 
regression relating serum calcium to urinary CaE values between normal 
subjects (Y = 0.32X -0.51), patients with primary hyperparathyroidism 
(Y = 0.42X -0.65) and those with malignant hypercalcaemia (Y = 0.25X - 
0.71). The calculated theoretical threshold for tubular calcium 
reabsorption (i.e. intercept on the X-axis) was significantly higher 
in primary hyperparathyroidism and hypercalcaemia of malignancy when 
compared with normals (Table 4.1)
Sequential data on renal calcium handling throughout sodium
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FIGURE 4.1
Relation between adjusted serum calcium values and urinary calcium 
excretion expressed as CaE in pmol/1 of glomerular filtrate (GF) in 
the study group. Dotted lines indicate normal range as defined by 
Peacock (114).
•  - Normal controls undergoing calcium infusions.
V  - Patients with primary hyperparathyroidism.
A  - Patients with malignant hypercalcaemia.
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FIGURE 4.2
Relation between serum adjusted calcium values and Cag values during 
sodium repletion of patients with malignant hypercalcaemia. Dotted 
lines indicate normal range defined by Peacock (114).
A -  initial values
values after 24-48 hours of sodium repletion.
A - values after > 96 hours of sodium repletion.
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FIGURE 4.3
Relation between serum adjusted calcium values and CaE values during 
sodium repletion in patients with malignant hypercalcaemia. Dotted 
lines indicate normal range defined by Peacock (114).
A -  Initial values.
A  - Values after > 48 hours of sodium repletion.
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FIGURE 4.4
Serum creatinine values during sodium repletion in patients with 
malignant hypercalcaemia. Points are means, bars are SEM.
PRE - At presentation.
-1 - 24 hours before assessment.
0 - After > 48 hours of sodium repletion
+1 - After > 96 hours of sodium repletion.
repletion were available in 19 patients. These subject were divided 
into two groups for reasons of clarity and to some extent, pattern of 
response (figures 4.2 and 4.3). In nine patients, renal calcium 
handling was assessed at three points during the saline infusions 
(figure 4.2). This shows that a leftward shift of the serum calcium 
vs CaE points generally occurred within the first 24-48 hours, 
indicating that renal tubular calcium reabsorption had fallen. 
However, there was little further change on continuing saline 
infusions 2 litres daily for 96 hours or longer. The reductions in 
serum calcium which occurred in these subjects after 48 hrs were 
largely due an improvement in GFR as manifest by a fall in serum 
creatinine (figure 4.4). Values before and after rehydration in a 
further 10 patients are shown in figure 4.3. In some patients a 
reduction in the setting of renal tubular calcium reabsorption 
occurred, often in combination with a reduced calcium load. Others, 
however showed a load dependent reduction in calcium alone, which 
again probably reflected the improvement of GFR on fluid repletion 
(4.3). Bone scans were performed in 17 patients with malignant 
disease. On division of these subjects into categories of "normal", 
"light tumour load" and "heavy tumour load", there was no significant 
correlation between extent of metastatic bone disease and urinary 
Ca/Cr values after rehydration. (Ca/Cr 'mean(SD) 1.05(0.91) vs 
1.30(0.66) vs 2.07(1.71) respectively).
4 .1.4 DISCUSSION
In this study, rehydrated patients with malignancy—associated 
hypercalcaemia showed evidence of increased renal tubular reabsorption 
of calcium, of a degree similar to that observed in primary
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hyperparathyroidism.
Several factors may influence the renal handling of calcium 
including acid-base disturbances, renal impairment, dehydration and 
sodium depletion (268). Although detailed acid-base studies and 
measurements of glomerular filtration rate were not performed, there 
was no significant difference in serum bicarbonate levels and serum 
creatinine levels between the three groups. Careful efforts were also 
made to ensure that all patients with malignant hypercalcaemia were 
replete in fluids and sodium at the time of study; all had received a 
minimum of 6 litres of 0.9% saline solution containing 900mmol of 
sodium. Thereafter sodium repletion was maintained by the continued 
infusion of 0.9% saline 2 litres daily. At the time of final 
assessment, serum creatinine and urea concentrations had stabilised to 
within fairly narrow limits and a high urine output was achieved in 
all cases. Previous workers who measured sodium balance during 
rehydration of severely hypercalcaemic cancer patients found the 
average deficit to be in the order of 200-600 mmol (147). This is 
considerably less than was received by all of the patients with 
malignant hypercalcaemia in this study. Sequential studies of renal 
calcium handling in a number of our patients revealed that, while 
renal tubular reabsorption of calcium often fell during the first 
24-48 hours of saline repletion, it remained relatively static 
thereafter. This suggests that, after the initial sodium deficit is 
replaced, continued sodium delivery at a moderate level does not 
alter the renal tubular reabsorption of calcium further. It must
be conceeded that the levels of urinary calcium excretion in normal 
subjects rendered acutely hypercalcaemic by calcium infusion may not 
strictly be comparable with those in more chronically hypercalcaemic
patients with malignancy and primary hyperparathyroidism. However, 
experience of other workers who have studied renal calcium handling in 
malignancy-associated hypercalcaemia suggests that urinary Ca^ , vs 
serum calcium points may often fall within the normal range (147,148), 
indicating that elevations in renal tubular calcium reabsorption are 
not simply a feature of chronic hypercalcaemia per se.
Notwithstanding the difficulties which are inherent in the 
clinical measurement of tubular calcium reabsorption (268), renal 
tubular reabsorption of calcium appeared to be increased in the 
majority of patients with malignant hypercalcaemia in this study. 
This finding contrasts with most previous work which has generally 
concluded that renal tubular reabsorption is depressed in cancer 
associated hypercalcaemia (3,23,27,93,147,148). There is relatively 
little information on the levels of urinary calcium excretion in 
relation to serum calcium in this situation however. In two studies 
where the above information is available, CaE vs serum calcium points 
have generally fallen within (147) or to the left of the normal range 
(148) , indicating that renal tubular calcium reabsorption was normal 
or depressed in cancer-associated hypercalcaemia. The discrepancy 
between our findings and those cited above may be partially due to 
differences in tumour type, which in both previous studies comprised 
mainly of breast and haematological cancers. Further, in Hosking's 
series, many patients had a substantial degree of renal impairment, 
and this may also have caused lower levels of tubular calcium 
reabsorption (153). Van Breukelen and his colleagues (148) in another 
study appear to have made no adjustment for serum albumin 
concentrations which are usually low in patients with cancer- 
associated hyperealcaemia. Finally, individual variations in renal
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tubular calcium reabsorption may have been overlooked in the latter 
study (143) since CaE vs serum calcium points were expressed as an 
average value for the study group as a whole, rather than 
individually.
In agreement with the previous study (chapter 3.2) and other 
published work (93), the renal tubular threshold for phosphate 
reabsorption was generally low in this group of patients with 
malignancy-associated hypercalcaemia, who had predominantly squamous 
and genito-urinary tumours.
The current data indicate that, in patients with malignancy 
associated hypercalcaemia, renal tubular calcium reabsorption is 
increased to a similar level as that in primary hyperparathyroidism. 
In the absence of sodium depletion and dehydration, this suggests that 
a humoral mediator is released in many patients with malignant 
hypercalcaemia which possesses a "PTH-like" effect on the renal 
tubular handling of both calcium and phosphate. By impairing the 
renal excretion of calcium, such a humoral mediator may explain the 
frequent occurrence of hypercalcaemia in malignant disease, when 
compared with benign conditions associated with increased bone 
resorption.
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4.2 RENAL TUBULAR REABSORPTION OF CALCIUM IN PATIENTS WITH NON-
PARATHYROID HYPERCALCAEMIA OF BENIGN AETIOLOGY AND IN 
NORMOCALCAEMIC AND HYPERCALCAEMIC CANCER PATIENTS WITH 
AND WITHOUT METASTATIC BONE DISEASE
4.2.1 INTRODUCTION
In the previous study, reference was made to the paucity of data 
concerning the renal tubular reabsorption of calcium in patients with 
hypercalcaemia of benign, non-parathyroid aetiology. There is, in 
addition, little information available on renal tubular calcium 
reabsorption in normocalcaemic patients with malignant disease. In 
this study, renal tubular handling of calcium was assessed in both 
hypercalcaemic and normocalcaemic patients with malignancy and in a 
small1 group of patients with hypercalcaemia of benign, non 
parathyroid aetiology.
4.2.2 PATIENTS AND METHODS
The patients with malignancy who were assessed comprised the 74 
subjects described in chapter 4.1, who had presented consecutively to 
Glasgow Royal Infirmary for bone scan examinations and thirteen 
patients with non-parathyroid hypercalcaemia of benign aetiology who 
had presented consecutively to Glasgow Royal Infirmary over a 5-year 
period. Hypercalcaemic patients with maligancy were rehydrated with 
intravenous 0.9% saline as previously described (chapter 4.1). 
Patients with benign non-parathyroid hypercalcaemia with serum calcium 
values of greater than 3 . 1 0  mmol / 1  were rehydrated using a similar 
protocol. Patients with milder degrees of hypercalcaemia were 
generally well-hydrated on a clinical basis and were not routinely
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given intravenous fluids. Biochemical analyses were made on blood 
samples and true fasting urine samples generally obtained after an 
overnight fast.
4.2.2 RESULTS
The aetiology of hypercalcaemia in patients with benign, non­
parathyroid hypercalcaemia was as follows: hypoparathyroidism and 
vitamin D toxicity-3 (23%), osteoporosis and vitamin D toxicity-2 
(15%), hyperthyroidism-3 (23%), immobilisation-5 (33%). Relevant 
clinical and biochemical details are shown in table 4.2. There were 
no significant differences in levels of serum calcium and serum 
albumin levels in patients with benign non-parathyroid hypercalcaemia 
compared with those who had malignant hypercalcaemia. Levels of serum 
phosphate and TmPO^ were significantly higher in the patients with 
benign hypercalcaemia, however.
The relation between urinary excretion of calcium expressed as 
CaE and serum calcium in the three groups of patients is shown in 
figure 4.5. With the exception of 3 out of the 4 hypercalcaemic 
breast carcinoma patients who were studied, the urine Ca^ vs serum 
calcium points in malignant hypercalcaemia generally fell to the right 
of the expected normal, indicating that renal tubular reabsorption of 
calcium was increased. In normocalcaemic cancer patients, and in 
patients with hypercalcaemia of benign, non-parathyroid aetiology, the 
points generally fell within the normal range indicating that renal 
tubular calcium reabsorption was normal. Although renal tubular 
reabsorption of calcium was slightly increased in two patients with 
benign, non-parathyroid hypercalcaemia, the renal tubular contribution 
to hypercalcaemia, was significantly lower than in malignant
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FIGURE 4.5
Relation between serum adjusted calcium values and Ca^ , values in the 
study group. Dotted lines indicate normal range defined by Peacock 
(114) .
#  - Normocalcaemic patients with malignancy.
O  - Hypercalcaemic patients with malignancies 
other than breast carcinoma.
0 ~  Hypercalcaemic patients with breast carcinoma.
♦  - Benign non parathyroid hypercalcaemia.
hypercalcaemia overall; renal tubular component of hypercalcaemia 
(mean (SEM)) = +0.54(0.05) mmol/1 (malignancy) vs +0.09(0.06) mmol/1 
(benign hypercalcaemia), (p<0 .0 0 1 )
4.2.4 DISCUSSION
These data indicate that renal tubular reabsorption of calcium is 
generally normal in normocalcaemic cancer patients both with and 
without bone metastases. In combination with the previous data 
concerning biochemical indices of bone resorption in normocalcaemic 
patients with metastastic bone disease (chapter 4.1), this finding 
helps to explain why such patients can maintain normocalcaemia in the 
presence of increased bone resorption; not only is the severity of 
bone resorption insufficient to cause hypercalcaemia, but also, the 
renal tubular threshold for excretion of calcium is normal, thus 
permitting elimination of excess calcium from the ECF.
In agreement with the previous study (chapter 4.1) renal tubular 
calcium was found to be elevated in most of the hypercalcaemic cancer 
patients, consistent with a parathyroid-hormone like effect on renal 
tubular calcium reabsorption. However, 3/4 of the the breast cancer 
patients - all of whom had a heavy skeletal tumour load - had normal 
renal tubular reabsorption of calcium. This suggests that a "local 
osteolytic” mechanism of hypercalcaemia may be more prevalent with 
this tumour type.
In patients with benign hypercalcaemia of non-parathyroid origin, 
renal tubular reabsorption of calcium was generally normal and was 
significantly lower than in patients with malignant hypercalcaemia. 
This indicates that the elevations in renal tubular calcium
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reabsorption noted previously (chapter 4.2) were not simply due to a 
non-specific effect of chronic hypercalcaemia per se, but rather, were 
the result of a "PTH-like" effect on renal tubular calcium 
reabsorption.
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4. 3 RELATION BETWEEN RENAL SODIUM HANDLING AND RENAL CALCIUM HANDLING
IN HYPERCALCAEMIA OF MALIGNANCY AND PRIMARY HYPERPARATHYROIDISM
4.3.1 INTRODUCTION
Reference has been made to the fact that renal tubular 
reabsorption of calcium may be elevated in patients who are sodium 
depleted (268). In this situation, it is thought that increased 
sodium reabsorption in the proximal renal tubule is accompanied by a 
concomitant increase in proximal renal tubular calcium reabsorption 
(176,267,268). In malignancy associated hypercalcaemia, normalisation 
of renal tubular calcium reabsorption after sodium repletion has 
previously been interpreted as evidence against a "PTH-like" effect of 
the putative humoral mediators of hypercalcaemia (147,148,259). In 
this study, the relation between urinary sodium excretion and renal 
tubular calcium reabsorption has been examined in patients with 
hypercalcaemia of malignancy. These data were compared with those in 
primary hyperparathyroidism, where renal tubular calcium reabsorption 
is known to be increased, due to the effects of PTH on the distal 
renal tubule.
4.3.2 PATIENTS AND METHODS
Data were obtained from two groups of patients; 31 with primary 
hyperparathyroidism and 36 with hypercalcaemia of malignancy, all of 
whom had presented consecutively to Glasgow Royal Infirmary.
All biochemical analyses were made on true fasting urine and 
blood samples, obtained after an overnight fast. Patients with primary 
hyperparathyroidism fell into two groups; 30 patients were normally
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hydrated on a clinical basis, and were receiving oral fluids only at 
the time of study. One patient who had presented with hypercalcaemia 
and severe dehydration was studied prior to receiving intravenous 
fluids. In seven patients with primary hyperparathyroidism, further 
studies were performed during acute saline infusions (see below). 
Twenty seven patients wth malignancy-associated hypercalcaemia were 
studied after rehydration with intravenous saline; a minimum of 6  
litres had been given initially, followed by 2 litres daily for 24 
hours prior to and during the study. Four patients with malignancy 
who were clinically dehydrated at presentation were studied before the 
administration of intravenous fluids. The remaining 5 patients had 
presented with stable hypercalcaemia and renal function documented for 
a period of at least 4 weeks prior to the study. These patients were 
normally hydrated on a clinical basis and were receiving oral fluids 
only prior to the study. In these patients, further studies were 
performed during acute saline infusions.
Saline infusion studies were performed as follows; in 
hyperparathyroidism, infusions of saline (0.9%) were commenced shortly 
after collection of baseline samples and were continued for 43 hours. 
The rate of infusion was 500 ml every 4 hours (450 mmol sodium 
chloride daily). In patients with malignancy, saline infusions were 
commenced after collection of baseline samples and were also 
continued, 500ml every four hours for 48 hours.
Statistical methods used were the Wilcoxon test for paired 
samples and Spearman's rank correlation coefficient.
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4.3.2 RESULTS
All 31 patients with primary hyperparathyroidism were known to 
have sustained hypercalcaemia (mean (SEM) serum calcium = 2.89 (0.02) 
mmol/1], with "innapropriately" detectable plasma iPTH values, in the 
absence of another identifiable cause of hypercalcaemia. In 20 
patients, the diagnosis was subsequently proven by surgical 
exploration of the neck. Serum creatinine values were within the 
normal range in most cases (serum creatinine; mean (SEM) = 81.8 (5.9) 
umol/1). Two subjects with renal stone disease had elevated creatinine 
values however (230, 150 umol/1, respectively). Serum albumin values 
were within the normal range in most cases (serum albumin; mean (SEM) 
=39.5 (1.1)g/1)-
Serum calcium values in patients with malignancy were; mean (SEM) 
= 3 . 2 1  (0.06) m m o l / 1 , significantly higher than in the
hyperparathyroid group (p<0.01). In all of these patients plasma iPTH 
values were low or undetectable. Serum creatinine concentrations were 
normal in most cases and were comparable with those in patients with 
primary hyperparathyroidism (serum creatinine mean (SEM) = 81.9 (4.9)
umol/1. Creatinine concentrations lay outwith the normal range in 3 
cases; (150, 150, 190 umol/1, respectively). Serum albumin values in 
patients with malignancy were generally reduced when compared to those 
in patients with primary hyperparathyroidism (serum albumin; mean 
(SEM) = 29.6 (0.7) g/1; p<0.001).
In figure 4.6, the relation between the notional renal tubular 
threshold for calcium reabsorption (TmCa/GFR) and urinary sodium 
excretion (NaEj is shown in patients with primary hyperparathyroidism. 
When data from the 30 normally hydrated patients only was considered,
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hypercalcaemia.
□  ~ Clinically dehydrated_
O “ Normally hydrated, receiving I.V. saline 2 
litres daily.
<0>- During acute saline loading, receiving I.V. 
saline 3 litres daily.
Cl /C l 60  n
Na7 Cr
(x10"3 )
♦
0
0
30
0
0
Oo
0
>0
*>
j ♦ o
0 0  0
oP o 8 o o
° O
& ‘
50 100
Clca/Clcr
(x!0“3 )
FIGURE 4.8
Relation between renal sodium clearance (ClNa/ClCr) and renal 
calcium clearance (ClCa/ClCr) during acute sodium loading of 
patients with malignancy and hyperparathyroidism.
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FIGURE 4.9
Response of serum calcium, TmCa/GFR and Na^ , in normally hydrated 
patients with primary hyperparathyroidism and malignant hypercalcaemia 
during saline infusions. Interrupted lines indicate normal ranges. 
Significant change from initial values: *=p<0.05, **=p<0.02.
Rx = Start of antihypercalcaemic drug therapy in patients with 
malignancy (not referred to in text).
there was no significant correlation between TmCa/GFR and NaE (r - 
0.27; NS). However, when data were included from the patients who was 
dehydrated and from the seven patients who were studied during acute 
saline infusions (2 values in each patient) there was a significant 
inverse correlation between TmCa/GFR and NaE (r = -0.49 p<0.002).
In figure 4.7, similar data is shown from the patients with 
malignancy associated hypercalcaemia. In the 27 patients who were 
studied after rehydration with intravenous saline, TmCa/GFR and Na£ 
were not significantly correlated (r = -0.16, NS). When data were 
included from 4 dehydrated patients and from the seven normally 
hydrated patients undergoing acute saline infusion studies, there was 
a significant inverse correlation (r = 0.60, p<0 .0 0 1 ).
In the 12 patients (7-hyperparathyroid, 5-malignancy) undergoing 
detailed studies prior to and during acute saline infusion studies, 
TmCa/GFR and NaE were not significantly correlated before saline 
infusions were commenced, either in primary hyperparathyroidism (n = 
7, r = -0.23, NS) or in malignancy (n = 5, r = -0.17, MS). When all 
the data were included from measurements made prior to, during and 
after saline infusions however, a highly significant inverse 
correlation was observed between TmCa/GFR and NaE in primary 
hyperparathyroidism (r = -0.72, p<0.001) and'in malignancy (r = 0.70, 
p<0.01). In both conditions there was a positive correlation between 
the ratio of sodium to creatinine clearance and calcium to creatinine 
clearance; (hyperparathyroidism; r = 0.73, p<0.005) , malignancy r = 
0.77, p<0.005) (figure 4.8).
The response of serum calcium, NaE  ^and TmCa/GFR to the acute
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saline infusions in hyperparathyroidism and malignancy is shown in 
figure 4.9. In primary hyperparathyroidism, there was a significant
rise in Na£ an(j a significant fall in both serum calcium and TmCa/GFR 
during the saline infusions. These changes were reversed when saline 
infusions were stopped. In malignancy, a similar pattern of response
was observed; a significant elevation in NaE during saline infusion 
was accompanied by a significant fall in TmCa/GFR. Serum creatinine 
concentrations were not altered significantly by saline infusions in 
either group of patients; serum creatinine concentrations before and 
after saline infusions in primary hyperparathyroidism were 
(mean (SEM)) 73.5 (4.9) and 73.5 (8.5) umol/1 respectively. In
malignancy the corresponding values were 8 6  (14.4) and 79 (15.5)
umol/ 1  respectively.
4.3.5 DISCUSSION
In this study, a close correlation was observed between urinary 
sodium excretion and renal tubular calcium reabsorption in patients 
with malignancy associated hypercalcaemia and primary 
hyperparathyroidism who had been sodium loaded. These findings concur 
with previous data: in various experimental circumstances, proximal 
renal tubular reabsorption of calcium has been shown to be correlated 
with that of sodium (176,266,267). Nonetheless, other data have 
suggested that proximal renal tubular reabsorption of calcium is 
relatively stable under normal conditions , and is a function of the 
filtered calcium load (268), whereas changes in net renal tubular 
calcium reabsorption are determined mainly by the effects of 
parathyroid hormone on the distal tubule (114). In clinical practice 
however, measurements of renal tubular calcium reabsorption reflect
103
the sum of changes in both proximal and distal tubular reabsorptive 
processes, and as such, do not distinguish between their relative 
contribution to TmCa/GFR. Interestingly, there was no significant
correlation between TmCa/GFR and urinary NaE values either in 
malignancy or primary hyperparathyroidism where patients were studied 
in a "steady state"- either receiving oral fluids or constant amounts 
of intravenous saline. This suggests that, in this situation, sodium- 
independant and probably humoral changes in distal renal tubular 
calcium reabsorption were of primary importance in determining TmCa/GFR.
In clinically dehydrated patients, TmCa/GFR was invariably raised 
presumably as the result of increased sodium-linked calcium 
reabsorption in the proximal renal tubule (268). Conversely, under 
conditions of acute sodium loading, there was a significant fall in 
TmCa/GFR suggesting that decreased sodium-linked calcium reabsorption 
in the proximal renal tubule was the major factor responsible for the 
fall in TmCa/GFR (176,266,267,283). Taken together, these findings 
suggest that sodium-related changes in renal tubular calcium 
reabsorption are of relatively minor importance under normal 
conditions, but may becom-e increasingly important at the upper and 
lower extremes of urinary sodium excretion.
In two previous studies of renal tubular calcium reabsorption in 
hypercalcaemia of malignancy, tubular calcium reabsorption was raised 
prior to sodium repletion but generally fell thereafter (147,148). 
These findings were taken as evidence against a renal tubular action 
of putative humoral mediators of hypercalcaemia. In the present study, 
however, TmCa/GFR values fell towards normal in patients with primary 
hyperparathyroidism who were saline loaded, suggesting that renal
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tubular reabsorption of calcium may be reduced by a sodium load, even 
in the presence of a PTH-mediated increase in distal renal tubular 
calcium reabsorption (114). A further relevant observation was that 
the relation between urinary sodium excretion and renal tubular 
calcium reabsorption was similar in patients with primary 
hyperparathyroidism and hypercalcaemia of malignancy. This lends 
support to the suggestion, made in chapter 4.1, that in hypercalcaemia 
of malignancy, there is exhibited a humoral mediator with a PTH-like 
effect on the renal tubular reabsorption of calcium. In two previous 
studies (147,148), renal tubular calcium reabsorption was assessed at 
relatively high rates of urinary sodium excretion (Na£ (median) 
=4.9mmol/l GF and 5.8mmol/l GF respectively); this suggests that the 
"normal" renal tubular reabsorption of calcium observed in some cases 
may, in fact have been the result of a sodium-linked reduction in 
proximal renal tubular calcium reabsorption, and as such, did not 
exclude a concomitant increase in distal renal tubular calcium 
reabsorption which was humorally-mediated.
These data emphasise the importance of measuring sodium excretion 
in any investigation of renal tubular calcium reabsorption. Caution 
must be exercised in the interpretation of data relating to renal 
tubular reabsorption of calcium in patients who are sodium-loaded or 
sodium depleted.
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CHAPTER 5
CALCIUM REGULATING HORMONES AND INTESTINAL CALCIUM 
ABSORPTION IN MALIGNANCY ASSOCIATED HYPERCALCAEMIA
106
5.1 CIRCULATING LEVELS OF VITAMIN D METABOLITES IN NORMOCALCAEMIC
AND HYPERCALCAEMIC PATIENTS WITH MALIGNANCY
5.i.1 INTRODUCTION
The data presented in chapters 3 and 4 suggest that in most 
patients with malignancy associated hypercalcaemia, evidence can be 
found for a humoral aetiology, whether or not bone metastases are 
present. It has been considered that the putative humoral mediator 
causing such hypercalcaemia possesses PTH-like properties with regard 
to renal tubular phosphate handling (6,7,8,9,93,259), nephrogenous 
cyclic AMP production (93), and renal tubular calcium handling 
(Chapter 4). Nevertheless, it is immunologicaily distinct from PTH or 
its fragments, such as circulate in primary hyperparathyroidism 
(93,130,131,132). Circulating levels of l,25(OH)2D3 have previously 
been found to be reduced in hypercalcaemia of malignancy when compared 
with primary hyperparathyroidism (93). It has therefore been 
considered unlikely that l,25(OH)2D3 plays a significant role in the 
pathogenesis of hypercalcaemia in malignancy. Moreover, measurement of 
1,25(0H)oD3 levels has been proposed as a means by which the 
hypercalcaemia of malignancy may be differentiated from that of 
primary hyperparathyroidism (93).
In this study, levels of circulating vitamin D metabolites were 
measured in relation to other hormonal regulators of calcium 
metabolism in normocalcaemic and hypercalcaemic patients with 
malignancy.
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5.1.2 PATIENTS AND METHODS
The study group comprised 8 8  patients with solid malignant 
tumours; 44 were hypercalcaemic (serum calcium >3.00 mmol/1 at 
presentation and 44 were normocalcaemic (serum calcium <2.60 mmol/1). 
Four normocalcaemic and 3 hypercalcaemic patients with breast 
carcinoma received Tamoxifen therapy and one normocalcaemic patient 
with prostatic carcinoma received stilboestrol therapy at the time of 
study. No patients were receiving vitamin D analogues or other 
medication known significantly to affect calcium homeostasis.
Prior to study, all hypercalcaemic patients were rehydrated with 
either intravenous or oral fluids for periods of between 24-72hrs. 
Biochemical analyses were made on true fasting urine samples and blood 
samples obtained after an overnight fast.
Statistical methods used were the Wilcoxon test for unpaired 
samples and Linear Regression Analysis.
5*1*3 RESULTS
Only two patients with hypercalcaemia of malignancy had 
detectable plasma iPTH levels (450, 680 ng/1, respectively). Data from 
these patients was excluded, as these patients may have had co­
existing primary hyperparathyroidism.
Plasma iPTH levels were undetectable in the remaining 42 patients 
with malignancy associated hypercalcaemia. In normocalcaemic cancer 
patients, iPTH levels lay within the normal range, appropriate to 
their normal serum calcium concentrations.
The commonest tumour type in hypercalcaemic patients was squamous
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TABLE 5.2
SEBUM CMCTDCKIN AND 25-HmOffVITAMIN D IEVELS
in psrars wrm malignant disease
SERUM SERUM
CALCCTCNIN 25 (QH)D
(ng/1) (mol/1)
NQRMlXALCAHyilC 36 27.5
26-48 11-48
(n=44) (15-1700) (<5-98)
HYPERCADCAEMIC 86 13.5
66-110 5-23
(n=42) (21-320) (<5-100)
SIGNIFICANCE
<0.001 <0.01
(p-value)
Values are median
interquartile range 
(range)
1,25(0H)2D
pmol.l’1
150 .
100
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FIGURE 5.1
Serum levels of 1,25 (OH)2 D in normocalcaemic and hypercalcaemic 
patients with malignancy. Dotted lines indicate normal range. 
Shaded zone indicates assay's limit of detection.
bronchial carcinoma, compared with breast carcinoma in the 
normocalcaemic group (Table 5.1). Hypercalcaemic patients were 
slightly, but significantly older than those who were normocalcaemic 
(p<0.05), and had significantly lower serum albumin levels (p<0.001) . 
Serum inorganic phosphate levels generally lay within the normal 
range, although serum phosphate was significantly lower in the 
hypercalcaemic group (p<0 .0 0 1 ).
Patients with hypercalcaemia had significantly higher plasma 
calcitonin concentrations than those who were normocalcaemic (p<0 .0 0 1 ) 
In the latter group, calcitonin levels generally lay within the 
reference range (Table 5.2). There was no significant correlation 
between plasma calcitonin level and serum calcium values in patients 
who were hypercalcaemic however (r = 0.18, NS). Overall, calcitonin 
did not correlate with either serum creatinine (r =0.17, NS) or serum 
1,25 (OH) 2 D levels (r = 0.09, NS).
Concentrations of 25 (OH) D were low in both groups of patients 
with malignancy when compared with our reference range (Table 5.2). 
Circulating levels of 1,25 (OH) 2 ^^ in hypercalcaemic and normocalcaemic 
patients with malignancy are shown in figure 5.1. Serum 1,25(OH) 2 D 
levels were significantly lower in the hypercalcaemic group (p<0 .0 1 ), 
when compared with the normocalcaemic group, where plasma 1,25(OH) 2 D 
levels generally lay within the reference range. A substantial 
proportion (18/42) of the hypercalcaemic patients had clearly 
detectable 1,25 (OH) 2 D levels however, (>24pmol/l) and this was 
considered to be an "innappropriate" response in patients with 
hypercalcaemia of non-parathyroid origin. In this subgroup of 
patients, the levels of l,2 5 (OH) 2 D were similar to those in a group
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FIGURE 5.2
Renal tubular threshold for phosphate reabsorption (TmP04) in 
normocalcaemic and hypercalcaemic patients with malignancy. Dotted 
lines indicate normal range. Bars are medians.
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FIGURE 5.3
Relation between serum adjusted calcium values and CaE in patients 
with hypercalcaemia of malignancy. Dotted lines indicate normal 
range defined by Peacock (114).
# -  1,25 (OH) 2 D < 24pmol/l 
O -  1,25 (OH) 2 D > 24pmol/l
of 18 patients with primary hyperparathyroidism: serum 1,25(OH)2 D 
median; interquartile range; range =69; 42-124; 31-240 pmol/1 (primary 
hyperparathyroidism) vs 53; 37-82; 24-170 pmol/1 (malignancy).
Serum concentrations of l,25(OH)2 D in patients with 
hypercalcaemia of malignancy did not correlate significantly with 
levels of precursor 25 (OH) D (r = 0.14, NS) , or with serum calcium (r 
= 0.19, NS) or creatinine levels (r = -0.23, NS).
The renal tubular threshold for phosphate reabsorption (TmPO^) 
was significantly depressed in hypercalcaemic when compared with 
normocalcaemic patients with malignancy (p<0.001) (figure 5.2). There 
was no significant correlation between serum inorganic phosphate 
levels or TmP0 4 levels and 1,25(OH)2 D levels in hypercalcaemic 
patients with malignancy (r = 0.21, NS; r = 0.18, NS, respectively).
Data on the renal tubular reabsorption of calcium was available 
in 3 5  patients with hypercalcaemia who had been rehydrated with 
intravenous saline, using the protocol described in chapter 4.1 
(figure 5.3). In the majority, renal tubular reabsorption of calcium 
was elevated, consistent with a PTH-like humoral effect on the kidney. 
It should be noted however, that 1,25(OH)2 D levels were frequently 
undetectable in patients who had increased renal tubular calcium 
reabsorption and viceiversa.
Serum calcium and 1,25 (OH) 2 D levels were followed in 14 patients 
during therapy with corticosteroids (figure 5.4). Concentrations of 
1,25(OH) 2 D were low or undetectable at the outset in 6 cases and did 
not change substantially during treatment. In 2 patients, an initially 
raised level of 1,25 (OH) 2 fell during treatment, whereas in one case
110
5.3
TIME (DAYS)
0 1  2 3 4 5 6 7 8 9  10
CALCIUM 
mmol.!1
1,25(0H)2D 
pmol.l 1
100
R Axprednisolone
FIGURE 5.4
Response of serum calcium and 1,25 (OH) 2  D levels in patients with 
malignant hypercalcaemia who were treated with prednisolone.
□  - initial 1,25(OH) 2 D £ 24pmol/l 
•  - initial 1,25 (OH) 2 D < 24pmol/l
the l,25(OH)2 D level rose. In the remaining 5 cases, detectable 
1,25(OH) 2 D levels were observed initially but remained substantially 
unchanged throughout treatment. Although serum calcium values fell on 
treatment in both patients who had raised levels of 1,25(OH) 2 D 
initially, serum calcium also fell in others who had undetectable 
levels of 1,25 (OH) 2 D. Thus a raised 1,25 (OH) 2 D level did not 
accurately predict which patients would respond to corticosteroid 
therapy.
The finding of a detectable 1,25(OH) 2 D level was not confined to 
any particular tumour type (table 5.3).
5.1.4 DISCUSSION
In malignancy-associated hypercalcaemia, endogenous parathyroid 
hormone secretion is suppressed (93,130,131,132). Since PTH is the 
principal factor which stimulates 1,25 (OH) 2 D synthesis in renal 
cells (80,81,157,284), one would expect l,25(OH)2 D levels to be low 
in malignancy-associated hypercalcaemia. Indeed, in a previous study, 
Stewart et al (93) drew attention to the fact that 1,25 (OH) 2 D levels 
were generally depressed in malignant hypercalcaemia when compared to 
primary hyperparathyroidism. In concurrence with these data, 
circulating levels of 1,25 (OH) 2 D in this study were undetectable in 
many patients with malignancy associated hypercalcaemia. However, in a 
substantial proportion af cases, 1,2 5 (OH) 2 D levels were 
"inappropriately" detectable and in three cases raised.
The reason for continued synthesis of 1,25(OH)2 D in this 
situation is unclear; while hypophosphataemia may directly stimulate 
renal l-fl(-hydroxylase activity in the absence of PTH (285), this is an
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unlikely explanation for the current findings as serum phosphate 
levels did not correlate with 1,25(OH) 2 D levels. Although it is 
possible that intracellular phosphate may have played a role in 
modulating the levels of 1,25 (OH) 2 D it was not possible to measure 
intracellular phosphate concentrations in this study. Other hormones 
such as prolactin, oestrogen, cortisol, androgens, insulin, calcitonin 
and growth hormone have all been shown to contribute to the regulation 
of l,25(OH)2 D synthesis in some circumstances (286,287). However, 
these hormones are unlikely to stimulate significant production of 
l,25(OH)2 D in the absence of PTH (285). Certainly, pharmacological 
doses of corticosteroids did not alter l,25(OH)2 D levels 
substantially in this study and there was no significant correlation 
between calcitonin levels and 1,25 (OH) 2 D levels.
In hypoparathyroidism, the low levels of 1,25 (OH) 2 D which are 
observed correlate with the levels of precursor 25 (OH) D (288). No 
such correlation was observed here, however, even though plasma levels 
of PTH were invariably undetectable in patients with malignant 
hypercalcaemia.
Athough documented, ectopic production of PTH is a rare cause of 
hypercalcaemia in malignancy (90). However, in many patients, a 
humoral factor is released, which mimics the effects of PTH on renal 
tubular phosphate reabsorption (6,7,8,9,93,259), nephrogenous cyclic 
AMP production (93) and renal tubular calcium reabsorption (Chapter 
4). The "inappropriately" detectable or raised levels of 1,25 (OH) 2 D 
observed in some hypercalcaemic cancer patients in this study suggests 
that the PTH-like effect of the putative humoral mediator may, in some 
cases, extend to stimulation of renal 1 -iX-hydroxylase activity.
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Our interpretation of the significance of detectable 1,25(OH) 2 D 
levels in this situation differs from that of Stewart et al (93), who 
concluded that the humoral mediator involved in malignancy-associated 
hypercalcaemia differed from PTH in failing to stimulate renal l-fl(- 
hydroxylase activity. However, their results clearly show that in a 
proportion of cases, 1,2 5 (OH) 2 D levels were detectable, thus 
indicating a possible PTH-like effect on 1,25(OH) 2 D synthesis. In a 
previous study, Coombes et al (86) noted that the intestinal 
absorption of calcium was generally depressed in both hypercalcaemic 
and normocalcaemic patients with malignant disease. Nonetheless, 
intestinal calcium absorption was raised in at least one of Coombes' 
hypercalcaemic patients. Although serum 1,25 (OH) 2 D levels were not 
measured by Coombes et al, this finding would concur with the current 
observation that 1,25 (OH) 2 D levels are raised in only a small 
proportion of patients with malignancy-associated hypercalcaemia.
It has been considered that in clinical practice, suppressed 
levels of 1,25 (OH) 2 D may provide a means by which the hypercalcaemia 
of malignancy could be distinguished from primary hyperparathyroidism 
(5,93). While this appears to hold true in many cases, the current 
data suggest that, in a proportion of cases, 1,25 (OH) 2 D levels may 
be raised to within the hyperparathyroid range. Thus it is evident 
that assessment of 1,25(OH) 2 D status would be of limited value in the 
differential diagnosis of these conditions.
Although it is clear that the kidney is the main site of 
synthesis for 1,25(OH) 2, cell lines derived from bone (289), malignant 
melanomas (290) and malignant lymphomas (91) have demonstrable 
activities of the 25 hydroxy-vitamin-D l-£<-hydroxylase enzyme in
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vitro. Moreover, low levels of 1,25 (OH) 2 D have been measured in the 
serum of anephric patients with sarcoidosis, suggesting that 
granulomatous tissue may also be a site of 1,25 (OH) 2 D synthesis 
(291,292). From these data, it is apparent that the detectable levels 
of 1,25(OH) 2  observed in this study could have derived from tissues 
other than the kidney.
While the source of the 1,25 (OH) 2 D is unclear, the presence of 
the active vitamin D metabolite in the serum of hypercalcaemic cancer 
patients could contribute to the pathogenesis of hypercalcaemia, by 
enhancing bone resorption (79,80), or by increasing intestinal calcium 
absorption (80,81,82). The latter effect, if confirmed, would be of 
theraputic importance, as hypercalcaemia in patients with elevated 
intestinal calcium absorption may respond to restriction of dietary 
calcium.
114
5.2 INTESTINAL CALCIUM ABSORPTION AND CIRCULATING 1,25 DIHYDROXY-VITAMIN D
LEVELS IN MALIGNANCY ASSOCIATED HYPERCALCAEMIA.
5-2.1 INTRODUCTION
In the previous study, attention was drawn to the fact that 
circulating levels of the active vitamin D metabolite 1,25(OH) 2 D may 
be "inappropriately" detectable or raised in some patients with 
hypercalcaemia due to solid malignant tumours. Previous studies have 
shown however, that intestinal calcium absorption is generally 
depressed in cancer patients (8 6 ). In primary hyperparathyroidism, 
where 1,25 (OH) 2 D levels are generally raised, intestinal calcium 
absorption is elevated (116). In this study circulating levels of 
1,25(OH) 2 D in malignancy-associated hypercalcaemia were related to 
intestinal calcium absorption.
5.2.2 PATIENTS AND METHODS
Sixteen patients with hypercalcaemia of malignancy and sixteen 
with primary hyperparathyroidism were studied. Patients were selected 
consecutively on the basis that their clinical condition was stable, 
they were able to take oral fluids and food, and that they had given 
informed consent to entering the study.
Patients with malignancy had generally been rehydrated with a 
minimum of 6 litres of intravenous saline prior to the study. During 
the study, these patients had stable hypercalcaemia and renal 
function, but in most cases, continued to receive saline infusions of 
2 litres daily to prevent possible dehydration. Patients with primary 
hyperparathyroidism had stable hypercalcaemia and renal function prior 
to the study and received oral fluids throughout.
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Intestinal calcium absorption in both groups of patients was 
assessed by means of an oral calcium load test essentially as 
described by Broadus et al (177). Briefly, this test entails measuring 
the urinary Ca/Cr ratio in a 2-hour urine specimen obtained after an 
overnight fast, with collection of a mid-point blood sample. A second 
2 -hour urine specimen and mid-point blood sample were obtained 
between 2-4 hours after the oral administration of a calcium load, 
given as effervescent calcium gluconate tablets dissolved in water 
(total dose of elemental calcium = 20 mmol). Prior to and during the 
test, patients were encouraged to drink 2 0 0  ml of water per hour to 
sustain an adequate diuresis.
The presence and extent of metastatic bone disease was assessed 
by standard radionuclide bone scan examination as described in chapter
■N
3.1.
Statistical methods used were the paired and unpaired Wilcoxon 
tests and Spearman's rank correlation coefficient.
5 .2.3 RESULTS
Relevant biochemical data prior to the oral calcium load are 
shown in Table 5.4. Serum albumin, iPTH and 1,25 (OH) 2 D levels were 
significantly higher, and fasting Ca/Cr ratio significantly lower in 
primary hyperparathyroidism when compared with hypercalcaemia of 
malignancy. While serum calcium values tended to be lower in the 
hyperparathyroid group, the difference was not statistically 
significant.
In figure 5.5, serum l,25(OH)2 D levels in patients with 
malignancy are shown in relation to the extent of metastatic bone
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FIGURE 5.5
Serum 1,25 (OH^ D levels in patients with hypercalcaemia of
malignancy. Dotted lines indicate normal range. Bars are medians.
#  - Heavy skeletal tumour load.
j2f- Light skeletal tumour load.
O  “ No evidence of bone metastases.
disease; 1,25 (OH) 2 D levels were significantly lower in patients with 
extensive bone involvement, when compared with those who had few or no 
metastases.
In figure 5.6, a similar relationship between urinary cyclic AMP 
levels and metastatic bone disease is shown. Although UcAMP levels 
tended to be higher in patients with few or no bone metastases, the 
difference between the groups was not statistically significant. 
Nonetheless, 1,25 (OH) 2 D levels and UcAMP levels were significantly 
correlated in patients with hypercalcaemia of malignancy overall (r = 
0.60, p<0.05). While l,25(OH)2 D levels correlated significantly with
TmPO^ values in patients with primary hyperparathyroidism (r = 0.68, 
p<0 .0 2 ), there was no significant correlation between these variables 
in hypercalcaemia of malignancy. Serum 1,25(OH) 2 D levels failed to 
correlate with serum phosphate in either group of patients.
The response of serum calcium values to the oral calcium load is 
shown in figure 5.7. In hyperparathyroidism, serum calcium values rose 
in all but one patient, who had chronic renal failure (serum 
creatinine = 260 umol/1 ), nephrocalcinosis and an undetectable
l,25(OH)2 D value. The rise was statistically significant in the 
hyperparathvroid group. In malignancy associated hypercalcaemia, serum 
calcium values did not change significantly. The mean (SEM) rise in 
serum calcium was significantly greater in patients with 
hyperparathyroidism (+0.19 (0.03) mmol/1) when compared with malignant 
hypercalcaemia (+0.03 (0.02) mmol/1) (p<0.01).
The response of urinary Ca/Cr values was similar; in primary 
hyperparathyroidism, Ca/Cr rose significantly from (mean (SEM)) 0.67 
(0.07) mmol/1 (basal) to 0.97 (0.10) mmol/1 (post calcium load)
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Urinary cyclic AMP excretion in patients with malignancy 
expressed as a molar—ratio of cyclic AMP to creatinine (UcAMP) 
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FIGURE 5.7
Serum adjusted calcium values before (PRE) and after (POST) oral 
calcium load in hypercalcaemia of malignancy (HM) and primary 
hyperparathyroidism (HPT). Dotted lines indicate normal range.
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FIGURE 5.9
Relation between change in serum calcium values after the oral 
calcium load and l,25(OH)2 D levels in hypercalcaemia of 
malignancy (HM).
TAHE 5.5
CLINICAL FEATURES IN RELATION TO TUMOUR TYPE AND EXTENT CF 
METASTATIC BCNE DISEASE IN HYPHO&CAEMIA CF MALIGNANCY
TUMOUR
TYPE
BCNE
METASTASES
SERUM
PTH
SERUM 
1,25 (CH)oD
URINE
CAMP/CREATININE
TmPO^ RENAL TUBULAR 
GCNIRIBUriCN TC
— HYPERCALCAEMIA1
(ng/l) (pnol/1 ) (ranol/iimol) (rrmol/lGF) (mmol/1 )
SQUAMOUS + UD 27 1 . 1 0 0.30 +0.39
SQUAMOUS o UD 97 1 . 2 2 0.70 ■KD.28
SQUAMOUS o UD 50 1 . 2 1 0.70 +0.69
SQUAMOUS + 250 62 ND 0.55 -0 . 0 1
SQUAMOUS o UD UD 0.81 0.60 +0 . 0 1
SQUAMOUS o UD 162 0.90 0.70 +0.52
SQUAMOUS + 850 58 ND 0.60 +0.35
HEPATOMA o UD 33 0.80 0.60 +1.09
A.C.U.P o UD 45 0.45 0.60 -0.03
BREAST +-+ UD 23 0.35 0.95 -0.09
BREAST ++ UD UD 1 . 1 0 0.90 -0.27
BREAST ++ UD UD 0 . 1 0 0.30 -0.05
BREAST ++ 260 UD ND 0.50 -HD.44
MYELOMA ++ 390 16 0.19 0.40 +0.49
A.C.U.P ++ UD UD 0.67 2 . 1 0 -0 . 0 2
SQUAMOUS ++ UD 18 0.40 0.60 -0.13
o - no evidence of bone metastases * — calculated by the method described
+ ~ light skeletal tunour load in table 2 .2 .
-H- - heavy skeletal tunour load
ND - not measured 
UD - undetectable
A.C.u.P = adenocarcinoma unknown primary 
Seven squamous carcinomas were of bronchial 
origin, one squamous carcinona of prostate.
(p<0.005). In malignant hypercalcaemia there was no significant 
change; 1.33 (0.19) mmol/1 (basal) vs 1.42 (0.17) mmol/1 (post calcium 
load) (individual data points for Ca/Cr values are not shown).
The relation between serum levels of 1,25 (OH) 2 D and the change 
in serum calcium after the oral calcium load is shown in patients with 
primary hyperparathyroidism and malignancy in figures 5.8 and 5.9 
respectively. In hyperparathyroidism, there was a significant 
correlation between these variables (r = 0.63, p<0.05) , but in
malignant hypercalcaemia, no significant correlation was observed (r = 
0.43, NS).
Selected biochemical variables reflecting PTH-like activity are 
related to clinical features such as tumour type and extent of 
metastatic bone disease in table 5.5. If expression of PTH-like 
activity is arbitarily defined as: 1,25(OH)2 D > 20 pmol/1; UcAMP > 
0.10 nmol/mmol creatinine; TmPO^ > 0.80mmol/l GF; and renal tubular 
contribution to hypercalcaemia of > +0.10mmol/l, PTH-like activity was 
expressed to some extent in all the patients' studied, irrespective of 
the tumour type or extent of metastatic bone disease. However, those 
with a heavy skeletal tumour load exhibited significantly fewer PTH- 
like features, when compared with those with few or no bone 
metastases; 11/27(40%) vs 30/34(88%) (X2 = 9.6 p<0.01).
5.2.4 DISCUSSION
These findings confirm that serum levels of 1,25(OH)2 D -or a
1,25 (OH) 2 D like substance - are detectable or elevated in a 
proportion of patients with malignancy - associated hypercalcaemia 
(93, Chapter 5.1). In this study, serum l,25(OH)2 D levels were
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highest in patients with squamous carcinoma, a tumour which is usually- 
associated with a humoral mechanism of hypercalcaemia (5,6,7,8,9,93). 
Conversely, in patients with breast carcinoma, and other tumours with 
extensive bone metastases, l,25(OH)2 D levels were generally 
suppressed, consistent with a "local-osteolytic" mechanism of 
hypercalcaemia (5). Although levels of precursor 25 (OH) D were not 
measured in this study, previous data (Chapter 5.1) indicate that the 
levels of this metabolite are generally low in cancer associated 
hypercalcaemia and do not correlate with levels of 1,25 (OH) 2 D. As in 
the previous study (Chapter 5.1) , hypophosphataemia could not be 
implicated as the cause of the elevation in 1,25(OH)2 D levels, as 
there was no correlation between serum phosphate and 1,25(OH)2 D 
concentrations.
Urinary cyclic AMP levels in our patients with malignant 
hypercalcaemia were generally elevated, but unlike 1,25(OH) 2 D levels 
were not significantly different in patients with a heavy skeletal 
tuomour load, when compared with those who had few or no metastases. 
These finding differ from those of Stewart et al (93) who were able to 
completely separate patients with "humoral" and "local osteolytic" 
mechanisms of hypercalcaemia by the pattern of nephrogenous cyclic AMP 
excretion. Although it is possible that calculation of nephrogenous 
cyclic AMP (NcAMP) in this study may have yielded different results, 
it was not possible to measure plasma cyclic AMP and hence calculate 
the NcAMP component in this study. Nonetheless, Rude et al (151), who 
measure both urinary cyclic AMP and NcAMP in hypercalcaemic and 
normocalcaemic cancer patients, found that levels of both may be 
increased in patients with a variety of tumour types, irrespective of 
the extent of metastatic bone disease.
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It was of interest that the detectable or raised levels of 
1,25(OH) 2 D in some cancer patients were not associated with a rise in 
serum calcium values after an oral calcium load. While the oral 
calcium load test is a rather crude index of intestinal calcium 
absorption, serum calcium values did rise significantly in primary 
hyperparathyroidism as would have been expected (116) , and here, the 
increment in serum calcium correlated significantly with the 
circulating level of 1,25(OH)2 D.
The reason for the poor correlation which was observed between 
these variables in the malignancy group is unclear. It is possible 
that the levels of vitamin D binding globulin may have been altered in 
the patients with malignancy, leading to lower levels of "free" 
1,25(OH) 2 D. This seems unlikely however, as in other conditions 
associated with hypoalbuminaemia, hepatic cirrhosis for example, total 
1,25(OH) 2 D and vitamin D binding globulin levels are both reduced, 
leading to normal concentrations of "free" 1,25(OH) 2 D (293). A 
further possibility would be that the substance recognised as
1,25(OH) 2 D in patients with malignancy may have been a different 
metabolite which was devoid of biological activity such as 19-nor-10- 
keto-25-hydroxy vitamin D (294). Although there is no evidence to 
suggest that such a metabolite is produced in vivo is is difficult to 
exclude this possibility using standard methods of 1,25(OH) 2 D 
measurement, as used in this and other studies (93). While Shigeno et 
al (295) have recently described excessive production of 1,24(R)- 
hydroxyvitamin D in a hypercalcaemic patient with oat cell carcinoma 
of the lung, this metabolite is known to be biologically active with 
respect to intestinal calcium absorption, having a potency similar to 
that of 1,25 (OH) 2 D-^ . Moreover, the vitamin D metabolite present in
120
the serum of our patients co-eluted with authentic 1,25(OH)2 D on 
standard and reverse phase HPLC; in contrast, 1,24 (R) -dihydroxyvitamin 
D may be distinguised from 1,25 (OH) 2 D3 by these procedures (294).
It is therefore possible that the intestinal effects of the active 
vitamin D metabolite were impaired in patients with malignant disease, 
due to "end-organ" resistance to the effects of 1,25(OH)2 D at the 
intestinal level. Indeed, it is recognised that a generalised 
malabsorptive state may occur in cancer patients with non- 
gastrointestinal tumours (296). With regard to this possibility, it is 
relevant to note that, in one patient with hypercalcaemia of 
malignancy who may have had coexistant hyperparathyroidism 
(PTH=850ng/l; patient 7, Table 5.5) serum calcium failed to rise after 
the oral calcium load.
From the current study, it is apparent that hyperabsorption of 
dietary calcium contributes little to the pathogenesis of cancer- 
associated hypercalcaemia even when circulating levels of 1,25 (OH) 2 D 
are raised. However, the coexistence of other PTH-like biochemical 
features in patients with "inappropriately" detectable or raised
1,25 (OH) 2 D levels, would be in keeping with the action of a humoral 
mediator with a PTH-like effect on renal 1-^-hydroxylase activity.
These observations corroborate those in the rat Leydig cell tumour 
model of humoral hypercalcaemia where 1,25(OH) 2 D levels are raised(14 9) 
.Together they provide further evidence to suggest that in human 
hypercalcaemia of malignancy, a humoral mediator is released, which is 
distinct from PTH, but which can interact with the PTH receptor in 
renal and skeletal tissues (144,145,146).
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5.3 URINARY CYCLIC ADENOSINE MONOPHOSPHATE EXCRETION IN HYPERCALCAEMIC
AND NORMOCALCAEMIC PATIENTS WITH MALIGNANCY; CORRELATION WITH 
CLINICAL FEATURES AND OTHER ASPECTS OF PTH-LIKE ACTIVITY
5.3.1 INTRODUCTION
Reference has been made to the importance of urinary cyclic AMP 
excretion as a biochemical "marker" of a PTH-like humoral mechanism 
of hypercalcaemia in malignancy (93). In the previous study (Chapter 
5.2) levels of urinary cyclic AMP excretion were generally raised in 
patients with malignant hypercalcaemia, with little difference 
between subgroups of patients who had extensive, when compared with 
little or no, evidence of metastatic bone disease.
In this study the levels of urinary cyclic AMP excretion have 
been assessed in a larger group of normocalcaemic and hypercalcaemic 
patients with malignancy, in relation to other relevant clinical and 
biochemical variables.
5.3.2 PATIENTS AND METHODS
The study group comprised 47 hypercalcaemic and 12 normocalcaemic 
patients with malignant disease, who had presented consecutively to 
Glasgow Royal Infirmary. The hypercalcaemic patients with malignancy 
were rehydrated with a minimum of 6 litres intravenous 0.9% saline 
solution prior to the study. During the study, most hypercalcaemic 
patients continued to receive 2 litres of intravenous saline 0.9% 
daily to prevent possible dehydration. The urinary cyclic AMP data in 
these patients were compared with those in "control" groups of 13 
patients with primary hyperparathyroidism, and 26 healthy volunteers.
The presence and extent of metastatic bone disease in patients
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with malignancy was assessed by standard radionuclide bone scan 
examination as described previously (chapter 3.1).
Statistical methods used were the Wilcoxon test for unpaired data 
and Spearman's rank correlation coefficient.
5.3.3 RESULTS
In table 5.6, relevant biochemical data are shown in patients 
with malignant disease, on division into four categories; 
normocalcaemic (n=1 2 ) , hypercalcaemic; heavy skeletal tumour load 
(n=15) , hypercalcaemic; light skeletal tumour load (n = 9) and 
hypercalcaemic; no evidence of skeletal metastases (n=21). In the 
patients with a heavy skeletal tumour load the tumour types were; 
breast carcinoma-7 (46%), myeloma-3 (20%), and one patient each (6 %) 
with prostatic carcinoma, squamous lung carcinoma, renal carcinoma, 
oat cell carcinoma of lung and adenocarcinoma, unknown primary. In 
the patients with a light skeletal tumour load, tumour types were; 
squamous lung carcinoma-7 (77%) and genitourinary tumours-2 (23%). In 
those with no evidence of bone metastases, tumour types were; squamous 
lung carcinoma-12 (57%), genitourinary tumours 6-(28%), primary liver 
cancers-4 (19%) and adenocarcinoma, unknown primary-L (4%). Of the 
normocalcaemic cancer patients, 9 (75%) had breast carcinoma and 3 
(25%) had squamous lung carcinoma. Four of the breast carcinoma 
patients had a heavy skeletal tumour load, two had a light skeletal 
tumour load and two had no detectable bone metastases. Two of the 
patients with bronchial carcinoma had a light skeletal tumour load and 
one had no detectable metastases.
From table 5.6, it can be seen that, in the normocalcaemic
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patients, serum albumin, serum calcium, urinary Ca/Cr and urinary 
OHP/Cr values were significantly lower than in those with 
hypercalcaemia. Conversely, TmPO^ and serum phosphate values were 
significantly higher in the normocalcaemic group, when compared to the 
hypercalcaemic patients without bone metastases. Serum creatinine 
values were similar in the normocalcaemic group with respect to the 
hypercalcaemic patients with a light skeletal tumour load or no 
metastases. Serum creatinine values in the heavy tumour load group 
were, however, significantly higher than those in the normocalcaemic 
group and in the patients with a light tumour load or no metastases. 
In the heavy tumour load group, serum phosphate, urinary Ca/Cr and CaE 
values tended to be higher than those in patients with a light tumour 
load or no metastases, although the differences in Ca/Cr and Ca£ were 
significant, only with respect to the patients who had no metastases, 
due to the small number of patients having a light skeletal tumour 
load. Levels of TmPO^ were similar in the three groups of patients 
with hypercalcaemia.
In figure 5.10, the relationship between serum calcium and urinary 
calcium excretion expressed as Ca£ is shown. As in previous studies, 
most hypercalcaemic patients showed evidence of increased renal 
tubular reabsorption of calcium. In patients with a heavy skeletal 
tumour load however, the renal tubular contribution to hypercalcaemia 
(279), was significantly less than in patients with a light skeletal 
tumour load or no metastases; (mean (SEM)) increase in renal tubular 
calcium reabsorption; =+0.11 (0.09) mmol/1; heavy tumour load, n=15) 
vs +0.50 (0.06) mmol/1; no metastases and light tumour load, n=23)
(p<0.002)].
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Relation between serum adjusted calcium values and urinary Ca£ 
values in patients with malignant hypercalcaemia. Dotted lines 
indicate normal range defined by Peacock (114).
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Urinary excretion of cyclic AMP, expressed as a molar ratio, 
relative to creatinine (UcAMP) in patients with malignancy and 
primary hyperparathyroidism. Dotted lines indicate reference 
range, derived from mean+ 2 SD UcAMP values in 26 healthy 
volunteers. Bars are medians. * = p<0.05 ** = P<0.02; from
hypercalcaemic patients with a heavy tumour load and 
normocalcaemic cancer patients.
Urinary excretion of cyclic AMP, expressed as a molar ratio 
relative to urinary creatinine in the study group is shown in figure 
5.11. Urinary cAMP values in the normocalcaemic patients and the 
hypercalcaemic patients with a heavy skeletal tumour load were 
significantly lower than those in patients with a light skeletal 
tumour load (p<0.05) or no metastases (p<0.02). Urinary cAMP values in 
the patients with primary hyperparathyroidism were significantly 
higher than in patients with a heavy skeletal tumour load (p<0.05) but 
were not significantly different from those in patients with a light 
skeletal tumour load or no evidence of bone metastases.
In patients with hypercalcaemia of malignancy, significant 
correlations were observed between the following variables; serum 
calcium vs TmPO^ (r= -0.56, n=47, p<0.001), serum creatinine vs serum 
phosphate (r= 0.52, n= 47, p<0.001) , serum phosphate vs UcAMP (r= - 
0.55, n=47, p<0.001).
5.3.4 DISCUSSION
In this study, raised levels of urinary cAMP were frequently 
noted in patients with malignant hypercalcaemia. Moreover, urinary 
cAMP levels were significantly higher in the patients with no 
evidence of bone metastases and a light skeletal tumour load when 
compared with those who had a heavy skeletal tumour load. These 
findings are in broad agreement with those of Stewart and his 
colleagues (93) who, using nephrogenous cAMP (NcAMP) excretion as a 
biochemical "marker" of humoral hypercalcaemia, found generally 
elevated NcAMP values in patients with squamous and genitourinary 
cancers and low levels in patients with haematological tumours and 
breast carcinoma. In this study, however, the levels of urinary cAMP
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did not clearly distinguish between "local osteolytic" and "humoral" 
mechanisms of hypercalcaemia in malignancy, at least, as judged by- 
bone scan extent of metastastic disease. In contrast, Stewart (93) 
was able to completely separate "humoral" from "local osteolytic" 
subgroups, by the pattern of NcAMP excretion. These differences may 
partly be due to Stewart's use of NcAMP values rather than the ratio 
of urinary cyclic AMP to creatinine, since the latter fails to take 
account of an elevation in plasma cAMP levels as a possible 
explanation for an elevated urinary excretion of cAMP 
(118). Nonetheless, Rude and his colleagues, who measured both NcAMP 
and urinary cAMP/creatinine levels in hypercalcaemia of malignancy 
also failed to obtain a clear distinction between subgroups of 
patients, on the basis of cAMP measurements (151).
The rather poor specificity of urinary cAMP levels as a marker of 
humoral hypercalcaemia is exemplified by the current finding (figure 
5.11) of grossly elevated UcAMP levels in two normocalcaemic patients 
with lung cancer and indeed, Kukreja and his colleagues (152) have 
also found elevated levels of NcAMP in many normocalcaemic patients 
with squamous lung carcinoma.
The differences the levels of UcAMP excretion in different 
subgroups of patients with malignancy were accompanied by other 
biochemical differences; hypercalcaemic patients in the heavy skeletal 
tumour load group differed from those with few or no bone metastases 
with respect to other biochemical variables such as urinary Ca/Cr, 
Ca„, serum creatinine and serum phosphate values, suggesting that the 
mechanisms of hypercalcaemia may have been different in these 
patients, depending more on the combination of renal glomerular
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failure and increased bone resorption, rather than increased renal 
tubular calcium reabsorption. Nonetheless, renal tubular calcium 
reabsorption did appear to be elevated and TmPO^ values were depressed 
in many patients with a heavy skeletal tumour load consistent with a 
"PTH-like" effect on the kidney. These features may have been partly 
attributable however, to the effects of chronic, severe hypercalcaemia 
per se (259) , since levels of TraPO^ correlated inversely with the 
severity of hypercalcaemia and since the elevation in renal tubular 
calcium reabsorption was significantly lower in patients with a heavy 
skeletal tumour load, when compared with those who had few or no 
metastases.
These observations confirm that, in patients with squamous 
carcinomas or genitourinary tumours, who characteristically have few, 
or no metastases, the mechanisms of hypercalcaemia may largely depend 
on a humoral mechanism, with biochemical evidence of "PTH-like" 
effects on renal tubular calcium and phosphate handling and cAMP 
excretion (5,7,8,9,93). In patients with breast carcinoma or myeloma, 
however, where metastases are usually extensive, humoral effects on 
renal calcium handling and cAMP excretion are less prominent (93) 
although reduced levels of renal tubular phosphate reabsorption 
do occur (259).
From a practical point of view, this study has shown that 
assessment of UcAMP excretion does not give a clear distinction 
between primary hyperparathyroidism and malignant hypercalcaemia, nor 
does it clearly define subgroups within a population of patients with 
cancer-associated hypercalcaemia. The cause of the elevation in UcAMP 
levels in some normocalcaemic cancer patients, and the relatively low
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levels which were noted in some patients without bone metastases is 
unclear at present. However these features probably indicate that the 
humoral mechanisms of hypercalcaemia in maligancy are heterogeneous, 
and that adenyl-cyclase stimulating factors may be released by tumours 
not associated with hypercalcaemia.
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CHAPTER 6
RELATIVE CONTRIBUTION OF RENAL TUBULAR AND BONE RE SORPTIVE 
MECHANISMS IN HUMORALLY-MEDIATED HYPERCALCAEMIA OF MALIGNANCY
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6.1 HUMORAL HYPERCALCAEMIA OF MALIGNANCY: METABOLIC AND
HISTOMORPHOMETRIC STUDIES DURING SURGICAL MANAGEMENT 
OF THE PRIMARY TUMOUR
6 .1.1 INTRODUCTION
In patients with "non-metastatic" hypercalcaemia, resection of 
the primary tumour results in a return of serum calcium levels to 
normal (7,8,9,138). Although there have been no detailed studies of 
calcium metabolism in this situation, it has generally been assumed 
that the fall of serum calcium is due to the removal of the source of 
a circulating osteoclast-activating substance (5,90,132). While 
accelerated osteoclastic bone resorption undoubtedly makes a major 
contribution to the pathogenesis of hypercalcaemia in many cases 
(139,140,141,142), the data presented previously in this thesis 
(chapter 4) suggest that a humorally-mediated increase in renal 
tubular reabsorption of calcium may also play an important pathogenic 
role.
In the present study the relative contribution of these factors 
to the pathogenesis of hypercalcaemia were assessed in 1 0  patients who 
underwent surgical exploration of tumours associated with humorally- 
mediated hypercalcaemia.
6.1.2 PATIENTS AND METHODS
Ten patients with solid malignant tumours who had presented with 
hypercalcaemia were studied. In all cases, clinical radiological and 
scintigraphic evaluation had shown no definite evidence of tumour 
metastases, and curative surgical resection of the tumour was
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contemplated. In six cases, "curative" surgical resection of the 
tumour was possible, in a macroscopic sense. In one patient, resection 
of the tumour was incomplete, leaving a substantial mass of tumour 
cells in situ. In the remaining three cases, surgical resection of 
the tumour was precluded by local tumour spread discovered during 
surgery. Three patients had received previous antihypercalcaemic 
therapy with the diphosphonate inhibitor of bone resorption 
aminohydroxypropylidene diphosphonate (APD). In one, (patient 7), APD 
had been given 25 days before the study. In the others (patients 4 and 
5) , therapy had been given between 6 and 9 days pre-operatively.
Biochemical analyses were made on blood and true fasting urine 
samples, obtained after an overnight fast, except on the day of 
surgery, when timed urine collections with mid-point blood samples 
were obtained.
Bone histomorphometry was performed on trephine biopsies (8 mm 
diameter) , obtained from the iliac crest in eight patients. In two 
others, bone samples were obtained from sections of rib , which were 
removed at thoracotomy. In two patients who were treated with A.FD, 
(patients 4 and 5 ), the bone biopsies had been obtained before therapy 
was commenced. In the other APD-treated patient (patient 7), the bone 
biopsy was obtained on post-operative day 8 , by which time serum 
calcium values had exceeded those observed prior to APD treatment.
The statistical test used in analysis of data was the paired 
Wilcoxon test.
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6.1.3 RESULTS
(a) Clinical details
In Table 6.1, relevant clinical details including tumour type, 
age, and intravenous fluid and drug therapy are shown. In agreement 
with previous series' of humoral hypercalcaemia (7,93,138), squamous 
carcinoma of the bronchus was the commonest tumour.
(b) Serum calcium
Changes in serum calcium are shown in figures 6.1 and 6.2,All 
patients were hypercalcaemic prior to surgery, but in 2 cases, 
(patients 4 and 5), serum calcium values lay at the upper limit of 
normal on the day of operation. These patients had both received APD 
therapy between days 6 and 9 preoperatively. In patients 1-6, where 
the tumour was resected, serum calcium values fell significantly 
within about 8-10 hours after resection of the tumour. In patients 7- 
9, where the tumour was not resected, there was no significant change. 
While serum calcium fell in the patient 10, who had a partial 
resection, normal levels of serum calcium were not attained.
(c) Serum phosphate
Changes in serum phosphate are shown in figures 6.3 and 6.4 Serum 
phosphate values were low or low normal in all cases preoperatively. 
In patients 1-6, serum phosphate rose significantly from about 4-6 
hours after tumour removal, whereas no significant change was observed 
in patients 7-9, whose tumours were not resected. In patient 10, when 
the tumour was partially resected, a transient rise in phosphate 
occurred, although the post-operative level was similar to the pre­
operative level.
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FIGURE 6.1
Biochemical response to surgical management in patients (1-6), 
where the tumour was resected; serum calcium (adjusted for 
albumin), urinary ca 1 c i u m / c r e a t i n i n e (Ca/Cr), urinary 
hydroxyproline/creatinine (OHP/Cr). Dotted lines indicate normal 
ranges. Significant difference from day before surgery indicated 
as *=p<0.05.
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FIGURE 6.2
Biochemical response to surgical management in patients where the 
tumour was not resected (7-9) or partially resected (10); serum 
calcium (adjusted for albumin), urinary calcium/creatinine 
(Ca/Cr), urinary hydroxyproline/creatinine (OHP/Cr). Dotted lines 
indicate normal ranges. Significant difference from preoperative 
day indicated by *=p<0.05.
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FIGURE 6.3
Biochemical response to surgical management in patients (1~6) 
where the tumour was resected; serum inorganic phosphate, renal 
tubular threshold for phosphate reabsorption (TmP04) and urinary 
sodium excretion (NaE). Dotted lines indicate normal ranges. 
Significant difference from day before surgery indicated by 
*=p<0.05.
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FIGURE 6.4
Biochemical response to surgical management in patients where the 
tumour was not resected (7-9) or partially resected (10); serum 
inorganic phosphate, renal tubular threshold for phosphate 
reabsorption (TmPO^) and urinary sodium excretion (NaE). Dotted 
lines indicate normal ranges. Significant difference from 
preoperative day is indicated by *=p<0.05.
(d) Serum creatinine
Serum creatinine values were within the normal range in all 
patients pre-operatively; (median (range) = 72.5 (55-110) pmol/1 and
did not change significantly after surgery (80 (50-135) pmol/1. In two 
patients who underwent nephrectomy however, creatinine rose from 
80pmol/l to 135pmol/l (patient 3) and 85pmol/l to 100pmol/l (patient 
6) .
(e) Serum albumin
Serum albumin values tended to be low pre-operatively; median 
(range) = 29.5 (26-42) g/1 and fell slightly after surgery to 28 (24- 
45) g/1, although the change was not statistically significant (Table 
6 .2) .
(f) Serum bicarbonate and chloride
Serum bicarbonate concentrations were within the normal range in 
all patients pre-operatively; (median (range) = 28 (25-31) mmol/l and 
did not change significantly thereafter; 27.5 (23-29) mmol/l. Serum
chloride concentrations were reduced in three cases preoperatively 
(patient 4; 95 mmol/l, patient 8 ; 94 mmol/l, patient 9; 92 mmol/l), 
but were normal in the remainder; median (range) = 99 (97-104) mmol/l. 
and did not change significantly after surgery 99 (95-104) mmol/l.
(g) Plasma parathyroid hormone (iPTH)
Before operation, iPTH levels were undetectable in all cases. In 
one patient (patient 2) iPTH rose to 490 ng/1 on the fourth post 
operative day. In the remainder, iPTH levels remained undetectable 
throughout the study period.
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(h) Nephrogenous cyclic AMP (NcAMP)
Levels of NcAMP were measured pre-operatively in three cases 
(patients 2,3,4). Values were elevated at 50, 60 and 42 nmol/1 GF 
respectively.
(i) Urinary calcium/creatinine ratio (Ca/Cr)
Changes in Ca/Cr values are shown in figures 6.1 and 6.2. In 
patients 1 -6 , whose tumours' were resected, there was a significant 
elevation in Ca/Cr values between 4-8 hours after resection of the 
tumour. A similar elevation in Ca/Cr values was noted in the patient 
10, whose tumour was partially resected. There was no significant 
change in Ca/Cr values in patients 7-9, whose tumours were not 
resected.
(j) Urinary sodium excretion (NaE)
The response of urinary Na£ values are shown in figures 6.3 and 
6.4. Changes in urinary Na£ values were similar to those of Ca/Cr 
values, in that there was a substantial rise in Na£ between 4-8 hours 
after resection of the tumour in patients 1-4, 6 , and 10. In patient 
5 however, urinary Na„ values fell on the dav of surererv desoite the
’ U Cu -
fact that Ca/Cr values in this patient rose slightly. In patients 7- 
9, there was no consistent pattern of change in NaE values on the day 
of surgery.
Urinary Na£ values were generally low on post-operative days 1 
and 2 .
(k) Urinary hydroxyproline/ creatinine ratio (OHP/Cr)
Urinary OHP/Cr values are shown in figures 6.1 and 6.2. Urinary 
OHP/Cr values were normal or moderately elevated in most patients 
preoperatively, except in patient 10 where OHP/Cr values were markedly
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raised. In patients 1-6, OHP/Cr values were transiently reduced on 
post-operative day 1 from the pre-operative level. In patient 7, 
OHP/Cr levels rose gradually throughout the study period, reaching a 
markedly elevated level by the fifth post-operative day. This patient 
also had increased resorption surfaces on bone biopsy (table 6 .2 )
(1) Serum calcium vs urinary calcium excretion (CaE)
The response of serum calcium vs urinary CaE values are shown in 
figures 6.5 and 6 .6 . In all patients, urinary excretion of calcium was 
reduced relative to serum calcium preoperatively, indicating that 
renal tubular calcium reabsorption was increased. Following resection 
of the tumour in patients 1 -6 , there was a rightward shift in the 
serum calcium vs CaE points to within the normal range, indicating 
that renal tubular calcium reabsorption had fallen. In patients 7-9, 
where the tumour was not resected, there was no significant movement 
of the points indicating that renal tubular calcium reabsorption was 
unchanged. In patient 10, there was a transient leftward shift of the 
points, indicating that renal tubular reabsorption had fallen during 
the immediate 4-8 hours after surgery but the points still lay to the 
right of the expected normal indicating that renal tubular calcium 
reabsorption had remained elevated above normal.
(m) Renal tubular threshold for phosphate reabsorption (TmPO^)
The response of TmPO^ is shown in figures 6.3 and 6.4. In all 
patients, TmPO^ values' were low, or low-normal pre-operatively. In 
patients 1-6 there was a significant elevation on TmPO^ from within 2 
hours of tumour resection and this was sustained therafter. TmPO^ 
values did not change significantly in patients 7-9 where the tumour 
was not resected, whereas in patient 10, TmP04 rose transiently.
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FIGURE 6.5
Response of serum adjusted calcium vs urinary CaE values to 
surgical management, in patients (1 -6 ) where the tumour was 
resected. Values are mean (SEM). Dotted lines indicate normal range 
defined by Peacock (114).
(T) “ preoperative value.
2 )- postoperative value.
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FIGURE 6.6
Response of serum adjusted calcium vs CaE values to surgical 
management in patients (7-9) O  where the tumour was not resected and 
in patient (10) ♦  where the tumour was partially resected. Values are 
mean (SEM) in patients (7-9). Dotted lines indicate normal range 
defined by Peacock (114).
(?)- preoperative value.
2 )- postoperative value.
TABLE 6.2
HisaaycRPiCMEiKcc eata in patienis umfrboing surgical trekment
GF TUMOURS ASSOCIATED WITH HOCRAL HXPERCAECAEMIA CF MtfJjQBBCY
PATIENT TOTAL ACTIVE NUMBER CF TOTAL ACTIVE
RESCRPTICN RESCRPTICN OSTEOCLASTS OSTEOID OSTEDID
1
2
3
4
5
6
7
8
9
10
SURFACE
(%)
0.70
3.20 
11.7
4.06
8.00
3.20
3.20 
12.1
SUREACE
(%)
0.00
0.40
5.29
1.92 
4.00 
1.10 
0.40 
5.10 '
PER imv- 
0.03
0.07
0.86
0.37
0.97
0.15
0.07
0.66
SUREACE SURFACE
(%)
23.5
12.8
14.5
9.19 
21.2
3.20 
12.8
26.7
(%)
1.25
1.20
2.50
0.36
2.40
1.10
1.20
0.39
Reference Range (< 7.3) (< 2.4) (< 0.28} (< 24) (< 2.0}
(n) Bone Histomorphometry
Histomorphometric data are shown in table 6.2. For technical
reasons, histomorphometry could not be performed in two cases;
patient 2 (poor staining) and patient 5 (fragmented biopsy). There was
no evidence of secondary tumour in any of the specimens. In most
cases, indices of bone resorption and bone formation were within the
normal range. The only significant abnormal findings were in patients
4, 7 and 10 where total and active resorption surfaces and number of
2
osteoclasts per mm were increased.
6.1.4 DISCUSSION
In humorally-mediated hypercalcaemia of malignancy, the elevation 
in serum calcium is attributed to excessive osteoclastic bone 
resorption, stimulated by an osteoclast activating substance released 
by tumour cells (5,6,7,8,138). On removal of the primary tumour, serum 
calcium returns to normal (7,8,9,138), by mechanisms which have 
hitherto been ill-defined.
If hypercalcaemia were indeed solely due to increased 
osteoclastic bone resorption, one would expect that the fall in serum 
calcium would be accompanied by a fall in urinary calcium excretion 
and hydroxyproline excretion, as the source of the putative osteoclast 
activating substance was removed. In this study, however, urinary 
calcium excretion was only slightly elevated prior to surgery, 
reflecting the importance of increased renal tubular reabsorption of 
calcium as a factor in the pathogenesis of hypercalcaemia. On removal 
of the primary tumour in six patients, there was a significant rise in 
the urinary excretion of calcium, a significant fall in renal tubular 
reabsorption of calcium and a rise in the renal tubular threshold for
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phosphate reabsorption. Subsequently, there was an elevation in serum 
phosphate and a reduction in serum calcium, both of which were 
sustained throughout the study. These changes are similar to those 
observed after parathyroidectomy in patients with primary 
hyperparathyroidism (297) and suggest that a principal effect of the 
putative humoral mediator had been PTH-like activity with regard to 
the renal handling of calcium and phosphate. The changes observed are 
unlikely to have resulted from the effect of a surgical operation per 
se, since they did not occur in the patients whose tumours were not 
resected. It must be acknowledged that blood transfusions which were 
given to the patients undergoing "curative" resection may have 
contributed to these changes. However, this effect did not appear to 
have been of major significance as blood transfusions given to a 
number of patients pre-operatively had little apparent effect on the 
biochemical parameters observed.
The rise in urinary sodium excretion which was observed after 
removal of the tumour is of interest, as elevated renal tubular 
reabsorption of calcium may occur as the result of sodium depletion 
(268). Our patients were not dehydrated or sodium depleted on a 
clinical basis however, and all had received intravenous infusions of 
saline in the immediate 24 hours before surgery. Moreover, in most 
cases, urinary NaE values fell within the normal reference range pre­
operatively. Although the mechanism of the rise in urinary sodium 
excretion is unclear, it may have been due to the calciuresis which 
was also noted (298). The natriuresis is unlikely to have been due to 
the effects of the intravenous fluids given during surgery, as no
rise in Na„ values occurred in the patients whose tumours were not E
resected.
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The bone histology and urinary hydroxyproline measurements also 
support a predominantly renal tubular, rather than bone resorptive 
mechanism of hypercalcaemia; in the eight patients where histological 
data was available, bone resorption was normal in four cases and only 
slightly elevated in the remainder. Although urinary hydroxyproline 
levels were slightly elevated in some patients preoperatively, there 
was little change in hydroxyproline after successfull surgical 
resection of the primary tumour, apart from a minor reduction on 
postoperative day 1 .
The biochemical findings in isolation would be insufficient 
evidence for a predominantly renal tubular action of the humoral 
mediator causing hypercalcaemia, due to the difficulties which are 
inherent in the interpretation of data in patients who are undergoing 
major surgical procedures. However, when taken in conjunction with the 
bone histomorphometric data, they indicate that hypercalcaemia in 
these patients was corrected mainly by a fall in the renal tubular 
calcium threshold, rather than a reduction in bone resorption.
These data differ considerably from those of previous workers, 
who have considered that humoral hypercalcaemia in malignancy is 
largely the result of accelerated bone resorption (5,7,8,9,93), but 
concur with the evidence presented in chapter 4, suggesting that the 
putative humoral mediator may have an additional site of action on the 
renal tubule. The absence of increased osteoclastic bone resorption 
which was observed in some patients is the most surprising finding to 
emerge from this study and contrasts with the marked increase in 
osteoclastic bone resorption and depressed osteoblastic activity 
reported by Stewart and his colleagues (139). In that study, however,
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four of the seven bone biopsies were taken from patients who were 
immobile with advanced malignant disease, and a further three had been 
obtained post-mortem. Bone samples were also obtained after death in 
two non-histomorphometric studies, where increased osteoclastic bone 
resorption was observed (140,141). It should be emphasised however, 
that bone resorption may be increased in bedridden patients dying from 
cancer who do not have hypercalcaemia (299), and in general terms, 
immobilisation may cause marked uncoupling of bone resorption and bone 
formation (300) , sufficient to precipitate severe hypercalcaemic 
crises in patients with mild hyperparathyroidism who had been confined 
to bed after fractures (301).
The differences in bone histology between this study and that of 
Stewart and his colleagues (139) is unlikely to have been due to 
differences in the nature of the humoral mediators involved, in view 
of the similarities in terms of tumour type, and biochemical features. 
The patients in our study were, however, a selected group in whom bone 
biopsies were obtained ante-mortem, in association with cancers at a 
less advanced stage than those studied previously (139,140,141,299).
A possible explanation would be that in the earlier stages, humoral 
hypercalcaemia is mediated by a renal tubular mechanism, whereas on 
progression of the disease, osteoclastic resorption plays a more 
important role, as the degree of immobility increases.
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6.2 DIFFERING MECHANISMS OF HYPERCALCAEMIA IN PATIENTS WITH
EARLY AND ADVANCED HUMORAL HYPERCALCAEMIA OF MALIGNANCY
6.2.1 INTRODUCTION
In the previous study (6.1),it was found that an elevated renal 
tubular threshold for calcium reabsorption, rather than an elevation 
in osteoclastic bone resorption was the predominant mechanism of 
hypercalcaemia in some patients with early malignant tumours. From 
these observations, it was speculated that the previously noted 
"uncoupling" of bone resorption and bone formation in humoral 
hypercalcaemia (139) may have been partly due to the immobilisation of 
advanced malignant disease.
In this study, histomorphometry and biochemical characteristics 
were assessed in a larger group of patients with humorally mediated 
hypercalcaemia, with particular reference to the effects of 
immobilisation. These data were compared with those in a group of 
patients with primary hyperparathyroidism, who were matched for the 
severity of hypercalcaemia.
6.2.2 PATIENTS AND METHODS
The study group comprised 15 patients with cancer-associated 
hypercalcaemia, in whom a humoral aetiology was suspected either 
because bone metastases were excluded by standard radiological and 
radionuclide bone scan examination ( 1 0 cases), or because the severity 
of metastatic disease thus demonstrated (<4 lesions) was thought to be 
insufficient to account for the hypercalcaemia (5 cases). In 8  
patients (described in chapter 6 .1 ), bone biopsies were taken prior
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to, or during surgical exploration of the primary malignant tumour. In 
the remaining 7 cases, 5 bone biopsies were obtained ante-mortem, and 
2 were obtained post-mortem.
All patients with malignancy were rehydrated with intravenous 
0.9% saline solution prior to the study. Three had received previous 
antihypercalcaemic therapy (2-APD, 1-mithramycin). In all three cases, 
however, serum calcium values had exceeded those observed before 
antihypercalcaemic therapy, suggesting that any suppressive effects on 
bone resorption had disappeared by the time of study. No patient had 
received previous anti-cancer chemotherapy, or other medication which 
may have significantly affected calcium homeostasis.
Data from the patients with malignancy were compared with those 
in a group of patients with primary hyperparathyroidism, who were 
selected on the basis that they had hypercalcaemia of similar 
severity. One patient w^ Lth primary hyperparathyroidism had been bed- 
bound for some weeks prior to study in another hospital with severe, 
undiagnosed hypercalcaemia. In this patient, the bone biopsy was 
obtained immediately prior to emergency neck exploration. The 
remaining 16 hyperparathyroid patients were normally hydrated on a 
clinical basis with stable hypercalcaemia and renal function. All were 
ambulant and attending hospital on a "day patient" basis.
Biochemical analyses were performed on blood and true fasting 
urine specimens, obtained after an overnight fast.
In all of the patients with hyperparathyroidism and 13 with 
malignancy, histomorphometry was performed on transiliac anterior 
iliac crest bone biopsies. In the two remaining patients,
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histomorphometry was carried out on a section of rib removed at 
thoracotomy in one, and on a vertebral body removed at post mortem in 
the other.
The degree of immobility in patients with malignancy was asseseed 
using a four point scale as follows:
(1) In patient, completely bed bound.
(2) In patient, limited mobility in hospital ward.
(3) Out patient, ambulant, but with restricted activity
(4) Out patient, fully ambulant, undertaking normal activity.
The stage of tumour advancement at the time of biopsy was
assessed simply by recording the interval between the time of death 
and the time of study.
Statistical methods used were the Wilcoxon test for paired 
and unpaired samples, and Spearman's rank correlation coefficient.
6.2.3 RESULTS
Relevant clinical and biochemical variables in patients with 
humoral hypercalcaemia of malignancy and primary hyperparathyroidism 
are compared in table 6.3. Serum albumin and iPTH levels were 
significantly lower, and urinary hydroxyproline levels significantly 
higher in the malignant group, although in other respects, the two 
groups were well matched. One patient with malignancy had a raised 
iPTH value; 1600ng/l. In this patient, post-mortem examination failed 
to reveal evidence of a co-incidental parathyroid adenoma. A sample of 
tumour tissue obtained at post-mortem examination was subsequently 
found to stain positively for PTH, using immunocytochemical methods, 
consistent with the rare syndromp of true ectopic PTH production.
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TAELE 6.3
CLINICAL AND BIOCHEMICAL rs?IATLS IN PATgNTS WITH BBCRAL HYFEKADCAEHIA 
CF MALIGNANCY AND PRBftKY HYPERPARAIHYIOIDISM
MAT.F/EEMAT.E
SERUM CALCIUM
(nmol/1)
SERUM PHOSPHATE 
(imol/1)
PLASMA iPTH 
(ng/1)
SERUM CREATININE
(Utol/1)
SERUM ALBUMIN
(g/i)
URINE Ca/Cr 
(nrnol/hrnol)
URINE CHP/Cr 
(yirol/hrool)
URINEB e
(imol/lGD
TIP IMF, G&MP
(nmol/IGF)
HnPO„
(irrroi/lGF)
RENAL TUBULAR
CALCIUM REABSQRFTICN 
(ntnol/1 )
4-
HUMORAL 
HYPERCALCAEMIA 
OF MALIGNANCY 
(n=15)
9/6
3.31(0.13) 
(2.80->4.50)
0.80(0.02)
(0.70-0.95)
106 (106) * 
(UD-1600)
92(5.5)
(55-180)
29(1.5)
(23-44)
1.02(0.17)
(0.35-2.40)
55(6)
(28-98)
2.00(0.14)
(0.90-2.74)
72(13)
(24-230)
0.63(0.04) 
(0.45-0.95)
-tO. 46 (0.07) 
(40.01—KL. 02)
PRIMARY
HYPERPARATHYROIDISM
(n=17)
5/12
3.17(0.11)
(2.70->4.50)
0.80(0.06)
(0.90-1.65)
1351(247)
(390-3600)
104(11.8)
(55-230)
39(1.8)
(30-47)
0.80(0.06)
(0.34-1.25)
36(5)
(17-74)
1.70(0.22)
(0.50-3.20)
53(8)
(8-133)
0.56(0.03)
(0.30-0.90)
40.40(0.08)
(-0.04-40.88)
STATISTICAL
SIGNIFICANCE
NS
NS
NS
p<0 . 0 0 1
NS
pcO.001
NS
p<0.02
NS
NS
NS
values are mean(SEM)
(range)
*one patient with mlignancy had a detectable iPIH value (1600ng/l) 
NS - no significant difference
4- - calculated by the method described in figure 2.2
Tumour types in patients with malignancy were: squamous carcinoma 
of the lung 9 (58.5%); squamous carcinoma of gallbladder 1 (6.5%); 
renal adenocarcinoma 3 (19.5%); cholangiocarcinoma 1 (6.5%);
adenocarcinoma, primary unknown 1 (6.5%). In table 6.4, selected
biochemical variables from the malignancy group are shown on further 
division by the clinical circumstances of the patients at the time of 
study. Serum calcium and creatinine levels were greatly elevated prior 
to death in two patients where post-mortem biopsies were obtained. 
Athough no urinary measurements were possible immediately prior to 
death in these patients, data from studies performed at an earlier 
stage in the patients’ illnesses were similar to those in the other 
patients with malignancy. Indeed, no significant difference in 
biochemical variables was observed between the subgroups of patients 
with malignancy, except in 5 patients where serum calcium values fell 
and serum phosphate values rose significantly after resection of the 
primary tumour, mainly due to changes in the levels of renal tubular 
calcium reabsorption and phosphate reabsorption.
Relevant histomorphometric data are shown in figures 6.7 and 6 .8 , 
grouped to indicate indices of bone formation and bone resorption. 
All indices of bone formation (TOS, AOS, AOV) , were significantly 
lower in the malignancy group. In contrast, indices of bone 
resorption (TRS, ARS, NO) , were similar in both. In the malignancy 
group, histological indices of active bone resorption (ARS, NO) 
correlated significantly with the calcium "flow" component of 
hypercalcaemia, as calculated from the biochemical data (r=0.65, 
p<0.05) ; r=0.62, p<0.05, respectively). In the hyperparathyroid group,
calcium flow did not correlate significantly with resorption indices, 
but TRS correlated significantly with serum calcium (r=0.62, p<0.02).
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FIGURE 6.7
Indices of bone formation in patients with primary 
hyperparathyroidism (HPT) and humoral hypercalcaemia of malignancy 
(HHM). AOV = absolute osteoid volume; AOS = active osteoid surface; 
TOS = total osteiod surface. Dotted lines indicate normal ranges. 
Bars are medians. In HHM group, symbols denote; surgically treated 
(tumour resected -O), (tumour not resected =□); surgery not 
considered (antemortem biopsy =#), (postmortem biopsy =H)* In 
HPT group, symbols denote; (mobile =0), (immobile =^) •
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FIGURE 6 . 8
Indices o f  b o n e  r e s o r p t i o n  i n p a t i e n t s  w i t h  p r i m a r y  
hyperparathyroidism (HPT) and hypercalcaemia of malignancy (HHM). TRS 
= total r e s o r p t i o n  surface, ARS = a ctive r e s o r p t i o n  surface, NO = 
number of o s t e o c l a s t s  per m m  . D o t t e d  lines i n d i c a t e  n o r m a l  range. 
Bars are medians. In the HHM group, symbols denote; surgically treated 
(tumour r e s e c t e d  = 0 ) ,  (tumour not r e s e c t e d  = □ ) ;  s u r g e r y  not 
considered ( a n t e m o r t e m  b i o p s y  = • ) ,  ( p o s t m o r t e m  b i o p s y  = M ) .  In the 
HPT group, symbols denote; (mobile = #  ), (immobile = ^ ) .
The relationship between TRS and AOS in hyperparathyroidism and 
malignancy is shown in figure 6.9. In both malignancy and 
hyperparathyroidism, there was no significant correlation between 
these variables when all patients were considered together. However, 
when the immobilised patients were excluded, there were positive 
correlations between AOS and TRS (r = 0.59, p<0.05), TOS and TRS 
(r=0.57, p<0.05) in the hyperparathyroid patients, but not in those 
with hypercalcaemia of malignancy. It is relevant to note that 
indices of bone resorption and formation were normal in a proportion 
of patients with both conditions. Conversely, in patients who were 
immobilised with severe hypercalcaemia, there was marked "uncoupling" 
of bone resorption and bone formation in both conditions.
Representative photomicrographs from 6 bone biopsies are shown in 
figures 6.10 - 6.15, demonstrating that in both conditions, the 
histological appearance of bone may be normal (figures 6 .1 0 , 6 .1 1 ), 
show increased bone resorption and formation (figures 6.12, 6.13), or 
show "uncoupling" of bone resorption and bone formation (figures 6.14, 
6.15) depending on the clinical circumstances.
In patients with hypercalcaemia of malignancy, there were 
significant correlations between the stage of tumour advancement, 
degree of immobility and severity of bone resorption. Thus, the 
correlation between TRS and degree of immobility was; r=0.75, p<0.01,
and the correlation between TRS and stage of tumour progression was 
r=0.87, p<0.01 (figure 6.16 and inset). Similar correlations were
observed between both other histological indices of bone resorption 
(ARS and NO) and these clinical variables (data not shown). The 
degree of immobility and stage of tumour advancement were inter-
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FIGURE 6.9
Relation between histological indices of bone resorption and bone 
formation in primary hyperparathyroidism (HPT) <J> and hypercalcaemia 
of malignancy (HHM) 6  . TRS - total resorption surface, AOS -
active osteoid surface. 0  - immobilised patients with HHM;
^  - immobilised patient with HPT.
FIGURE 6.10
Photomicrograph (xl34 magnification; toluidine blue stain) of bone 
from patient with primary hyperparathyroidism and mild hypercalcaemia 
(2.75 mmol/1) showing normal bone architecture. Note smooth bone 
surfaces, with no evidence of increased resorption. A seam of osteoid 
is arrowed.
FIGURE 6.11
Photomicrograph (xl34 magnification; toluidine blue stain) of bone 
from an ambulant patient with HHM who had mild hypercalcaemia (3.10 
mmol/1), showing normal bone architecture. Note smooth bone surfaces 
with no evidence of osteoclastic resorption.
FIGURE 6.12
Photomicrograph (xl34 magnification; toluidine blue stain) of bone 
from patient with HPT showing evidence of increased bone turnover. 
Note areas of osteoclastic bone resorption (closed arrows) in close 
proximity to osteoid seams (open arrows) Patient fully mobile with 
moderate hypercalcaemia (3.25 mmol/1).
FIGURE 6.13
Photomicrograph (xl34 magnification; toluidine blue stain) of bone 
from a patient with HHM showing evidence of increased bone turnover. 
Patient had limited mobility around hospital ward and moderate 
hypercalcaemia (3.25 mmol/1). Note evidence of osteoblastic activity 
and extensive oseoid seams (open arrows), in close proximity to 
osteoclastic bone resorption (closed arrows).
FIGURE 6.14
Photomicrograph (xl34 magnification; toluidine blue stain) 
from a patient with HPT who had severe hypercalcaemia (serum 
>4.50 mmol/ 1 ) and who was immobilised before the biopsy was taken. 
Note florid osteoclastic bone resorption (closed arrows). No osteoid 
is visible.
of bone 
calcium
FIGURE 6.15
Photomicrograph (xl34 magnification; toluidine blue stain) of bone 
from a patient with HHM. The bone biopsy was obtained post-mortem in a 
patient who had been immobilised for some time prior to death with 
severe hypercalcaemia (serum calcium >4.5 mmol/1). Note florid 
osteoclastic bone resorption (closed arrows). No osteoid is visible.
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FIGURE 6.16
Relation between stage of tumour advancement in HHM and extent of 
bone resorption, represented by total resorption surface (TRS). Inset 
shows the relation between TRS and degree of immobility. Symbols 
represent; surgically treated (tumour resected =0), (tumour not 
resected =□), not surgically treated (antemortem biopsy =•), 
(postmortem biopsy =H).
related (r=0 .8 6 , p<0 .0 1 ).
6.2.4 DISCUSSION
It is generally considered that increased osteoclastic bone 
resorption alone plays the major role in the pathogenesis of humoral 
hypercalcaemia of malignancy, due to the osteoclast activating effect 
of h u m o r a l  s u b s t a n c e s  r e l e a s e d  by t u m o u r  tissue 
(5,7,8,9,77,78,93,105). Hitherto, it has been proposed that the 
putative humoral mediators of hypercalcaemia in malignancy differ from 
PTH both structurally (9 3,130,144,145,146) and functionally,in being 
devoid of PTH-like effects on renal l-o(-hydroxylase activity and renal 
tubular reabsorption of calcium (93). Moreover, in a previous 
histomorphometric study of patients with humoral hypercalcaemia of 
malignancy (139), marked increases in osteoclastic bone resorption 
were observed in the presence of depressed bone formation, suggesting 
that the skeletal effects of the putative humoral mediator were also 
quite distinct from those of PTH.
In this study, wide variability in bone histology was found in 
patients with both primary hyperparathyroidism and malignant 
hypercalcaemia, depending on the clinical circumstances; osteoclastic 
bone resorption was normal in bone biopsy specimens from the majority 
of patients with early tumours, but was greatly increased in post­
mortem biopsies from patients who had been immobilised in the terminal 
stages of their illness.
These differences in bone histology did not appear to be due to 
differences in the nature of the humoral mediator causing 
hypercalcaemia as clinical and biochemical charachteristics were
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fairly uniform in patients with humorally-mediated hypercalcaemia; the 
majority had squamous or genitourinary cancers (6 ,7 ,8 ,9 3 ), and with 
one exception iPTH levels were depressed (93,130,132). Despite this, 
levels of urinary cyclic AMP were raised (93,151) and TmPO^ values 
were low or low/normal (6,7,93,148). While most patients with 
malignancy were hypercalciuric in absolute terms (93) , the levels of 
urinary calcium excretion were not significantly different from those 
in hyperparathyroidism, reflected by a similar elevation of renal 
tubular calcium reabsorption was in both conditions. Since levels of 
serum calcium, serum creatinine, and urinary sodium excretion were 
similar in both conditions, the elevation in renal tubular calcium 
reabsorption in malignancy is unlikely to have been due to factors 
such as renal failure, dehydration or sodium depletion. Rather, these 
observations suggest that there was a PTH-like effect on renal tubular 
calcium reabsorption in the patients with malignancy (Chapter 4).
The importance of these renal tubular effects in the 
pathogenesis of hypercalcaemia is demonstrated by the biochemical 
response observed in the 5 patients with malignancy who had resectable 
(n=4) or partially resectable (n=l) tumours. As alluded to in the 
previous study (Chapter 6.1) , biochemical and histomorphometric 
indices showed that osteoclastic bone resorption was normal or only 
slightly elevated prior to surgical resection, and that the fall in 
serum calcium values post-operatively was due mainly to a reduction in 
renal tubular calcium reabsorption.
An intriguing feature in this study was the fact that,in many 
cases, these PTH-like effects on the kidney occurred in the absence of 
osteoclastic bone resorption. These findings concurr, with the data
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of Caverzasio and his colleagues however, who found that in the rat 
Leydig cell tumour model of humoral hypercalcaemia of malignancy 
(HHM) , elevations in renal tubular calcium reabsorption occurred 
before osteoclastic bone resorption became raised (302). In other 
studies, D'Souza was unable to inhibit bone resorption stimulated by 
extracts of the rat Leydig cell tumour in vitro, using synthetic 
analogues of PTH at concentrations which completely abolished their 
adenylate cyclase stimulating activity (150). Thus, from the current 
findings and those referred to above, it would appear that, in the 
early stages of HHM, the adenylate cyclase stimulating factors possess 
potent PTH-like effects on the kidney. However, at these 
concentrations, the adenylate-cyclase stimulating factors do not 
appear to possess significant stimulatory effects on osteoclastic bone 
resorption. These observations are of interest since PTH itself is 
recognised to cause hypercalcaemia in most patients with primary 
hyperparathyroidism by increasing renal tubular reabsorption of 
calcium, rather than by increasing bone resorption (114)
On the basis of D'Souza's work, referred to above (150), Mundy 
has suggested that the accelerated bone resorption in HHM may be 
largely due to release of the transforming growth factors, rather than 
the PTH-like factors (90). A further possibility however, raised by 
the present study, is that the combined effects of immobilisation and 
the adenylate cyclase stimulating factors may have acted 
synergistically on the skeleton to increase osteoclastic bone 
resorption in patients with more advanced tumours.
We w e r e  able to c o n f i r m  Stewart's o b s e r v a t i o n  that i n d i c e s  of 
bone f o r m a t i o n  a r e  g e n e r a l l y  l o w e r  in H H M  t h a n  in p r i m a r y
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hyperparathyroidism (139). However, greatly increased bone resorption 
with depressed bone formation were also noted in one immobilised 
patient with hyperparathyroidism, suggesting that "uncoupling" of bone 
cell activity is not a specific feature of HHM, as suggested by 
Stewart (139) , but rather, may occur when a humorally-mediated 
increase in bone resorption occurs in combination with immobilisaton. 
Although indices of bone formation did not correlate significantly 
with degree of immobilisation or stage of tumour progression in 
patients with HHM, these subjects were less physically active, more 
cachectic and more unwell than those with hyperparathyroidism. It is 
possible therefore, that the combination of these factors may have 
resulted in lower rates of active bone formation. An alternative 
explanation would be the release of substances such as the tumour 
necrosis factors, which have been shown to directly inhibit bone 
formation in vitro and are thought to be partly responsible for the 
cachexia associated with cancer (51).
The present studies confirm that the humoral mediators in HHM 
are similar to PTH with regard to their effects on the kidney (93). 
They are also analogous to PTH with respect to their skeletal effects, 
in that enhanced renal tubular reabsorption of calcium was a more 
important mechanism of hypercalcaemia than increased bone resorption 
in patients with early tumours (114). While we confirmed that 
osteoclastic bone resorption is "uncoupled" from bone formation in 
patients with advanced HHM (139,140,141), these abnormalities may have 
been partly explained by the effects of immobilisation. From our data, 
it is unclear whether the florid increases in osteoclastic bone 
resorption associated with advanced HHM are wholly explained by the
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combined effects of the adenylate-cyclase stimulating factors and 
immobilisation or whether other tumour-associated bone resorbing 
substances also play a pathogenic role at this stage (78,104,51).
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CHAPTER 7
MANAGEMENT OF MALIGNANCY ASSOCIATED HYPERCALCAEMIA
150
7.1 COMPARISON OF AMINOHYDROXYPROPYLIDENE DIPHOSPHONATE, MITHRAMYCIN
AN D  CORTICOSTEROIDS/CALCITONIN IN THE TREATMENT OF MALIGNANCY 
ASSOCIATED HYPERCALCAEMIA
7.1.1 INTRODUCTION
Hypercalcaemia asoociated with malignant disease is probably the 
most common indication for the use of medical antihypercalcaemic 
therapy in hospital practice (179). Clinicians are faced with a 
variety of drugs for such treatment including glucocorticoids, 
calcitonin, phosphate, mithramycin, diphosphonates and prostaglandin 
synthetase inhibitors. There is no uniformly effective 
antihypercalcaemic treatment available which is also well tolerated 
however. In view of this, it is surprising that only two substantial 
comparative studies of antihypercalcaemic therapy have been reported 
(186,189). In this study, the effects of aminohydroxypropylidene 
diphosphonate (APD), mithramycin and the combination of 
corticosteroids and calcitonin - three of the most powerful 
antihypercalcaemic regimens available (189,244) - have been compared 
in the treatment of cancer-associated hypercalcaemia.
7.1.2 PATIENTS AND METHODS
Thirty-nine patients who presented consecutively to Glasgow Royal 
Infirmary with cancer-associated hypercalcaemia - defined as serum 
calcium (adjusted for albumin) greater than 2.80 mmol/1 - were 
studied. A patient was selected for study if the clinician in charge 
of the patient had considered that antihypercalcaemic therapy was an 
appropriate form of management, usually because of symptoms 
attributable to the hypercalcaemia. All patients or their families
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gave informed consent to entering the study.
The patients were initially rehydrated with intravenous 0.9% 
saline, 500ml every 4 hours for a minimum of 48 hours, then 500ml 
every 6 hours for 12 hours before administration of drug therapy. 
During treatment, saline infusions of 2 litres daily were continued 
until serum adjusted calcium had fallen below 2.80 mmol/1 and/or until 
the patients' clinical state of hydration was judged adequate and a 
liberal fluid intake (>2 litres daily) was established. APD was given 
as an intravenous infusion of 15mg in 250ml saline each day until 
serum calcium was normal (2.60 mmol/1), or a nadir was reached. 
Mithramycin was given as an infusion of 25mcg/kg body weight in 500 ml 
5% dextrose and repeated after 2 days if serum calcium remained above 
2.90 mmol/1. Corticosteroids (prednisolone) 40mg daily were given 
orally in divided doses (or an equivalent parenterally in patients 
unable to swallow), combined with salmon calcitonin 400 IU every 8 
hours by subcutaneous injection, both agents being continued 
throughout the 9 days of the study.
Biochemical analyses were performed on true fasting urine samples 
and blood samples obtained after an overnight fast.
The presence of metastatic bone disease was determined by a 
combination of standard radionuclide bone scans and skeletal 
radiographs.
The Wilcoxon tests for paired and unpaired data and the Chi- 
square tests with Yates' correction were used in statistical analyses, 
as was appropriate.
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Before antihypercalcaemic therapy and throughout the study 
patients were interviewed and symptoms recorded. Symptoms were 
categorised into one of five groups:
(1) Central Nervous System - confusion, obtundation, psychosis,
depression.
(2) Gastrointestinal - nausea, vomiting, anorexia, constipation.
(3) Renal - polyuria, thirst.
(4) General - malaise, fatigue.
(5) Pain - usually due to bone or visceral involvement by tumour.
To assess the symptomatic response, individual patient-symptoms 
were summed and the total numbers compared before and after 
antihypercalcaemic treatment in each group.
Statistical methods used were the Wilcoxon test for paired and 
unpaired samples and the Chi Squared test with Yates' correction.
7.1.3 RESULTS
Squamous carcinoma of lung and breast cancer were the commonest 
tumours, accounting for 48% and 17%, respectively of the whole study 
group; the remainder comprised various other solid tumours and one 
myeloma. There was no significant difference in the proportions of 
tumour types between the three treatment groups. Skeletal radiographs 
and bone scans showed no evidence of metastases in six of the APD 
treated patients compared with four in each of the other treatment 
groups. Serum albumin levels were generally low (30.4 (5.8) g/1; mean 
(SD)) and did not differ between the groups. Plasma iPTH levels were 
low (<400 ng/1) or undetectable in all patients.
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Anti-cancer therapy given during the trial included local 
radiotherapy for bone metastases (one patient in each group) and 
continuous hormone therapy (stilboestrol - one APD-treated patient; 
tamoxifen - one patient each in the mithramycin and 
corticosteroid/calcitonin groups). Two patients in the APD group had 
surgical resection of the primary tumour on day seven. Biochemical 
data from these subjects were not included in statistical analysis at 
day 9, although serum calcium values were normal at this point in both 
cases (2.35, 2.45 mmol/1 respectively). One patient each in the
corticosteroid/calcitonin and mithramycin groups and two in the APD 
group died of complications of the tumour on days 1, 7, 2, and 4 of 
the study respectively. Two patients in the corticosteroid/calcitonin 
group were withdrawn from the study because of clinical deterioration 
(figure 7.1) and were successfully tretaed with mithramycin. One 
mithramycin-treated patient died of hypercalcaemic crisis despite 
repeated mithramycin administration and aggressive saline diuresis 
(fig 7.1).
During rehydration, most patients' serum calcium values fell but 
in some, hypercalcaemia grew worse (figure 7.1). Serum calcium fell 
significantly by day 1 of antihypercalcaemic therapy in the 
corticosteroid/calcitonin and mithramycin groups and by day 2 in the 
APD group. The fall in serum calcium was most rapid in the 
corticosteroid/calcitonin group; a median fall of 0.35 mmol/1 took 24 
hours in this group compared with 48 hours in the mithramycin group 
and 72 hours in the APD group. Although APD had the slowest onset of 
action, its effect was better sustained; serum calcium values were 
significantly lower in APD-treated patients at both 6 and 9 days in 
the corticosteroid/calcitonin-treated patients and mithramycin-treated
154
APD CS/CT
SERUM
CALCIUM
m m o l/l
50 n
At
30-
TIME
days
FIGURE 7.1
Response of serum calcium to antihypercalcaemic therapy. Interrupted 
line are medians, dotted lines are interquartile ranges, and solid 
lines are ranges. P - presentation Rx - at start of treatment. Open 
triangles show response of individual patients who either died t or 
were withdrawn 0  due to clinical deterioration. Normal range 
indicated between horizontal interrupted lines.
Significant difference from Rx *=p<0.05; **=p<0.01; ***=p<0.005.
Significant difference from APD group □=p<0.05.
patients at 9 days.
Figures 7.2 and 7.3 show the changes in fasting urinary Ca/Cr and 
OHP/Cr ratios, which in this situation, are thought to reflect changes 
in bone-resorption (153). APD caused a progessive reduction in Ca/Cr, 
significant from day 1, and in OHP/Cr significant from day 2. In the 
mithramycin group, Ca/Cr was significantly reduced on day 2 only, but 
OHP/Cr was significantly reduced on days 2 and 3. In the 
corticosteroid/calcitonin group there was no significant change in 
Ca/Cr, but OHP/Cr fell significantly on day 1.
When all 39 patients were considered together, there was a 
significant fall in the median serum creatinine level during initial 
rehydration from 80 umol/1 (range 50-350 umol/1) to 75 umol/1 (range 
45-210 umol/1), just before treatment (p<0.01). After 
antihypercalcaemic treatment, serum creatinine fell further in the 
corticosteoid/calcitonin group from day 2 onwards to a nadir of 60 
umol/1 (range 35-100 umol/1) on day 9 (p<0.05). Serum creatinine did 
not change significantly from the pre-treatment level in the other 
groups.
In figure- 7.4, the components of the calcium-lowering response 
are depicted in terms of the "normal" relation between urinary calcium 
excretion (CaE) and serum calcium (114) , using the median values for 
each treatment group at each point in time. Changes in renal tubular 
calcium reabsorption result in a horizontal movement of the points, 
whereas changes in filtered load cause a diagonal shift, parallel to 
the slopes indicating the normal range (279). Changes in filtered load 
may either result from changes in glomerular filtration rate or net 
bone resorption (279). The initial fall in serum calcium after
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FIGURE 7.2
Response of fasting urinary calcium/creatinine (Ca/Cr) values to 
antihypercalcaemic therapy. Interrupted lines are medians; dotted 
lines are interquartile ranges; solid lines are ranges. Normal range 
is indicated by horizontal interrupted lines.
P - presentation, Rx " at start of treatment.
Significant difference from day Rx *=p<0.05; **=p<0.01;***=p<0.005.
Significant difference from APD group □=p<0.05; from mithramycin
group A=p<0.05;
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FIGURE 7.3
Response of fasting urinary hydroxyproline/creatinine (OHP/Cr) values 
to antihypercalcaemic therapy. Interrupted lines are medians, dotted 
lines are i n t e r q u a r t i l e  ranges, sol i d  lines are ranges. H o r i z o n t a l  
interrupted line i n d i c a t e s  n o r m a l  range. P - p r e s e n t a t i o n ;  R x - at 
start of treatment.
Significantly d i f f e r e n t  f r o m  d a y  R x *=p<0.05; **=p<0.01;
***=p<0.005. S i g n i f i c a n t l y  d i f f e r e n t  f r o m  m i t h r a m y c i n  a n d  
corticosteroid/calcitonin g r o u p s  □=p<0.05; S i g n i f i c a n t l y  
different from mithramycin group A=p<0.05.
rehydration was due to a reduction in renal tubular calcium 
reabsorption, as reflected by a general shift in the points to the 
left. In the APD group, subsequent falls in serum calcium were due to 
a lower filtered calcium load, which was in turn due to a fall in bone 
resorption (figures 7.2 and 7.3). In the corticosteroid/calcitonin 
group, an important component of the early fall in calcium was a 
reduction in renal tubular calcium reabsorption , reflected by a shift 
in the points on figure 7.4 further to the left of those after 
rehydration. There was a subsequent load-dependant reduction in serum 
calcium in this group, due mainly to a fall in glomerular filtration 
rate, although there was also a transient reduction in bone resorption 
(figure 7.3). In the mithramycin group, the early load-dependant 
reductions in serum calcium were due to a fall in bone resorption 
(figures 7.2, 7.3). Subsequently, the renal tubular reabsorption of 
calcium also appeared to fall.
There were symptomatic improvements in each treatment group,
particularly in the manifestations of hypercalcaemia on the central
nervous system, gastro-intestinal tract and kidney ("specific"
symptoms). Thus, for all treated patients, 34 of 61 "specific"
symptoms (55%) improved, compared with 7 out of 42 (16%) "non-
2
specific" symptoms such as malaise, fatigue and pain (X =11.2, 
p<0.001). A better response was observed in patients whose post­
treatment serum calcium values remained below 2.80 mmol/1 on three or 
more consecutive days; 27 out of 38 (71%) "specific" symptoms improved 
compared with 7 out of 23 (30%) in those with poor hypercalcaemic 
control (X^=11.2, p<0.001). This was reflected by a slightly better 
response in the APD group where control of hypercalcaemia was best in 
the long term, but the differences in symptomatic improvements between
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FIGORE 7.4
Relation between serum adjusted calcium and urinary calcium excretion 
(as Ca^ ,) during antihypercalcaemic therapy. Data points are medians. 
Dotted lines indicate normal range defined by Peacock (114).
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the APD group (58% "specific", 31%, "non-specific") and the other 
groups (mithramycin 42% and 8%, coticosteroid/calcitonin 50% and 7%) 
did not reach statistical significance. Side-effects of mithramycin 
included nausea, vomiting and malaise in two cases, mild 
thrombocytopaenia in one and rises in serum aminotransferases and 
gamma-glutamyl transpeptidase in eleven. Transient pyrexia occurred in 
four of the APD group and local thrombophlebitis at the infusion site 
in two. Surprisingly, none of the corticosteroid/calcitonin group 
complained of nausea or vasomotor symptoms, but many found the 
frequent injections of calcitonin uncomfortable.
In the whole study group, the median overall survival time was 
short (39 days; range 3-420 days) ; it did not differ significantly 
between the groups. Only six patients survived for more than six 
months (three - APD; 2 -mithramycin; 1 - corticosteroid/calcitonin) 
and the common factor in these patients was administration of 
additional anticancer therapy which induced a remission in the primary 
tumour.
7.1.4 DISCUSSION
In agreement with previous studies the hypercalcaemia we observed 
was due to a combination of increased bone resorption
(148.236.253.256.259) and raised renal tubular reabsorption of calcium 
(236, Chapter 4) , with impaired glomerular filtration in some cases
(147.236.259). As was noted in chapter 4, volume re-expansion with 
intravenous saline only partially corrected the abnormal renal 
handling of calcium, slightly reduced serum calcium and serum 
creatinine and had no effect on the increased calcium load derived 
from bone resorption, confirming that rehydration alone is an
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unsatisfactory treatment for cancer-associated hypercalcaemia
(147,259).
All three drug regimens produced a significant fall in serum 
calcium from the levels achieved with rehydration. Although the 
corticosteroid/calcitonin combination reduced serum calcium levels 
most rapidly, it seldom reduced them to normal. Nonetheless, the 
response was well-sustained throughout the 9 days of study in all but 
two cases. The slow onset of action of APD was compensated for by 
progressive and consistent control of hypercalcaemia later. About half 
of the APD-treated patients remained mildly hypercalcaemic throughout 
the study, despite almost complete inhibition of bone resorption (as 
reflected by the normal urinary Ca/Cr values) in all patients by day 
9. This phenomenon reflects the contribution of a hormone-mediated 
rise in renal tubular calcium reabsorption to the pathogenesis of 
hypercalcaemia (253), which in this situation, is postulated to be due 
to the effects a "PTH-like" mediator (chapter 4). Hydroxyproline 
excretion remained high in some patients after APD treatment, probably 
owing to soft tissue catabolism, rather than continued bone 
resorption (248). Although some of the lowest post-treatment serum 
calcium levels were recorded in the mithramycin group, about half of 
the patients had started to relapse by day 9. The antihypercalcaemic 
effect of mithramycin could probably have been enhanced by repeated 
daily doses, but this was not justifiable in view of the potential 
toxicity (218).
Our results show that the three theraputic regimens bring about 
their calcium-lowering effects in different ways. In agreement with 
previous studies (148,259), APD progressively reduced bone resorption
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with little change in renal tubular calcium handling. In contrast, the 
rapid effect of the corticosteroid/calcitonin regime was mainly due to 
a reduction in renal tubular calcium reabsorption. The reduction in 
calcium load with continued administration of these agents could 
largely be explained by the improvement in glomerular filtration rate 
rather than a substantial fall in bone resorption. These findings 
contrast with the generally held view that both corticosteroids and 
calcitonin act principally by inhibiting bone resorption
(207,240,241). In a recent study of calcitonin alone, Hosking and 
Gilson noted that the renal tubular rather than skeletal effects of 
calcitonin were most important in determining the early calcium- 
lowering response in malignant hypercalcaemia (236). We have confirmed 
these observations and shown that, in the longer term also, it is the 
renal rather than skeletal effect of the corticosteroid/calcitonin 
combination which sustains the reduction in serum calcium.
Surprisingly, mithramycin appeared to have effects on both bone 
resorption and renal tubular handling of calcium. Although, as found 
previously (220,221) the initial fall in serum calcium was due to a 
reduction in bone resorption, there was also a reduction in renal 
tubular calcium reabsorption from day 3 onwards. Possible mechanisms 
for this action include direct tubular damage (218) , an anti-tumour 
effect (219) or inhibition of release by the tumour of putative 
humoral mediators affecting renal calcium handling.
The very limited duration of survival confirms the poor prognosis 
of cancer-associated hypercalcaemia, and emphasises that its 
treatment should probably be reserved for patients who have 
troublesome symptoms. The finding that "non-specific" symptoms such
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as malaise, fatigue and pain responded less well than "specific" 
symptoms of hypercalcaemia referrable to the central nervous system, 
gastrointestinal tract and kidney, probably reflects that the former 
were due to the underlying malignant process, rather than the high 
serum calcium levels. The better symptomatic response in patients with 
good control of hypercalcaemia indicates that it is more important to 
control serum calcium levels in this syndrome, than to give less 
effective antihypercalcaemic agents such as corticosteroids (209,210), 
in the hope that they will bring about a general improvement in well­
being. There was no evidence to suggest that patients who received 
corticosteroids improved more in terms of symptoms such as malaise, 
fatigue or anorexia.
In this study, APD was the most effective treatment for 
malignancy associated hypercalcaemia in the medium-term. For rapid 
control of severe hypercalcaemia however, APD was less suitable 
because of its slow onset of action. In this situation, calcitonin
(236,240,241), mithramycin (223,224) or intravenous phosphate 
(185,186) may be more appropriate.
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7.2 TREATMENT OF CANCER-ASSOCIATED HYPERCALCAEMIA WITH COMBINED
AMINOHYDROXYPROPYLIDENE DIPHOSPHONATE AND CALCITONIN
7.2.1 INTRODUCTION
In the previous study (chapter 7.1) , aminohydroxypropylidene 
diphosphonate (APD) was found to give better long-term control of 
hypercalcaemia in malignancy than either mithramycin or 
corticosteroids plus calcitonin. APD was found to be the least 
suitable agent for the acute treatment of hypercalcaemia however, 
because of its relatively slow onset of action. In this study the 
effects of combined treatment with APD and calcitonin were studied in 
patients with cancer-associated hypercalcaemia.
7.2.2 PATIENTS AND METHODS
Eight patients with hypercalcaemia due to various malignant 
tumours were studied. Four patients had squamous lung carcinoma and 
one patient each had carcinoma of breast, kidney, gallbladder and 
myeloma. All patients were initially rehydrated with 0.9% saline 3 
litres daily for at least 48 hours, followed by 0.9% saline 2 litres 
daily for 12 hours prior to, and during treatment until the patient's 
clinical state of hydration was judged adequate.
Drug treatment was given as follows; APD as an intravenous 
infusion of 15mg daily in 250 mis 0.9% saline and salmon calcitonin 
100 IU every eight hours by subcutaneous injection. Both agents were 
given for six consecutive days.
Biochemical analyses were made on true fasting urine samples and 
blood samples, obtained after an overnight fast.
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FIGURE 7.5
Biochemical response to treatment with APD and calcitonin. Top panel 
shows serum calcium, bottom panel fasting urinary calcium/creatinine 
(Ca/Cr) and inset, serum calcium vs urinary Ca£. Dotted lines indicate 
normal ranges, which in the case of the inset is that defined by 
Peacock (114). Points are medians, interrupted lines are 
interquartile ranges. *=p<0.05 and **=p<0.02 from day 0 for serum 
calcium and Ca/Cr. P = presentation.
The paired Wilcoxon test was used for statistical analysis.
7.2.3 RESULTS
Both serum calcium and urinary Ca/Cr values fell significantly 
and progressively between days 1-12 of the study (figure 7.5). Urinary 
OHP/Cr values also fell significantly from a mean (SEM) of 63(9) 
umol/mmol before treatment to 38 (9) on day 1 and 42 (8) on day 12 
(p<0.02, p<0.05, respectively from pretreatment value). Serum
creatinine fell from 152 (22.5) umol/1 at presentation to 129 (20.9) 
after rehydration (p<0.05). Creatinine fell further to 110 (19.6) on 
day 1 and 99 (20.5) on day 12 (p<0.02, p<0.05, respectively from
pretreatment value).
In terms of the "normal" relation between serum calcium and 
urinary calcium excreted (CaE), the calcium lowering effect of drug 
treatment was due to a further fall in renal tubular calcium 
reabsorption from that achieved by rehydration and a reduction in 
filtered calcium load, as reflected by a downward and leftward shift 
of the points in figure 7.5 (inset). The fall in filtered calcium 
load was in turn, due mainly to a reduction in bone resorption, but 
also to an improvement in glomerular filtration rate. After treatment 
was stopped (days 9 and 12), the points shifted vertically downwards, 
indicating that renal tubular calcium reabsorption had risen, although 
bone resorption remained supressed.
7.2.4 DISCUSSION
In this study, the rapid calcium lowering effect was largely due 
to an acute reduction in both bone resorption and renal tubular
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calcium reabsorption. A similar response was noted in the previous 
study (7.1), using a combination of corticosteroids and calcitonin, 
and it was probably mediated by the renal and skeletal effects of 
calcitonin alone (236). In accordance with previous findings, the 
reduction in renal tubular calcium reabsorption was sustained for the 
duration of calcitonin treatment, but reversed thereafter. Indeed, 
longer term control of hypercalcaemia was achieved mainly by 
supression of bone resorption, and this was probably due to the more 
sustained anti-osteoclast effect of APD (148,259). The small increase 
in OHP/Cr values which remained after treatment concurs with previous 
data which has indicated that, in this situation, a substantial 
proportion of urinary hydroxyproline may derive from tissues other 
than bone (236,259). In all cases, correction of hypercalcaemia was 
associated with an improvement in symptoms in the absence of any drug- 
related side effects.
In this study, the combination of APD and calcitonin gave better 
long-term control of hypercalcaemia than the corticosteroid/calcitonin 
regime previously studied and was more rapidly acting than APD alone. 
No significant side effects were encountered as the result of 
treatment, making this, regime superior to mithramycin and intravenous 
phosphate, which are rapidly acting but potentially toxic 
(218,190,191,192,193). Combined treatment with APD/calcitonin may 
therefore be particularly useful in the treatment of severe 
hypercalcaemia where a rapid but sustained effect is desired. As the 
main action of calcitonin was to "buy time" during the initial 48 
hours while the APD took effect, it may be possible to limit the use 
of calcitonin to this initial period, with obvious advantages in terms 
of cost.
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7.3 RELATIONSHIP BETWEEN MECHANISMS OF HYPERCALCAEMIA IN MALIGNANCY
AND RESPONSE TO ANTIHYPERCALCAEMIC THERAPY
7.3.1 INTRODUCTION
The calcium-lowering response to antihypercalcaemic therapy in 
hypercalcaemia associated with malignant disease is variable (303). 
Although the reasons for this are at present unclear, they may relate 
to differences in the pathophysiological mechanisms of hypercalcaemia 
in different patient-groups (5,93). In this study, the 
pathophysiological mechanisms of hypercalcaemia in 50 patients with 
hypercalcaemia of malignancy were related to the calcium-lowering 
response after antihypercalcaemic drug therapy.
7.3.2 PATIENTS AND METHODS
Fifty patients who presented consecutively to Glasgow Royal 
Infirmary were studied, selected on the basis that the clinician in 
charge of the patient had considered that antihypercalcaemic therapy 
was an appropriate form of management. Prior to the study, all 
patients were sodium-repleted with a standard regime of intravenous 
saline 0.9%, 3 litres daily for a minimum of 48 hours, then 2 litres 
daily for at least 12 hours before administration of 
antihypercalcaemic therapy. Patients were treated with one of four 
antihypercalcaemic regimens; aminohydroxypropylidene diphosphonate 
(APD), (n=14), mithramycin (n=15) , corticosteroid/calcitonin (n = 13), 
APD/calcitonin (n=8). These patient-group are essentially as described 
in the previous sections (7.1 and 7.2), with the addition of a few 
extra patients who were treated with one of the above regimens, but 
were not included in either of the above studies. Drug therapy was
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administered as described in sections 7.1 and 7.2.
Biochemical analyses were made on fasting blood samples and true 
fasting urine samples, usually obtained after an overnight fast. The 
relative contribution of impaired renal glomerular filtration, 
increased renal tubular calcium reabsorption and increased calcium 
flow from bone resorption to the pathogenesis of hypercalcaemia was 
assesssed using the method described by Nordin (279)
The presence and extent of metastatic bone disease was assessed by 
bone scan examination as described in chapter 3.1. In three patients 
with myeloma and in others where abnormalities of doubtful 
significance were seen on the bone scan, account was taken of 
additional information gained by radiological skeletal survey and/or 
post-mortem examination.
In assessing the calcium-lowering response, the lowest post­
treatment calcium values were used in statistical analysis. In two 
patients where serum calcium did not fall after antihypercalcaemic 
therapy was given, the last serum calcium value prior to death or 
administration of an alternative drug regime was used.
Biochemical analyses were made on true fasting blood and spot 
urine samples.
Methods used in statistical analysis, were the paired and unpaired 
Wilcoxon's tests and Spearman's rank correlation coefficient.
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7.3.3 RESULTS
In analysis of results, patients were divided into three groups on 
the basis of the extent of metastatic bone disease. In patients 
without bone metastases and a light skeletal tumour load (n=32) , 
squamous carcinoma of lung was the commonest tumour accounting for 65% 
of cases, followed by hepatoma (12%), other squamous carcinoma (9%), 
adenocarcinoma, unknown primary (9%), renal carcinoma (3%) and 
anaplastic carcinoma (3%). In the heavy tumour load group, breast 
carcinoma was most common (55%), followed by myeloma (16%), squamous 
lung carcinoma (5%), oat cell lung carcinoma (5%), anaplastic lung 
carcinoma (5%), adenocarcinoma, unknown primary (5%) and renal 
carcinoma (5%) .
Relevant biochemical variables after sodium repletion and before 
administration of antihypercalcaemic therapy in the three groups are 
shown in Table 7.1. CaE values were significantly higher in the heavy 
skeletal tumour load group when compared with both other groups. 
While serum creatinine, phosphate, TmPO^ and urine Ca/Cr values were 
significantly higher in the heavy skeletal tumour load group when 
compared with those with no metastases, there was no significant 
difference with respect to the light tumour load group. Plasma iPTH 
values (data not shown) were low or undetectable in all but two 
patients; one with squamous carcinoma of the gallbladder (PTH- 
1600ng/l) and one with squamous carcinoma of the lung (PTH-850ng/l).
In figure 7.6, the levels of serum calcium are shown in the three 
groups, after breakdown into separate components of altered 
glomerular filtration rate (GFR), renal tubular calcium reabsorption,
166
TABLE 7.1
BIOCHEMICAL VARIABLES EEEORE ANHHYPEHCADCAEMIC THERAPY
NO DETECTABLE LIGHT SKELETAL HEAVY SKELETAL
METASTASES TUMOUR IPftD TUMOUR LOAD
NUMBER 20 12 18
SERUM CALCIUM 3.12 3.20 3.05
(nmol/1) (2.75-4.30) (2.50-3.80) (2.60-4.15)
SERUM PHOSPHATE 0.72 0.85 1.00
(mmol/I) (0.40-1.55) (0.55-1.25) (0.65-1.80)
SERUM CREATININE 72 70 100
(ymol/1.) (45-240) (45-190) (55-160)
SERUM ALBUMIN 30 29 29
(nmol/1) (22-41) (23-35) (24-41)
URINE Ca/Cr 1.17 1.54 1.45*
(nrnol/tmnl) (0.22-2.40) (0.12-2.50) (0.76-3.20)
* ■*• * 4.
Cag 89 110 151 +
(UPl/lGF) (13-556) (7-182) (64-384)
TfrPn., 0.50 0.65 0.82*
(nrnoi/lGF) (0.30-0.90) (0.30-1.50) (0.25-2.10)
URINE CHP/Cr 56 49 69
(ymol/ftmol) (35-146) (36-161) (33-130)
URINE Nag 2.83 3.15 2.74
(imol/lGr) (0.37-6.70) (0.67-6.70) (0.21-4.55)
values are medians 
(range)
*** p<0.001 fran no metastases group
* p<0.05 from no metastases group 
+ p<0.05 from light tunour load group
Serum 
Calcium 
(mmol/O 
+ 1.5
+ 1.0
+ 0.5
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FIGURE 7.6
Pathogenic mechanisms of hypercalcaemia before treatment in terms of 
renal and skeletal components on division by the extent of metastatic 
bone disease. Serum calcium values on the abscissa are referred to a 
zero value of 2.50mmol/l. GFR-increment of hypercalcaemia due to 
impaired glomerular filtration; TUBULAR THRESHOLD-increment due to 
alteration in renal tubular calcium reabsorption; FLOW-increment 
attributable to increased bone resorption.
A  -Heavy skeletal tumour load 
O  -Light skeletal tumour load 
# -No detectable bone metastases
Bars are medians. NS/NSD - no significant difference
and calcium flow. Patients with a heavy skeletal tumour load had a 
significantly (p<0.05) greater impairment of GFR than those with no 
metastases. Conversely, the renal tubular component of hypercalcaemia 
was significantly (p<0.01) lower in the heavy skeletal tumour load 
group. The calcium flow component was significantly (p<0.05) higher 
in the heavy tumour load group when compared with the no metastases 
group.
A highly significant correlation was found between serum calcium 
values before treatment and the renal tubular component of 
hypercalcaemia (r=0.83, p<0.001). In absolute terms, the renal tubular 
component of hypercalcaemia was raised in most patients prior to 
treatment (figure 7.7). Patients in the heavy skeletal tumour load 
group tended to have lower renal tubular calcium reabsorption than 
those with no metastases and a light skeletal tumour load.
On statistical analysis, other significant correlations were 
observed between the following pre-treatment variables; serum calcium 
vs serum creatinine (r=0.52, p<0.005), serum calcium vs GFR component 
of hypercalcaemia (r=0.53, p<0.005) and serum creatinine vs serum 
phosphate (r=0.36, p<0.05).
The response to the individual antihypercalcaemic drug regimes in 
terms of the components of hypercalcaemia are shown in figures 7.8- 
7.10. The flow component was reduced in most cases, although the 
response was least consistent in the corticosteroid/calcitonin treated 
patients (figure 7.8). The renal tubular component was significantly 
reduced after treatment with corticosteroid/calcitonin, mithramycin 
and APD/calcitonin regimens. While APD alone did not significantly 
reduce the tubular component of hypercalcaemia overall, the tubular
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Response of calcium "flow" component to antihypercalcaemic therapy, on 
division of patients by type of treatment received. PRE -before 
treatment, POST -after treatment.
APD- aminohydroxypropylidene diphosphonate 
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FIGURE 7.9
Response of the renal tubular component of hypercalcaemia to 
antihypercalcaemic therapy, on division of patients by the type of 
treatment received. PRE- before treatment, POST- after treatment.
APD- aminohydroxypropylidene diphosphonate 
CT/CS- calcitonin and corticosteroids 
MITH- mithramycin 
CT/APD- calcitonin and APD
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Response of renal glomerular component' of hypercalcaemia to 
antihypercalcaemic therapy on division of patients by type of 
treatment received. PRE- before treatment, POST- after treatment.
APD- aminohydroxypropylidene diphosphonate 
CT/CS- calcitonin and corticosteroids 
MITH- mithramycin 
CT/APD- calcitonin and APD
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component did fall in patients with the most severe hypercalcaemia 
before treatment (fig 7.9). Thus, initial serum calcium values were 
(median (range)); (3.37 (3.00-4.50) mmol/1) in 8 patients where the 
renal tubular component fell, compared with (2.90 (2.80-2.92) mmol/1)
in 6 where the renal tubular component rose or remained static 
(p<0.01). The increment of hypercalcaemia attributable to impaired 
GFR was relatively minor in most cases (figure 7.10), but tended to 
fall after treatment. The fall in the GFR component was significant 
only in the APD/calcitonin group. From figures 7.8 - 7.10, it can be 
seen that, there was no quantatative difference in the response to 
antihypercalcaemic therapy in patients with different degrees of 
metastatic bone disease.
Relevant biochemical variables after antihypercalcaemic therapy 
are shown in table 7.2, on division of patients by the extent of 
metastatic bone disease. Although four distinct drug regimens were 
used, the relative proportion of patients treated with any one regimen 
was similar in each "metastatic" group (figures 7.8 - 7.10).
In each of the three groups, serum calcium, urinary Ca/Cr, OHP/Cr 
and CaE values fell significantly from the pre-treatment level. In 
the light tumour load group, serum phosphate fell and in the no 
metastases group, Na£ values fell.
In figure 7.11, serum calcium values and the components of 
hypercalcaemia are shown after antihypercalcaemic therapy, on division 
into three groups by the extent of metastatic bone disease. The only 
significant differences between the groups after antihypercalcaemic 
treatment were in terms of serum calcium values and the renal tubular 
component of hypercalcaemia, which were significantly lower in
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TAKE 7.2
BIOCHEMIiCM. VARIABLES AFTER ANHHYEERCMCAEMIC THERAPY
NO DETECTABLE 
METASTASES
LIGHT SKELETAL 
TUMOUR LOAD
HEAVY SKELETAL 
TUMOUR IGAD
NUMBER
SERUM CALCIUM 
(nttol/1)
SERUM PHOSPHATE 
(rrrrpl/I)
SERUM CREATININE
(jjnol/L)
SERUM ALBUMIN
(g/i)
URINE Ca/Cr 
(irmol/irniol)
Cag
(pPl/LGF)
TtriFO^
(imat/LGF)
URINE CHP/Cr 
(ppl/farol)
(ntrpl/lGF)
20
2.70 
(2.25-3.90)
0.70
(0.50-1.40)
77
(50-210)
30
(21-40)
0.36++
(0.06-2.40)
34^
(5-264)
0.55
(0.10-1.30)
39^
(15-147)
2.07++
(0.24-6.24)
12
2.75 
(2.35-3.30)
0.77+
(0.45-1.05)
72
(45-120)
28
(24-35)
0.45++
(0.07-2.80)
33 ++
(3-196)
0.70
(0.30-0.80)
35+
(18-120)
2.60 . 
(0.10-5.84)
18
2.504"H’ * 
(2.05-2.95)
0.82
(0.55-1.95)
72
(40-180)
30
(24-41)
0.52’ 
(0.13-1.53)
39 
(8-116)
0.50
(0.20-1.65)
41++
(14-112)
2.27
(0.10-3.85)
values are medians +++ p<0.001 from
(range) ++ p<0.02 from
+ p<0.05 from
p<0.05 fran
+ 2.0
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Calcium
(mmol/l)
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FIGURE 7.11
Pathogenic mechanisms of hypercalcaemia after administration of 
antihypercalcaemic therapy, on division by the extent of metastatic 
bone disease. Serum calcium values on abscissa are referred to a zero 
value of 2.50mmol/l. GFR- increment of hypercalcaemia due to
impaired glomerular filtration rate; TUBULAR THRESHOLD- increment 
attributable to alteration in renal tubular calcium reabsorption; 
FLOW- increment attributable to increased calcium "flow" from bone 
resorption.
A -Heavy skeletal tumour load 
O  -Light skeletal tumour load 
0 -No detectable bone metastases
bars are medians. NS/NSD -no significant difference.
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FIGURE 7.12
Relation between post-treatment renal tubular component of 
hypercalcaemia and serum calcium values after antihypercalcaemic 
treatment.
O - APD treated patients
JCT- calcitonin/APD treated patients
□  - mithramycin treated patients
<^ > - corticosteroid/calcitonin treated patients
Horizontal dotted lines indicate reference range for serum calcium.
patients with a heavy skeletal tumour load (p<0.05).
On statistical analysis, only three pre-treatment biochemical 
variables correlated significantly with post-treatment serum calcium 
values. These were; serum calcium pre-treatment (r=0.37, p<0.05) , 
serum phosphate pre-treatment (r= -0.39, p<0.02) , and the renal
tubular component of hypercalcaemia pre-treatment (r= 0.61, p<0.001).
When patients were considered separately on the basis of the drug 
treatment given, there was a significant correlation between the renal 
tubular component of hypercalcaemia pre-treatment in the APD-treated 
patients (n=14, r=0.65, p<0.01) , the APD/calcitonin-treated patients 
(n=8, r=0.95, p<0.001) and the corticosteroid/calcitonin treated
patients (n=13, r=0.65, p<0.01). In mithramycin-treated patients, 
there was also a positive correlation, but this failed to reach 
statistical significance (n=15, r=0.41, p>0.05).
In figure 7.12, the relationship between post-treatment serum 
calcium values and the renal tubular component of hypercalcaemia post­
treatment is shown. There was a highly significant correlation 
between these variables in the study group as a whole (r=0.71, 
p<0.001). Post-treatment serum calcium values and the post-treatment 
renal tubular component of hypercalcaemia were also significantly 
correlated when patients were divided by the type of treatment 
received; APD (r=0.65, p<0.01) ; APD/calcitonin (r=0.78, p<0.05) ; 
mithramycin (r=0.82, p<0.005) , corticosteroid/calcitonin (r=0.92,
p<0.002).
Other components of hypercalcaemia post-treatment which correlated 
with post-treatment serum calcium values were the post-treatment flow 
component of hypercalcaemia (r=0.37, p<0.05) in the study group as a
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whole, and in the subgroup treated with APD alone (r-0.82, p<0.005). 
There was no significant correlation between the GFR component of 
hypercalcaemia and serum calcium values at any stage.
7.3.4 DISCUSSION
In this study, patients without detectable bone metastases and 
those with a light skeletal tumour load had similar mechanisms of 
hypercalcaemia; renal tubular reabsorption of calcium and calcium 
"flow" from bone resorption were both increased, probably as the 
result of the renal tubular (chapter 3) and osteoclast-stimulating 
effects (5,93,139,140,141,142) of humoral mediators released by tumour 
tissue. In patients with a heavy skeletal tumour load, bone 
resorption was raised to a significantly higher level, possibly as the 
result of metastatic bone destruction (2,3,5,25). Serum creatinine 
values were also significantly higher in patients with a heavy 
skeletal tumour load, leading to a much higher filtered load of 
calcium per unit of glomerular filtrate when compared with those who 
had few or no metastases. This was offset by the generally lower 
levels of renal tubular calcium reabsorption, resulting in similar 
total serum calcium values in the three groups of patients.
The status of renal calcium handling in the hypercalcaemia of 
malignancy has been the subject of much debate in recent years. In 
early studies, renal tubular calcium reabsorption was found to be 
depressed (147,148), leading to the belief that hypercalcaemia of 
malignancy was mediated by a purely "bone-resorptive" mechanism, 
either as the result of metastatic bone destruction (2,3,25), or in 
association with humoral substances which stimulate osteoclastic bone 
resorption (64,77,78,93,105). The work previously presented in this
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thesis suggests that renal tubular calcium reabsorption is frequently 
elevated in patients with cancer-associated hypercalcaemia, 
particularly in solid tumours such as squamous lung carcinoma. These 
observations indicate that hypercalcaemia in these tumour may be due, 
in part, to a PTH-like effect on the renal tubular calcium 
reabsorption. Recently, studies have suggested that humorally- 
mediated increases in renal tubular calcium reabsorption appear to be 
a common feature of malignancy-associated hypercalcaemia, irrespective 
of tumour type and extent of metastatic bone disease (304,305).
In the present study, the renal tubular component of 
hypercalcaemia was found to progressively increase as serum calcium 
values rose; all patients with serum calcium values of more than 
3.00mmol/l had elevated renal tubular calcium reabsorption in absolute 
terms, using the method of calculation described by Nordin (279). 
Although this may have been due to a PTH-like effect on the renal 
tubule, it is perhaps more likely to have been due to an artefect 
introduced by the method of calculation. In clinical practice 
assessment of renal tubular calcium reabsorption is problematic; it 
depends on comparing data from normal subjects who have been rendered 
acutely hypercalcaemic by calcium infusion, with those in chronically 
hypercalcaemic patients who often have far higher serum calcium values 
(268). Current methods of assessment fail to take account of possible 
differences in urinary sodium excretion between acutely hypercalcaemic 
control subjects and chronically hypercalcaemic patients, even though 
alterations in urinary sodium excretion may profoundly affect urinary 
calcium excretion in clinical practice (176,266,268,283,298,305). 
Since tubular reabsorption of sodium and calcium are closely linked in 
the proximal renal tubule (267,268), it may be anticipated that, in
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any given patient, filtered sodium load would have to rise in 
proportion with filtered calcium load to maintain renal tubular 
calcium reabsorption at a constant level, with increasing degrees of 
hypercalcaemia.
In this study, a standard protocol of sodium repletion was used, 
with the result that urinary NaE values were similar in most patients, 
notwithstanding the severity of hypercalcaemia. Accordingly the 
progressive rise in renal tubular reabsorption of calcium which was 
observed with increasing hypercalcaemia may have been due, in part, to 
relative sodium deficiency, rather than a humorally-mediated increase 
in renal tubular calcium reabsorption. The apparent reduction in 
renal tubular calcium reabsorption which occurred in APD-treated 
patients with more severe hypercalcaemia lends support to this 
hypothesis, since APD therapy does not alter renal tubular calcium 
reabsorption in Paget's disease or osteoporosis (148). From the above 
considerations, it would appear that the algorithm used for 
calculation of renal tubular reabsorption of calcium is not accurate 
in patients with severe hypercalcaemia, using the current methods of 
sodium repletion.
Notwithstanding these doubts about the accuracy, in absolute 
terms, of the renal tubular calcium reabsorption data, information can 
be gained by comparisons of renal tubular calcium reabsorption between 
different patient-groups. Thus, the significantly greater fall in 
renal tubular calcium reabsorption which was observed in calcitonin 
and mithramycin-treated patients suggests that these agents did indeed 
possess a true inhibitory effect on renal tubular calcium 
reabsorption (235, 236, chapter 7.1). Moreover, the levels of renal
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tubular calcium reabsorption were significantly different in different 
groups of patients with cancer-associated hypercalcaemia; in patients 
with no metastases and a light skeletal tumour load levels were higher 
than those in patients with a heavy skeletal tumour load. This 
suggests that in the latter, a humorally mediated increase in renal 
tubular calcium reabsorption was less likely to have contributed to 
the pathogenesis of hypercalcaemia. The variable response to 
antihypercalcaemic therapy also lends support to the hypothesis that 
the mechanisms of hypercalcaemia were different in different patient- 
groups. Serum calcium values after treatment were strongly related to 
the level of renal tubular calcium reabsorption both pre- and post­
treatment, irrespective of the type of treatment given. This was 
also reflected by the fact that patients with a heavy skeletal tumour 
load (who had generally lower levels of renal tubular calcium 
reabsorption), also had a significantly better response to 
antihypercalcaemic therapy. It should also be noted however, that the 
calcium-lowering effect of decreased bone resorption was also enhanced 
in the heavy tumour load group by the greater degree of renal 
glomerular failure before treatment.
It has previously been recognised that the calcium-lowering 
response to diphosphonate therapy is incomplete in patients with 
humorally-mediated elevations in renal tubular calcium reabsorption 
(148,253). The current data suggest that, an incomplete response is 
also observed in this situation, when other antihypercalcaemic agents 
such as mithramycin and corticosteroids/calcitonin are used.
The inverse relationship which was observed between the extent of 
metastatic bone disease, impairment of glomerular filtration rate and
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levels of renal tubular calcium reabsorption in this study is also of 
interest.lt suggests that the hypercalcaemia in patients with a heavy 
skeletal tumour load may principally have been of the disequilibrium 
type (4), where increased bone resorption leads to severe 
hypercalcaemia because of . intravascular volume depletion, with a 
resultant impairment of GFR and hyperphosphataemia (305). In patients 
with few or no metastases however, the hypercalcaemia more closely 
resembled that of primary hyperparathyroidism and was due to 
humorally-mediated increases in renal tubular calcium reabsorption 
(chapter 3) , and bone resorption (5) , but with preservation of a 
relatively normal GFR. These differences in the mechanisms of 
hypercalcaemia can partly explain the variable response to 
antihypercalcaemic therapy in malignant disease; elevated levels of 
renal tubular calcium reabsorption as the result of humoral aetiology 
appear to be associated with a particularly poor response.
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CHAPTER 8
NEW THOUGHTS ON THE PATHOGENESIS 
OF MALIGNANCY ASSOCIATED HYPERCALCAEMIA;
AN APPRAISAL OF THE CURRENT WORK IN RELATION
TO EXISTING KNOWLEDGE
8.1 NEW THOUGHTS ON THE PATHOGENESIS AND MANAGEMENT
OF MALIGNANCY-ASSOCIATED HYPERCALCAEMIA
The hypercalcaemia associated with malignancy has classically 
been attributed to the excessive release of skeletal calcium by 
accelerated osteoclastic bone resorption, either on a multifocal 
basis, due to metastatic bone disease, or on a systemic basis due to 
the osteoclast activating effects of circulating humoral mediators 
which are released by tumour tissue (5,50). A variety of substances 
have been invoked in the pathogenesis of cancer-associated 
hypercalcaemia including; circulating prostaglandins (64), factors 
which stimulate bone resorption by enhancing local production of 
skeletal prostaglandins (77,78), transforming growth factors 
(90,97,104,105), platelet-derived growth factors (90), epidermal 
growth factor (103), tumour necrosis factors (51), interleukin 1 (47), 
parathyroid hormone (PTH) (124,125,126,127,128) and 1,25 (OH) 2  
(87,88,89). These factors share in common, the ability to stimulate 
bone resorption in tissue culture. However, with the exception of PTH 
and 1,25 (OH) 2 none have been shown to be capable of causing
hypercalcaemia when administered systemicaily, either because of their 
rapid metabolism or because of the efficient renal homeostatic 
mechanisms which tend to preserve normocalcaemia at the expense of 
hypercalciuria (4,5,90). Recent evidence has indicated that ectopic 
PTH production is an extremely rare cause of cancer-associated 
hypercalcaemia (93,130,131, 137,138). Similarly, excessive production 
of 1,25 (OH) 2 D3 by tumour tissue is observed only in a small group of 
patients with hypercalcaemia due to certain lymphomas (87,88,89).
In recent years, much interest has focussed on the release of
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"PTH-like " factors by tumours associated with the hypercalcaemia of 
malignancy (93,143,144,145,146). Although these factors are 
structurally and immunologically distinct from PTH (130,137), they 
appear to interact with adenyl-cyclase linked PTH receptors in vitro 
(143,144,145,146). It has been proposed that tumours which release 
these factors may be clinically identified by raised urinary excretion 
of nephrogenous cyclic AMP (NcAMP) and reduced renal tubular threshold 
for phosphate excretion (TmPO^) - end organ effects which are similar 
to those encountered in patients with primary hyperparathyroidism 
(93). The relationship between release of these factors and the 
pathogenesis of hypercalcaemia has hitherto been unclear however, 
since the PTH-like factors are relatively weak stimulators of bone 
resorption in tissue culture (90,150). Moreover, they have thought 
to differ from PTH in failing to stimulate l,25(OH)2 
synthesis and have not been considered to cause an elevation in renal 
tubular calcium reabsorption (93). In other words, they have been 
thought to lack the very properties which account for hypercalcaemia 
in primary hyperparathyroidism (113,114,116).
The data presented in this thesis suggests however, that 
humorally-mediated elevations in renal tubular calcium reabsorption 
play a significant role in the pathogenesis of malignant hypercalcaemia 
(chapter 4.1). Such elevations in renal tubular calcium reabsorption 
were not due to coexistant primary hyperparathyroidism or ectopic 
production of PTH, since iPTH levels were generally suppressed* 
Dehydration and sodium depletion were similarly excluded as possible 
causes, firstly since careful efforts were made to ensure that 
patients were normally hydrated on clinical basis, and secondly, since 
the renal handling of calcium in relation to sodium was
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indistiguishable from that in primary hyperparathyroidism (chapter 
4.3, reference 305). Nor did the raised levels of renal tubular 
calcium reabsorption appear to be a non-specific effect of chronic 
hypercalcaemia per se, since renal calcium handling was generally 
normal in patients with benign non parathyroid hypercalcaemia (chapter 
4.3) and in some patients with malignant hypercalcaemia due to breast 
carcinoma and myeloma (chapters 4.3, 5.2, 5.3, 7.3).
In marked contrast to the accepted dogma that accelerated bone 
resorption plays the principal role in cancer-associated 
hypercalcaemia, raised levels of renal tubular calcium reabsorption 
were the predominant cause of hypercalcaemia in patients with early 
tumours, where little evidence of raised bone resorption was found on 
a histological basis (chapters 6.1, 6.2). These data corroborate 
recent findings in the rat Leydig cell tumour model of humoral 
hypercalcaemia, which indicate that an elevation in renal tubular 
calcium reabsorption is the initial event in the pathogenesis of 
hypercalcaemia, occurring before bone resorption becomes elevated 
(302).
In agreement with the data of Stewart, who identified patients 
with humoral hypercalcaemia on the basis of their raised NcAMP 
excretion (93), PTH-like effects on renal calcium handling were most 
frequently noted in patients with squamous lung cancer and 
genitourinary cancers and were less apparent in patients with 
extensive metastatic disease due to breast carcinoma and myeloma 
(chapters 7.3, 4.1, 5.2, 5.3). Indeed, patients falling into the
latter category tended to exhibit fewer "PTH-like" features (raised 
urinary cyclic AMP excretion, detectable 1,25(OH) 2 levels reduced
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TmPO^ levels), when compared with those who had other solid tumours 
(chapter 5.2, 5,3).
Although 1,2 5 (OH)2 D levels were elevated to within the 
hyperparathyroid range in some patients with solid tumour 
hypercalcaemia (chapters 5.1, 5.2), intestinal calcium absorption was
generally supressed, suggesting that there was end organ resistance to 
the effects of the active vitamin D metabolite in this situation 
(chapter 5.2). The finding of detectable 1,25(OH)2 D levels suggests 
however that, as in the Leydig cell tumour model of humoral 
hypercalcaemia (149) , the putative PTH-like humoral factor in human 
humoral hypercalcaemia of malignancy may frequently possess a 
stimulatory effect on renal 1- (A - hydroxylase activity.
In some patients with extensive metastatic bone disease due to 
breast carcinoma and myeloma, elevations in renal tubular calcium 
reabsorption were noted, as were other PTH-like features such as 
raised urinary cAMP excretion, and depressed TmPO^ levels. It is 
probable that in some of these patients, the hypercalcaemia was due, 
in part to the renal tubular effects of PTH-like humoral mediators. 
However, since the elevations in renal tubular calcium reabsorption 
were generally less marked in patients with these tumours when 
compared with those in patients with squamous carcinoma and other 
solid tumours (chapters 4.2, 5.2, 5.3), they may have been partly due 
to innacuracies introduced by the methods of calculating the renal 
tubular component of hypercalcaemia (chapter 7.3).
However, it is apparent from these and other studies (93), that 
hypercalcaemic cancer patients may no longer simply be classified on 
the basis of metastatic bone involvement since evidence for a humoral
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aetiology can be found in the majority of cases, irrespective of the 
presence of metastatic bone disease. From the current studies, 
possible exceptions are patients with extensive metastatic bone 
disease due to myeloma and breast carcinoma, where hypercalcaemia may 
occur as the result of multifocal osteolysis, in combination with 
renal glomerular failure (chapter 7.3). In breast carcinoma, the 
latter occurrs as the inevitable result of a disequilibrium 
hypercalcaemia (4) and in myeloma, there is an additional nephrotoxic 
effect of the immunoglobulin fragments (28).
One of the most interesting findings to emerge from these studies 
was the difference in the mechanism of hypercalcaemia between patients 
with early and advanced malignant tumours (chapter 6.2). It has now 
become clear that most cancers associated with hypercalcaemia produce 
factors which are capable of resorbing bone (90). The PTH-like factors 
however, while released by about 80% of tumours associated with 
hypercalcaemia, do not posses strong bone resorbing properties in 
vitro (150). The progressive increase in bone resorption which was 
noted with advancing disease in chapter 6.2 lends support to Mundy’s 
suggestion that the hypercalcaemia of malignancy may be due to the 
interaction of a number of tumour-produced factors (90). It may be 
that the PTH-like factors are exhibited at an early stage and mainly 
determine the renal tubular abnormalities associated with the 
humoral hypercalcaemia syndrome. Subsequently other factors, possibly 
the transforming growth factors, may be released in increasing 
amounts, explaining the accelerated bone resorption. A further 
possibility which has not been considered previously and which was 
raised by the current studies, is that immobilisation may have acted 
in combination with the PTH-like factors to synergistically increase
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bone resorption in patients with advanced tumours. The relevance of 
elevated levels of NcAMP excretion in normocalcaemic cancer patients 
is difficult to explain at present (152) , but may be due to the 
release of other factors by the tumour, ectopic antidiuretic hormone 
for example, which enhance NcAMP production by binding to non PTH 
adenyl-cyclase linked receptors in the kidney (277).
From the point of view of patient management, the present studies 
indicated that control of hypercalcaemia is worthwhile in patients 
with advanced malignant disease to improve symptoms although 
anthypercalcaemic therapy appeared to have little effect on patient 
survival (chapter 7.1). Indeed, the only long term survivors were 
those in whom the tumour was a stage whch was amenable to surgcal 
resection.
Since hypercalcaemia in patients with advanced disease was due, 
in part, to the calcium-elevating effects of accelerated bone 
resorption, osteoclast inhibitory drugs continue to play an important 
role in the management of hypercalcaemia in this situation (303). 
Although the second generation diphosphonates such as APD and Cl2 MDP 
(253) appear to be the most effective agents currently available in 
this respect, the calcium lowering response is limited in patients 
with humorally mediated hypercalcaema due to the elevations in renal 
tubular calcium reabsorption. In view of this, future approaches to 
the management of cancer associated hypercalcaemia may well involve 
the combined use of inhibitors of bone resorption and other agents 
which inhibit the renal tubular component of hypercalcaemia such as 
calcitonin (chapter 6.2) , mithramycin (Chapter 6.1) or the new 
cytoprotective agent WR 2721 (265).
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